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1 Executive summary 
1.1 Background 
Prior to my PhD candidature, I published the first trial-based cost-effectiveness analyses of 
surgically-induced weight loss (bariatric surgery) as a treatment for people with obesity and recent-
onset type 2 diabetes (1, 2). During this research, I identified several gaps in the current literature 
regarding the burden of severe obesity and the economic consequences of treatment. In the context 
of identification of a topic of international interest and importance, combined with opportunities to 
access data to fill current evidence gaps, I embarked upon my PhD titled “The burden of severe 
obesity and the efficiency and equity of treatment”. 
1.2 Research questions 
The overall research question addressed by this PhD is: 
What is the burden of severe obesity and what is the current efficiency and equity of treatment? 
The following six minor research questions are answered by the thesis. 
Part 1. Burden of severe obesity: 
1. How has the prevalence of severe obesity changed in Australian adults over the past two 
decades and what are the characteristics of the current severely obese population?  
2. What is the utility-based quality of life 1 associated with severe obesity?  
3. What are the healthcare utilisation and cost burdens associated with severe obesity?  
1 An economic measure of quality of life 
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Part 2. Efficiency and equity of treatment (bariatric surgery) 
4. How does the healthcare utilisation and cost burden in the severely obese population 
change after treatment using bariatric surgery? 
5. Could the technical efficiency 2 of bariatric surgery be improved by prioritizing patients 
according to their glucose profile (normal, prediabetes, diabetes) at the time of surgery?  
6. Is access to bariatric surgery equitable across different socioeconomic groups?  
Each question constitutes a research stream in the thesis. 
1.3 Publications constituting thesis 
My PhD is formatted as a thesis by publication. A summary of publications which answer the 
research questions is provided in Table 1. In summary, during the duration of my PhD candidature, I 
have published/prepared: 
 8 lead-author original research publications (5 long format, 3 short format) and 1 co-author 
original research publications (long format).  
 2 letters which relate to my PhD topic. 
Table 1: Summary of publications constituting PhD thesis 
No. Manuscript citation Summary 
status  
Format Data source  Stream 
1 Keating C, Backholer K, Gearon E, 
Stevenson C, Swinburn B, Moodie M, 
Carter R, Peeters A. Prevalence of class I, 
II and III obesity 1995 to 2011/12 in 
Australia, Obesity Research and Clinical 
Practice. 2015 Mar 3. pii: S1871-
403X(15)00024-1. doi: 
10.1016/j.orcp.2015.02.004. [Epub 
ahead of print] 
Published Original 
article 
(long) 
Australian 
Bureau of 
Statistics 
National 
Health 
Surveys  
1 (Prevalence) 
2 Keating C, Backholer, Peeters A. Global, 
regional, and national prevalence of 
overweight and obesity in children and 
adults during 1980—2013: a systematic 
analysis for the Global Burden of 
Disease Study 2013 (correspondence). 
The Lancet, Volume 384 , Issue 9960 , 
2107 – 2108, 
doi: http://dx.doi.org/10.1016/S0140-
6736(14)62367-9. 
 
Published Letter N/A 1 (Prevalence) 
2 Maximising outputs (i.e. health benefits or cost savings) from a given input (allocation of surgical resources) 
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No. Manuscript citation Summary 
status  
Format Data source  Stream 
3 Keating, C. L., Peeters, A., Swinburn, B. 
A., Magliano, D. J. and Moodie, M. L. 
(2013), Utility-based quality of life 
associated with overweight and obesity: 
The Australian Diabetes, Obesity, and 
Lifestyle study. Obesity, 21: 652–655. 
doi: 10.1002/oby.20290 
Published Original 
article 
(short) 
The Australian 
Diabetes, 
Obesity and 
Lifestyle study 
2 (Utility) 
4 Keating CL, Moodie ML, Richardson J, 
Swinburn BA. Utility-based quality of life 
of overweight and obese adolescents. 
Value Health. Jul-Aug 2011;14(5):752-
758. 
Published Original 
article 
(long) 
Obesity 
Prevention in 
Communities 
Project 
(Australia) 
2 (Utility) 
5 Keating, C. L., Moodie, M. L., Bulfone, L., 
Swinburn, B. A., Stevenson, C. E. and 
Peeters, A. (2012), Healthcare Utilization 
and Costs in Severely Obese Subjects 
Before Bariatric Surgery. Obesity, 
20: 2412–2419. 
doi: 10.1038/oby.2012.124 
Published Original 
article 
(long) 
Medicare 
(Australia’s 
National 
Health 
Insurer)  
3 (Healthcare 
burden) 
6 Keating CL, Peeters A, Swinburn BA, 
Carter R, Moodie ML. Pharmaceutical 
utilisation and costs before and after 
bariatric surgery.  International Journal 
of Obesity 37, 1467–1472; 
doi:10.1038/ijo.2013.24 
Published Original 
article 
(long) 
Medicare 
(Australia’s 
National 
Health 
Insurer)  
4 (Healthcare 
burden after 
treatment) 
7 Keating CL, Ananthapavan J.  Revisional 
Surgery after Laparoscopic Adjustable 
Gastric Banding in a National Australian 
Cohort JAMA Surg. 2014;149(8):874-
875. doi:10.1001/jamasurg.2014.93 
Published Original 
article 
(short) 
Medicare 
(Australia’s 
National 
Health 
Insurer)  
4 (Healthcare 
burden after 
treatment) 
8 Neovius M, Narbro K, Keating C, 
Peltonen M, Sjöholm K, Agren 
G, Sjöström L, Carlsson L. Health Care 
Use During 20 Years Following Bariatric 
Surgery. JAMA. 2012;308(11):1132-
1141. doi:10.1001/2012.jama.11792 
Published Original 
article 
(long) 
Swedish 
Obese 
Subjects (SOS) 
Study 
4 (Healthcare 
burden after 
treatment) 
9 Keating C, Neovius M, Sjoholm K, 
Peltonen M, Narbro K, Eriksson J, 
Sjostrom L, Carlsson L. Pre-Operative 
Glucose Status and Health Care Use 
During 15 Years Following Bariatric 
Surgery, Under  review. 
 
 
Under review  Original 
article 
(long) 
Swedish 
Obese 
Subjects (SOS) 
Study 
5 (Efficiency) 
11 
 
No. Manuscript citation Summary 
status  
Format Data source  Stream 
10 Keating C, Peeters A, Neovius M. 
Beyond BMI: the need for new 
guidelines governing the use of bariatric 
and metabolic surgery 
(correspondence). The Lancet Diabetes 
& Endocrinology. 2014;2(6):448-9. 
Published Letter N/A 5 (Efficiency) 
11 Keating C, Backholer K, Stevenson C, 
Moodie M and Peeters A. Differences in 
the Rate of Bariatric Surgery across 
Socio-economic Groups. JAMA Surgery. 
2015 Apr 1;150(4):367-8. doi: 
10.1001/jamasurg.2014.3180. 
Published Original 
article 
(short) 
Australian 
Bureau of 
Statistics 
National 
Health 
Surveys and 
National 
Hospital 
Morbidity 
database. 
6 (Equity) 
1.4 PhD findings and significance (lead author studies) 
Introduction to severe obesity 
The World Health Organisation defines three sub-classes of obesity severity (class-I body mass index 
(BMI): 30.0-34.9 kg/m2, class-II: 35.0-39.9 kg/m2 and class-///͗ шϰϬ͘Ϭ ŬŐͬŵ2) (3). Severe obesity is 
defined as class-II or class-III obesity. 
Part 1. Burden of severe obesity in Australian adults 
My PhD research found that the prevalence of severe obesity has doubled in Australian adults over 
the last twenty years, and currently affects one in ten adults. In 2011-12, women were more likely to 
be severely obese, including twice as likely to be class-III obese. The prevalence of severe obesity 
was higher in groups with greater levels of socioeconomic disadvantage, such that severe obesity 
affected 6.2% and 13.4% in the least and most disadvantaged quintiles respectively(4). This research 
defined the socio-demographic distribution of severe obesity for the first time in Australia; this will 
enable interventions to be designed for, and targeted towards the highest risk groups. I 
disseminated lessons from this research in a letter which advocated the need to report obesity 
trends stratified by socioeconomic position and obesity severity category within future obesity 
surveillance studies(5).  
My research also found that severe obesity is associated with a large burden at an individual level 
(quality of life), but also importantly at the societal level (government healthcare costs). For the 
adult population, I analysed the Australian Diabetes, Obesity and Lifestyle (AusDiab) study sample 
and found that relative to healthy weight, reductions in utility-based quality of life (UQoL, an 
economic measure), were 1.2%, 2.0% and 6.9% for class-I, class-II and class-III obesity respectively 
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(6). This was the first study internationally to report UQoL according to each obesity class. These 
results indicate that class-III obese Australian adults would be willing to forgo 6.9% of their 
remaining life to spend it in perfect health. For the adolescent population, I analysed data from the 
Obesity Prevention in Communities (OPIC) sample and found that relative to healthy weight, obesity 
was associated with a 5.9% reduction in utility and a 0.025 utility reduction with each BMI z-score 
standard deviation(7). These UQoL results for both adults and adolescents can be utilised to inform 
more sensitive cost-effectiveness analyses of obesity interventions, by incorporating UQoL data 
which are specific to the sub-classes of obesity.  
Next I sought to quantify the healthcare costs attributable to severe obesity. I analysed observed 
data sourced from Australia’s national health insurer, Medicare, and found that healthcare costs 
incurred by the Australian government for people with severe obesity (prior to receiving bariatric 
surgery) are more than double the comparable costs for the age- and sex- matched general 
population(8). The cost differences were largely driven by greater annual healthcare costs relating to 
treating diabetes, cardiovascular disease and depression in the severely obese subjects. These 
results can be utilised to quantify the burden of severe obesity, a condition which is increasing at 
alarming rates in many countries and which is associated with far more serious consequences than 
mild obesity. The data can also be adopted as “cost offsets” within cost-effectiveness analysis 
relating to interventions targeting severe obesity.  
Part 2. Efficiency and equity of treatment (bariatric surgery) 
Bariatric surgery is currently the only available intervention which induces large and sustained 
weight loss in severely obese patients (9) and therefore was adopted as the “treatment” modality in 
my analyses.  
Firstly, I assessed the effect of bariatric surgery on the healthcare utilisation and costs for a 
nationwide population of severely obese patients receiving Medicare-subsidised (<90% of all cases) 
laparoscopic adjustable gastric banding (LAGB) in Australia. In an analysis of observed 
pharmaceutical use in the year prior to surgery and the two years after surgery, I observed an overall 
reduction in pharmaceutical use after surgery(10). This included an approximate halving in the use 
of drugs to treat type 2 diabetes. However, these savings were partially offset by greater utilisation 
of therapies related to post bariatric surgery management. This study was significant because it 
demonstrated that bariatric surgery leads to reductions in pharmaceutical utilisation in the ‘real 
world’ (rather than trial) setting. With regards to medical services, I assessed revisional surgery rates 
in the same national cohort of LAGB patients and found that revisional surgery was required by one 
in five patients in the three years after surgery (11). Therefore, whilst bariatric surgery is associated 
with dramatic weight loss and improvements in many clinical end points, this study highlights the 
need to balance the benefits of surgery with the risk of adverse events, the need for reoperations, 
and the associated costs for each patient. Key strengths of these two register linkage studies were 
that the population analysed was the entire national population of Australians receiving Medicare-
subsidized gastric banding (no selection bias), data analysed were observed healthcare use data 
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maintained by the Australian government (rather than self-reported), and data were sourced via 
register linkage for all subjects (no loss to follow-up). 
Next, I examined the allocation of bariatric surgery to severely obese patients with regards to both 
technical efficiency (according to glucose profile at the time of surgery) and equity (across 
socioeconomic groups). Based on analysis of observed healthcare data for individuals participating in 
the Swedish Obese Subjects Study over up to 15 years, I found that bariatric surgery is associated 
with greater long-term health care use for patients with normal glucose at the time of surgery, 
trade-offs between increased hospital use and reduced drug use for patient with pre-diabetes and 
lower health care use for patients with type 2 diabetes, relative to conventional therapy  
counterparts (12). These results suggest that the benefits (potential for cost savings) of bariatric 
surgery will be maximised if patients with diabetes and pre-diabetes are prioritised to receive 
treatment. This evidence can be utilised to inform potential revisions to bariatric surgery eligibility 
guidelines, which have been called for by many groups (13). In relation to eligibility guidelines, 
I highlighted, in a letter (14), the need to consider economic as well as efficacy evidence when 
considering revisions. 
In relation to equity of access to bariatric surgery, I examined treatment rates for all Australian 
adults receiving bariatric surgery in 2011-12 according to socioeconomic position. I found that 
severely obese Australians in the two most disadvantaged quintiles were approximately 40% less 
likely to receive bariatric surgery relative to severely obese counterparts in the two least 
disadvantaged quintiles (15). These inequalities risk further widening the already large inequalities in 
the prevalence of severe obesity previously described, and contributing to future inequalities in 
health. Increasing funding to treat severe obesity using bariatric surgery in public hospitals in 
Australia may contribute to a reduction in the current socioeconomic inequalities in severe obesity. 
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2 Introduction 
2.1 Background 
Prior to my PhD candidature, I published the first trial-based cost-effectiveness analyses of 
surgically-induced weight loss (bariatric surgery) as a treatment for people with obesity and recent-
onset type 2 diabetes(1, 2) (Appendix 1). During this research, I identified several gaps in the current 
literature regarding the burden of severe obesity and the economic consequences of treatment. My 
lead-author analyses led to considerable international interest: 
- Since 2009, these two manuscripts have been cited >160 times collectively. 
- The research has been translated to policy; the articles are cited as a key economic reference 
in the International Diabetes Federation’s Position Statement on clinical guidelines for the 
treatment of type 2 diabetes in subjects with obesity(16). 
- The research led to an invitation to present at the World Congress of Interventional 
Therapies for Type 2 Diabetes (New York, 2011). 
- Presentation of this research at the International Congress on Obesity (Stockholm, 2011), led 
to an invitation to collaborate with the Swedish Obese Subjects Study, the largest and 
longest bariatric surgery study in the world(17).  
In the context of identification of a topic of international interest and importance, combined with 
opportunities to access data to fill current evidence gaps, I decided to embark upon my PhD titled 
“The burden of severe obesity and the efficiency and equity of treatment”. 
2.2 Research questions 
The overall research question addressed by this PhD is: 
What is the burden of severe obesity and what is the current efficiency and equity of treatment? 
The following six minor research questions are answered by the thesis. 
Part 1. Burden of severe obesity: 
1. How has the prevalence of severe obesity changed in Australian adults over the past two 
decades and what are the characteristics of the current severely obese population?  
2. What is the utility-based quality of life 3 associated with severe obesity?  
3. What are the healthcare utilisation and cost burdens associated with severe obesity?  
3 An economic measure of quality of life 
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Part 2. Efficiency and equity of treatment (bariatric surgery) 
4. How does the healthcare utilisation and cost burden in the severely obese population 
change after treatment using bariatric surgery? 
5. Could the technical efficiency 4 of bariatric surgery be improved by prioritizing patients 
according to their glucose profile (normal, prediabetes, diabetes) at the time of surgery?  
6. Is access to bariatric surgery equitable across different socioeconomic groups?  
Each question will constitute a research stream. 
2.3 Structure of thesis 
The remainder of the thesis includes four major chapters, followed by Appendices as summarised 
below: 
 Chapter 3:  Literature Review: including overview of applied economics in healthcare, severe 
obesity and bariatric surgery. 
 Chapter 4:  Methods and Results: including all published/submitted manuscripts constituting 
my thesis.  
 Chapter 5: Discussion: including synthesis of findings for each research stream, significance 
and priorities for future research. 
 Appendix 1: Lead author manuscripts critical to PhD background. 
 Appendix 2: Author contribution statements. 
4 Maximising outputs (i.e. health benefits or cost savings) from a given input (allocation of surgical resources) 
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3 Literature review 
3.1 Introduction 
My PhD focuses on the burden of severe obesity and the efficiency and equity of treatment for 
severe obesity. My PhD quantifies the burden of severe obesity using two economic measures; 
utility-based quality of life and healthcare utilisation, which are both key inputs into cost-
effectiveness evaluation. I also identified a paucity of evidence relating to both measures during my 
previous cost-effectiveness analysis of bariatric surgery to treat recent type 2 diabetes(1, 2). The 
literature review describes the theoretical context for the need for cost-effectiveness evaluation in 
the healthcare sector, including failures of the private market to deliver healthcare. Cost-
effectiveness analysis methods including data requirements are reviewed. Other considerations 
informing the allocation of healthcare service, specifically equity concerns are also reviewed. The 
clinical context for this PhD is severe obesity, therefore, next the literature review provided 
background information around the prevalence, health risks, treatment options, utility-based quality 
of life and healthcare utilization associated with severe obesity. Finally, the key treatment option for 
severe obesity; bariatric surgery is discussed, including its surgical modalities, clinical outcomes, 
eligibility and utilisation in Australia. The literature review was undertaken early during the PhD 
(2012), to synthesise existing research and highlight gaps leading to the relevant PhD publications.  
3.2 Applied economics in the healthcare sector 
3.2.1 Economics and microeconomics    
The discipline of economics is primarily concerned with determining how to maximise social 
wellbeing in the face of scarce resources. Microeconomic theory is devoted to the description and 
analysis of competitive markets, including the buying and selling behaviours of agents (such as firms, 
households or individuals)(18).  Microeconomic theory purports that consumer well-being (often 
described as “utility” within the economics literature) will be maximised within the competitive 
market, and this will ultimately lead to the highest level of welfare for the population(19). 
The attainment of a perfectly competitive market is underpinned by five key assumptions, as 
summarised below. 
x Individuals are the best judges of their own welfare needs. More specifically, using rational 
decision-making, individuals can identify their own needs, and then compare their own 
preferences against market options and prices to select products and services which best 
satisfy their needs(20). 
x Consumers have sufficient information to compare market options and make informed 
choices(20). Consumers should possess comprehensive information about the opportunity 
costs and value of the goods or services on offer(21), such that they may predict the likely 
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utility gained from their purchase. The situation when one party has information not 
available at any cost to the other party is known as asymmetric information(22). 
x No positive or negative externalities associated with consumer decisions. A consumption 
externality exists when one person’s consumption of a good or service has an effect on the 
utility of another person(23) that is not taken into account by the consumer or supplier(23). 
Externalities can be positive (benefit a third party), or negative (disadvantage a third party). If 
significant externalities exist, the market cannot operate at optimum efficiency(20). 
x Supply and demand are independently determined. Therefore suppliers will seek to use 
their inputs most efficiently to produce those goods and services that consumers 
demand(23). 
x No suppliers have monopoly power.  Monopoly power is the ability of one supplier to 
influence the market prices or prohibit the entry of new firms into the market(23).  
3.2.2 Rationales for government intervention within health care 
There are two key rationales for rejection of the delivery of healthcare through the private market 
system: market failures in healthcare and social justice. These concepts are described below. 
Market “failure” in healthcare. It is a widely shared view that the healthcare sector fails to meet the 
above key assumptions of the private competitive market and hence cannot be relied upon to 
facilitate the efficient allocation of healthcare services. Therefore, governments in many countries, 
have rejected a reliance on the private market in healthcare. The following characteristics of the 
health care sector are contrary to competitive market assumptions. 
x Consumers typically have incomplete information about their health care needs, treatment 
options and relative costs and effectiveness of each(24). Therefore, there is an asymmetry of 
information between health care suppliers and consumers. Consequently, patients are 
dependent on health professionals to make judgments regarding their welfare, 
disempowering consumers as the best judges of their own welfare(25). For example, 
patients usually have insufficient information to appraise the risks vs the benefits of potential 
surgery, such as bariatric surgery for weight loss. Consumer dependence is further 
exacerbated by the fact that their mental state may be compromised due to pain, stress or 
disability(26). Alternatively, should health care consumers decide to make their own 
decisions based on insufficient information, consumption mistakes may have dire 
ramifications, including potentially irreversible damage(26). Whilst theoretically, information 
asymmetry can be mitigated by consumers’ ability to source information, this is often not 
feasible because of the critical time dimension of health care needs(26). 
x Other risks associated with information asymmetry in healthcare include moral hazard, 
whereby people tend to use private information to their own advantage, adversely affecting 
the outcomes for the other party(22). For example, doctors may exploit patients’ poor 
knowledge of treatment regimes, by manipulating patterns of care to maximise their own 
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financial gain by recommending many short visits rather than one or two long visits. This 
phenomenon, known as supplier-induced demand, adversely affects the outcome for patient 
because they pay more than necessary for treatment(20). Supplier-induced demand is 
contrary to the market assumption that supply and demand are independently 
determined. 
x The health care sector frequently incurs positive externalities. For example, when one 
consumer is inoculated against a communicable disease, in addition to reducing their own 
risk of catching the disease they are also reduce the risk for (and hence benefit) numerous 
third parties(20). Another positive externality unique to health care is the moral satisfaction 
(benefit) that the community as a whole derives from knowing that all fellow citizens, 
particularly the poor have access to quality health services(25).  
x Finally within health care, suppliers often hold monopoly power. In most towns and even 
cities of moderate size, the market is too small to support enough hospitals or practitioners 
in each specialty to fulfil the requirements of a competitive market. These constraints are 
even more significant when specialty care is considered. Such a condition is a form of natural 
monopoly(27).  
Social justice. The incompatibility of the health care sector with competitive market assumptions 
means that this model cannot be relied upon to efficiently allocate health care resources, creating 
an economic rationale for government intervention in health care funding and service delivery(21). 
However, the failure of the market to deliver health care is not the primary reason for government 
intervention. Most governments intervene to safeguard the equity of access to health care for 
all(28).  
The consideration of a sick person unable to access health services because of inadequate finance 
evokes a feeling of concern which distinguishes health care from most other goods and services(28). 
Consequently, health care earns the unique perceived status as a universal right(29), which should 
be accessible to all people, regardless of ability-to-pay(21) and irrespective of previous decisions(30) 
in some settings. 
The ‘market failure’ and ‘social justice’ arguments provide two key rationales for government in the 
design of public institutional arrangements in an attempt to maximise society’s desired healthcare 
outcomes within the available budget24.  
3.2.3 Types of government intervention 
Government intervention includes:  
x Regulation of health care. Given consumers have insufficient knowledge to judge the 
professional competence of health services provision, the government assumes responsibility 
for ensuring services meet acceptable standards through regulation(28). Typical health care 
regulations include compulsory qualifications for health care professionals, certification of 
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quality standards of pharmaceuticals and medical technologies(31), accreditation of hospitals 
with defined quality protocols(27), and restriction of activities by insurers(32). For example, 
in Australia the health insurance system is regulated by the Health Insurance Act, which 
prescribes that insurers must not discriminate against individuals when setting premiums or 
paying benefits. The identification of quality benchmarks which health care suppliers are 
evaluated against, is a form of regulation which helps mitigate adverse outcomes of 
asymmetric information such as supplier-induced demand and over-utilisation of high 
technology medicine(28). 
x Tax or subsidy policies. Taxes and subsidies enable the government to deter activities that it 
wishes to restrict (by taxing them) and encourage activities it wishes to expand (by 
subsidising them). Subsidies can be targeted at specific groups in the population, such as the 
elderly, unemployed or low income individuals to decrease the price of health care supplied 
by private, fee charging suppliers(28). Subsidies provide a method for offsetting negative 
externalities. For example, when preventative measures against communication disease are 
subsidised, the likelihood that individuals will find the benefits outweigh costs and purchase 
the treatment is increased. As a consequence, the community at large will be better off, 
eliminating the potential negative externality of increased risk for third parties because one 
consumer decided not to pursue preventative measures due to the high cost(28). 
x Direct health care services provision. The underlying objective of direct health service 
provision by government is improvement of the health of the population at large. In most 
industrialized countries this is achieved through the operation of tax-financed universal 
public health insurance(33). Within this system, hospitals and health professionals are 
funded by the government, enabling health service provision to be free at the point of 
service (28). Unlike the market model, this system ensures equitable access to the entire 
population including the poor, elderly and unemployed(32), who may contribute little or 
nothing to the tax system. Within the context of finite budgets, governments often rely on 
economic evaluation to assist in the allocation of their budgets (discussed in detail in next 
section). 
3.2.4 Economic evaluation in healthcare  
In the context of finite healthcare budgets, many governments around the world utilise applied 
economic evaluation, whereby the costs and benefits of various policy options are systematically 
evaluated, to inform the non-market allocation of services. Economic evaluation involves explicitly 
evaluating and ranking, from better to worse, the economic efficiency of various policies, programs 
and services to inform priority-setting(34).  Economic evaluation is concerned with ‘what ought to 
be’, and therefore aims to identify policy options which will move society closer to its inherently 
valued ‘ideals’(18). This field of applied economics is known as “normative economics”.  
Two established normative economic evaluation foundations exist, ‘welfarism’ and ‘extra-
welfarism’. The selection of a normative economic foundation, that is, which school of thought is 
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followed to define efficiency, has significant implications on the tools and methods utilised to inform 
resource allocation decision-making. For example, alternative foundations may approach the same 
policy evaluation with a distinct perspective and comparator(s), as well as unique methods to 
identify and measure costs, and to measure, value and aggregate benefits(35). Historically, most 
normative economic evaluation within the healthcare sector has been conducted within the neo-
classical tradition, specifically Paretian welfarist economics. However, within more recent decades, 
an alternative normative economic foundation, extra-welfarism, has become the dominant 
framework. This transition has manifested in marked variations in applied economic evaluation 
methods, most notably, the shift in the measurement of benefits from ‘utility’, based on individual 
self-assessments, to ‘Quality Adjusted Life Years’ (QALYs), from a societal perspective(36) (discussed 
further in section 3.2.5). 
Before highlighting the conceptual differences between each foundation, it is important to 
acknowledge the shared economic hallmarks of each. Adherents of both normative foundations 
would agree that: i) opportunity costs, not accounting or financial costs are the most relevant cost 
concept for inclusion in the economic evaluation, ii) the analysis of marginal costs versus marginal 
benefits is fundamental for measuring the efficiency of various policy options, and iii) that a clear 
concept of benefit is central to undertaking economic evaluation(35).  
Welfarism and cost-benefit analysis. Welfarism was conceived in the 1920’s to assist decision-
makers to identify the most economically efficient policy option(s). The welfarist framework, 
involves individuals ranking policy options in order of their preference via the allocation of utility 
measurements(36). Next, the relative desirability of each policy option is determined with reference 
to the sum of the utility attained by individuals benefiting from that policy(36). 
Welfarists strive to identify the situation(s), known as Pareto optimality, whereby it is impossible to 
make one individual better off without making another worse off. Pareto optimality reflects the 
point at which ‘allocative efficiency’ is reached, whereby resources are produced and allocated so 
that they produce the optimal level of each output, and these are distributed in accordance with the 
value that consumers attribute to them(35).
However, the state of Pareto optimality was found to be rarely feasible in practice and therefore, 
the attention of welfarists shifted to the notion of the ‘potential Pareto improvements’ (PPI) as the 
objective in determining the relative superiority of policy options. A PPI exists when the benefits 
attributable to a policy that accrue to the ‘gainers’ are large enough that they can compensate the 
‘losers’, such that they are no worse off than prior to the policy, whilst the ‘gainers’ retain a net 
benefit(36). The potential for a pareto optimal outcome is assessed with a Hicks Kaldor 
compensation test, where an outcome is considered more efficient if those that are made better off 
could “in theory” compensate those that are made worse off (36). 
The welfarist foundation is built upon four key assumptions. Firstly, utility maximisation, which 
purports that, when presented with a set of options, individuals have the capacity to rank the 
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options according to their preferences in a consistent fashion(35). Secondly, consumer sovereignty, 
which maintains that individuals are the best judges of their own welfare, and therefore assessment 
of individual welfare should be based on ‘self-assessment’. Thirdly, consequentialism, which holds 
that any policy or program must be judged exclusively in terms of its resulting outcomes. Finally, 
welfarism, which is the proposition that the goodness of any resource allocation must be judged 
solely on the basis of the utility levels attained by individuals in that situation(35). 
Cost-benefit analysis (CBA) is the accepted method for applying the welfarist objective of identifying 
potential Pareto improvements. Within CBAs, both costs and benefits are measured in monetary 
terms and by reference to the preferences of the individuals affected by the policy(37). The end 
product of a CBA is a measure of the sum by which the total benefits realised by all individuals as a 
result of a policy exceed or fall short of the total costs. Therefore, the relative superiority of policy 
options is decided according to whether the policy’s net social benefits exceed its net social 
costs(37). 
Extra-welfarism and cost-utility / cost-effectiveness analysis. During the 1960’s, several prominent 
economists rejected the Paretian welfarist foundation as the basis for economic evaluation in the 
healthcare sector. As early as 1963, Paul Feldstein proposed “should not health care be allocated to 
maximise the level of health of the nation instead of the satisfaction which consumers derive as they 
use health services?”(35).  
Economists including Amartya Sen and Anthony Culyer pursued this question most passionately and 
explored the consequences of incorporating societal value judgements within normative economic 
frameworks(18). Sen advocated the need to consider the level of deprivation of certain 
characteristics of people, for example their health condition, socioeconomic status, moral worth or 
severity of pain, within economic evaluations as the basis for prioritising resource allocations(38). In 
what became known as the “capabilities approach”, Sen also redefined poverty, moving away from a 
focus on income, and instead defining it based on capabilities and freedoms, to pursuits such as a 
healthy long life, engagement in the economy and participation in political actions(39).  
Culyer built on Sen’s theories to conceive an alternative normative economic foundation known as 
‘extra-welfarism’. Culyer proposed that the most relevant ‘characteristic’ for evaluating healthcare 
policies is ‘health’ and included this as the proximate maximand (as opposed to utility) for 
conducting normative analysis in the health sector(26). 
Culyer also had reservations regarding whether individuals are really able to demand their optimum 
level of health care (as is required for welfarism’s utility maximisation) suggesting that people do not 
always know what is best for them. Therefore, extra-welfarism is founded upon the allocation of 
resources based on deprivation of health, or ‘need’, as opposed to ‘demand’ for healthcare(40). At 
the conceptual level, this also implies the rejection of the notion of welfarism – because ‘need’ 
supersedes the ‘individuals perceived utility’ as the basis for resource allocation(41).  
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The economic evaluation methods most compatible with the conceptual foundation of extra-
welfarism are cost-effectiveness analysis (CEA) and cost-utility analysis (CUA). Both methods 
emphasise health status as the primary maximand(40). Both involve the comparison of one or more 
intervention (options for change) with a comparator, which is typically “current practice”. In CEA, 
program benefits are measured in natural units of outcome, for example, cases of disease averted. 
For CUA, benefits are measured in quality (or disability) adjusted life years (QALY/DALY), a general 
health measure which seeks to capture changes in both the quality of life and quantity of life 
remaining. QALYs represent the number of years in full health that are equivalent to an actual health 
profile that includes periods of less than full health (discussed further in section 3.2.5). Accordingly, 
it can serve as the outcome measure for a wide range of health interventions(42).  
The results for both CEA and CUA are summarised as an incremental cost-effectiveness ratio (ICER). 
The ICER is the ratio of the change in costs to incremental benefits of a therapeutic intervention or 
treatment, calculated as ICER = (C1 – C2) / (E1 – E2), where C1 and E1 are the cost and effect in the 
intervention or treatment group and where C2 and E2 are the cost and effect in the control care 
group(36). For resource allocation, the decision rule is to adopt all interventions with incremental 
cost-effectiveness ratios less than or equal to a particular agreed value(35), for example, 
$50,000/QALY in Australia(43). However, the appropriate value for this threshold is the source of 
significant debate (44-46). 
Although welfarism has closer ties with accepted economic theory, the objectives of society and 
healthcare decision-makers are incompatible with those upheld by welfarist theory, and thus 
welfarism loses its normative relevance as the theoretical basis for providing practical advice to 
policy-makers. In contrast, extra-welfarism is founded on the specific concerns of the healthcare 
sector, in particular, a focus on health as the maximand and the prioritisation of resources according 
to severity of need. Therefore, extra-welfarism currently provides the most relevant, philosophically 
appropriate and valid foundation to achieve quality and consistency in decision-making within the 
healthcare sector.  
3.2.5 Cost-utility analysis (CUA) 
As described above, cost-utility analysis involves the measurement of the units of benefit as health-
adjusted life years (HALYs). Health-adjusted life years (HALYs) are summary measures of population 
health that allow the combined impact of death and morbidity to be considered simultaneously. This 
feature makes HALYS useful for comparisons across a range of illnesses, interventions, and 
populations. Two key types of HALYS exist: quality-adjusted life years (QALYs) and disability adjusted 
life years (QALY / DALY). 
QALYs are an outcome measure which combines the duration and quality of survival, and can 
therefore be used to compare interventions targeting diverse disease areas. QALYs are usually 
calculated as the “utility index” for a particular health state multiplied by the length of time (in 
years) spent in that state(42) (refer to section 3.2.6 for further details). These measures satisfy the 
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requirements of economic theory by eliciting from individuals the ‘utility’ which they attribute to 
various health states and hence, the strength of their preferences for them(30).  
In contrast, DALY values for diseases and other non-fatal health outcomes are obtained through a 
process which attempts to quantify the (lack of) desirability of different conditions and injuries by an 
expert group of health professionals. The DALY valuation exercise is built upon a person trade-off 
method which explicitly addresses trade-offs between life and HRQL for people with different 
diseases(47). DALYS also involve "social weighting", in which the value of each year of life depends 
on age (general preference towards younger populations)(47). The DALY is the metric adopted in the 
Global Burden of Disease studies (48). 
Some authorities have indicated their preference for cost-utility analysis as their preferred 
technique for economic evaluation; for example, the United States Public Health Service Panel on 
Cost-effectiveness in Health and Medicine(49), the United Kingdom National Institute for Health and 
Clinical Excellence(50) the Canadian ‘Common Drug Review’(51) and the Australian Pharmaceutical 
and Medical Service Advisory Committees(52).  
Current limitations of CUA include:  
x Measures provide an aggregate value of a proposed policy without regard for the distribution 
of costs and benefits. However, economists can perform a subsequent distributional analysis 
to show how the costs and benefits are borne by different groups in the community to 
complement the economic evaluation(53).  
x Health interventions may be cost-effective on an individual basis, however the scale 
(population-based) of the programs may preclude them from being funded due to budget 
limits(54). 
x QALYs/DALYs suffer from poor sensitivity when comparing the efficacy of two competing but 
similar programs in the treatment of minor health problems.  
x It may too difficult to quantify the benefits using QALYs/DALYs for certain preventive 
programs where the impact on health outcomes may occur well into the future.  
Nevertheless, whilst there is room for improvement with regard to the scope of QALYs in applied 
evaluations, there is little doubt that these measures of benefit are more valid and reliable than the 
monetary valuations required under CBA. 
3.2.6 Data requirements for cost-utility analysis (QALYS)  
Utility-based quality of life (UQoL). The quantification of a 'utility index' which is a measure of 
utility-based quality of life in cost-utility analysis requires two tasks. Firstly, the health state under 
investigation is described, and secondly, a scaling technique such as the time trade-off or standard 
gamble is used to attach a numerical value to the health state. This value should measure the 
strength of a person's preference (utility) for the health state. The values are elicited by requesting 
reference subjects to reveal their willingness to trade quantity and quality of life(55). 
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Two key approaches to this two-stage procedure are utilised: holistic and multi-attribute utility 
measurement. Holistic measurement involves the construction of a scenario or vignette which 
describes the health state (Step 1). Next, the entire scenario is 'scaled' (Step 2): i.e. a survey is 
administered to elicit 'utility' values specifically for that scenario(56). 
The multi-attribute utility approach involves the construction of a generic ‘descriptive system’ which 
is capable of describing a wide range of health states and utility weights are attached to every 
possible state. This is typically achieved by measuring a limited number of health states and using 
these to calibrate a model which is then used to infer the utility values of every other health state in 
the ‘descriptive system’. The fully scaled MAU instrument may then be used to estimate the utility of 
all possible health states described by the models’ descriptive system(57).  
Multi-attribute utility instruments are similar to general health profile instruments, because they 
include questions relating to multiple dimensions of health-related quality of life. However, multi-
attribute utility instruments differ from general health profiles because their scoring takes into 
account the relative importance of each area of QoL as judged by a reference population.  
A key strength of the utility-based quality of life (utility) metric is that scores reflect the subjects’ 
willingness to forgo life expectancy in order to return to perfect health. Utility indexes are scored 
between 0.00 and 1.00 (worst to best). A calculated utility loss of 0.05 can be interpreted as 
meaning that to avoid the poorer health state an individual would be willing to forgo 5% of 
remaining life expectancy in the best health state, i.e. U = 1.00 (55). Additionally, some health states 
are regarded as being worse than 0 and are given a negative value (20).  
Intervention costs and cost offsets. Whilst the unit of benefits in CUA is QALYS/DALYS, the cost is 
measured in dollars. The cost typically includes two broad cost types, i) costs of the intervention 
being assessed, and ii) costs saved due to reductions in healthcare utilisation attributable to the 
healthcare improvements facilitated by the intervention, known as “cost offsets”.  
There are three basic steps involved in intervention costing from an economic perspective. These 
are: 
i) Identification of the costs for inclusion within the evaluation; 
ii) Measurement of resources used by the intervention and comparator; and 
iii) Valuing the resources used by the intervention (42). 
 
The identification and measurement of intervention costs requires an understanding of exactly what 
activities the intervention(s) and its comparator(s) involve. This involves identifying “who, does 
what, to whom, when, where and how often”. The answers to these questions culminate in a series 
of carefully defined steps, often referred to as an ‘event pathway’. Other important aspects of 
intervention costing include: 
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x All costs should be identified, even if they are not subsequently included. All inclusion / 
exclusion criteria should be clearly defined and justified(36). 
x A costing perspective should be defined, which will inform the “breadth” of costs to be 
included in the analysis. For example, a healthcare as third party perspective would capture 
all costs and cost offsets incurred by healthcare agencies in the Commonwealth, State and 
Territory governments(36). 
x The costing approach should be identical for the intervention and its comparator(s)(36).  
If an intervention prevents future disease or treats current disease so that future complications are 
avoided, the projected healthcare costs in the eligible population are likely to be lower following the 
intervention. The differences in projected healthcare costs between the intervention and 
comparator situation are identified as cost offsets. Disease-specific healthcare expenditure 
estimates are utilised as cost offsets in cost-effectiveness analysis.  
Discounting rate. Individuals in society typically prefer to consume a product or service now rather 
than delay the consumption until sometime in the future. This reflects a positive rate of time 
preference, or “discount rate”. Within economic evaluation, the present value of future costs or 
outcomes is estimated by applying a discount rate. It is standard practice to apply the same discount 
rate to costs and outcomes, and to maintain a constant rate over time. Discounting tends to have a 
greater impact on cost-effectiveness ratios for interventions where the costs occur upfront (little 
effect of discounting) but outcomes occur sometime later (such as in cancer screening or 
vaccination)(42). The preferred discount rate varies. In Australia, the discount rate nominated by the 
Pharmaceutical Benefits Advisory Committee is 5%(58).  
3.2.7 Additional considerations beyond CEA  
Policy relevance is greatly improved if cost-effectiveness information is combined with information 
on broader issues influence healthcare decisions, such as  
 capacity of the intervention to reduce inequity; 
 acceptability to stakeholders; 
 feasibility of implementation;  
 strength of the evidence base; 
 reach and size of impact; 
 sustainability; and 
 potential for other consequences (side effects). (59) 
This PhD has a particular interest in socioeconomic inequalities that exist in severe obesity and the 
effect of current interventions on these inequalities. In Australia, disadvantaged people have higher 
mortality and morbidity rates and are less likely to receive good health care at an early stage in an 
illness or disease (60). Socioeconomic inequalities are observed for many health-related indicators 
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for both males and females and are evident irrespective of how socioeconomic position is measured. 
The health burden in the Australian population attributable to socioeconomic disadvantage is large; 
and much of this burden is potentially avoidable(61). The National Health and Medical Research 
Council states that “it is important to ensure that people with low incomes have access to health 
care. Access to health services is multi-dimensional and includes availability, geographic access, 
affordability and acceptability”(62). Equity is increasingly being incorporated alongside cost-
effectiveness analysis. 
An approach known as multi-criteria analysis (MCA) is gaining popularity, to systematically assess 
and compare interventions relative to an explicit set of objectives (which may include effectiveness, 
cost and any other factors such as equity etc) identified by the authority. MCA provides a number of 
options for aggregating the data according to predefined criteria to provide indicators of the overall 
performance of options. A key feature of MCA is its emphasis on the judgement of the decision 
making team, in establishing objectives and criteria, estimating relative importance weights and, to 
some extent, in judging the contribution of each option to each performance criterion (63). 
3.3 Severe obesity  
3.3.1 Prevalence 
Obesity is emerging as the most important preventable risk factor for morbidity and mortality in 
many high income countries(3). dŚĞƉƌĞǀĂůĞŶĐĞŽĨ ďŽĚǇŵĂƐƐ ŝŶĚĞǆ ;D/Ϳ шϰϬ kg/m2 is increasing 
twice as fast as that for BMI 30–34.9 kg/m2 in the United States(64). Similar trends have been 
reported in Australia; between 1980 and 2000, ƚŚĞƉƌĞǀĂůĞŶĐĞŽĨŽďĞƐŝƚǇ;D/шϯϬŬŐͬŵ2) doubled, 
whilst the prevalence of obesity class-///;D/шϰϬŬŐͬŵ2) increased fourfold(65). The prevalence of 
D/шϰϬŬŐͬŵ2 Australia in 2000 was 0.5% in males and 2.4% in females (Figure 1). The population 
ǁŝƚŚĞŝƚŚĞƌĂD/шϰϬ kg/m2 or BMI 35-39.9 kg/m2 with an obesity-related morbidity is described as 
severely obese. 
Figure 1: Percentage of urban Australian adults aged 25-64 in each obesity category (based on 
BMI) in 1980 and 2000 
 
Source: Walls et al, 2010 
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3.3.2 Health risks 
As BMI increases above the healthy range (BMI 18.5-25 kg/m2), health risks increase 
exponentially(66). Three out of four ĂĚƵůƚƐǁŝƚŚĂD/шϰϬ kg/m2 have at least one obesity-related 
morbidity(67), with the risk of type 2 diabetes being particularly high (up to 93/42-fold higher for 
women/men relative to healthy-weight adults)(68, 69). A BMI of 40 or higher is associated with a 2-
fold higher risk for all-cause mortality than are BMIs of 30-34.9 kg/m2(70). 
3.3.3 Demographics 
A socioeconomic gradient in obesity, where greater prevalence of obesity is observed in more 
disadvantaged groups, has been reported in most developed countries(71). These socioeconomic 
gradients are generally more consistent and pronounced for women(72). Internationally, two 
previous studies have reported a greater risk of severe obesity in more socioeconomically 
disadvantaged groups(73) (74). However to our knowledge, no previous study has explored the 
relative or absolute differences in the prevalence of obesity classes I, II and III(3), across 
socioeconomic strata. 
3.3.4 Options for treating severe obesity 
Lifestyle and pharmacological interventions facilitate very modest and often poorly sustained weight 
loss in the severely obese(9, 75). In contrast, bariatric surgery is the only currently available option 
which facilitates significant and sustained weight reduction(76, 77). It is recommended that bariatric 
surgery be considered for eligible people who have failed to lose weight through less intensive 
methods such as dietary change, exercise and medication (78). Therefore bariatric surgery is the 
“facilitator” of successful weight loss assessed in this PhD. 
3.3.5 Utility-based quality of life  
The association between high body mass index (BMI) and low health-related quality of life is well 
established(79). However, few studies have employed utility-based quality of life (UQoL) 
instruments to assess this relationship in population samples. Three studies which have assessed this 
topic are summarised in Table 2. Significant reductions in UQoL associated with obesity in the 
general population are reported by all studies (range: 2-11.0% relative to healthy weight)(80-82). 
However, for all studies, bodyweight categories were based on self-reported height and weight 
which are often unreliable, particularly in obese persons(83). Furthermore, few studies stratify by 
obesity sub-classes (I-III) as defined by the World Health Organisation (WHO). Studies also frequently 
control for obesity-related morbidities, therefore utility weights reflect the loss associated to obesity 
per se and not its consequent morbidity. Obesity prevention is likely to prevent both obesity and 
associated morbidity so utility scores capturing both are warranted for use in economic evaluation.  
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3.3.6 Healthcare utilisation  
Increased healthcare costs are observed in the severely obese population, which range from 65-
113% higher relative to healthy-weight subjects(84-90). Nine studies addressing this topic are 
summarised in Table 3. Direct comparison of studies is limited due to different methodologies, 
particularly the healthcare costs included (which range from all healthcare resources to prescription 
pharmaceuticals only) and the time horizons for data collection (range from 1-8 years).  
However, previous studies examining healthcare costs in the severely obese have been limited by a 
reliance on patient self-reported healthcare utilisation data, which is often under-reported, 
particularly by those receiving more therapies(91), or by an absence of data stratified by therapeutic 
categories. Many studies also adopt bodyweight categories based on self-reported height and 
weight which are often unreliable, particularly in obese persons(83). Furthermore, most studies are 
from the USA context, and therefore the transferability of findings to setting with a universal health 
insurance, such as Australia is uncertain.  
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Table 2: Studies assessing utility-based quality of life in the overweight/obese general population 
Study (chronological) Methods Results 
 Study sample Height and weight 
data   
MAU 
instrument(s) 
Co-morbidities controlled 
for 
Impact of 
overweight*  
Impact of obesity* 
Trakas et al., 2001, 
Canada(82). 
N=38,151, age 
range 20-64. 
Self-reported HUI-III None Not significant  Significant mean utility loss; 4% 
for morbidly obese  
 
Jia and Lubetkin, 2005, 
USA(92) 
N=13,646 adults, 
age range: 
unspecified.  
Self-reported EuroQol EQ-5D 
and EQ-VAS  
Asthma, hypertension, 
diabetes, heart disease, 
stroke, emphysema 
Significant mean 
utility losses on 
1/2 measures; 
1.3% according 
to the EQ-5D. 
Significant mean utility loss on 
both measures; 3.3% for BMI 
30-35 and 7.3% for BMI>35 (EQ-
5D) and 3.2% for BMI 30-35 
4.8% for BMI>35 and (EQ-VAS). 
 
Sach et al., 2006, UK(81) N=1,612, age 
range: 45-99. 
Self-reported  EQ-5D, EQ-VAS 
and SF-6D. 
Back pain, hip pain, knee 
pain, heart disease, 
stroke, asthma, cancer, 
diabetes, rheumatoid 
arthritis, osteoarthritis. 
Not significant. 
 
Significant mean utility loss on 
all measures; 4% (EQ-5D), 3.8% 
(SF-6D) and 5.0% (EQ VAS). 
Table notes: MAU; multi-attribute utility, NR; not reported, HUI-III; Health Utilities Index Mark 3, *where raw results and results controlling for potential confounders are 
presented the latter are included in table. EQ-5D: EuroQol 5 dimension, EQ-VAS: EuroQol visual analogue scale, SF-6D: Short Form 6 dimension.
30 
 
Table 3: Healthcare costs associated with obesity (studies which stratify by obesity severity class) 
Study (stratified by  gender 
when available) 
 
Methods 
Sample size 
% by which costs are higher than 
for healthy weight group 
Author Country & 
reference 
year(s) 
Costs included*** 
Source 
for costs 
Time 
horizon 
(years) 
Height and 
weight 
Cl
as
s-
I 
Cl
as
s-
II 
 
Cl
as
s-
II/
III
  
Cl
as
s-
III
  
Cl
as
s-
I 
Cl
as
s-
II 
 
Cl
as
s-
II/
III
  
Cl
as
s-
III
  
Wee et al., 
2005(90) 
USA, 1998 Inpatient care, outpatient 
hospital care, ambulatory 
visits, emergency visits 
prescription medication. 
Self-
reported 
1 Measured 1,538 476 
 
236 35 44 
 
65 
Narbro et al.,  
2002 
(Swedish 
Obese 
Subjects)(88) 
Sweden, 
general; 1994-
1999, 
intervention: 
1987-1992 
Prescribed pharmaceuticals 
Self-
reported 
6 Measured 
  
1294 
   
77 
 
Quensenberry 
et al.,  
1998(89) 
US, 1993 Hospitalisations, laboratory 
services, outpatient visits, 
outpatient pharmacy and 
radiology services. 
Database 
linkage  
1 Self-reported 6,003 
 
896 
 
25 
 
44 78 
Arterburn et 
al.,  2005(85) 
US, 2000 Office and hospital based care, 
home healthcare, dental 
services, vision aids, prescribed 
medicines. 
Self-
reported 
1 Self-reported 2,534 893 
  
23 
 
45 81 
31 
 
Study (stratified by  gender 
when available) 
 
Methods 
Sample size 
% by which costs are higher than 
for healthy weight group 
Author Country & 
reference 
year(s) 
Costs included*** 
Source 
for costs 
Time 
horizon 
(years) 
Height and 
weight 
Cl
as
s-
I 
Cl
as
s-
II 
 
Cl
as
s-
II/
III
  
Cl
as
s-
III
  
Cl
as
s-
I 
Cl
as
s-
II 
 
Cl
as
s-
II/
III
  
Cl
as
s-
III
  
Durden et al.,  
2008(93) 
US, 2003-2005 Inpatient, emergency room, 
outpatient & outpatient 
pharmacy. 
Database 
linkage  
2 Self-reported 1,4826 
 
878 
 
22 
 
73 
 
Daviglus et 
al.,  2004 
males 
(females)(94) 
USA 1984-2002 Inpatient and outpatient care. 
Database 
linkage  
Eight 
Measured 
(note 
measurement 
was 20 years 
prior to 
healthcare 
data) 
1,430 
 
197 
 
41 (55) 
 
90 
(99)  
Finkelstein et 
al., 2005 
males 
(females)(95) 
USA, 2000-
2001 
  
Self-
reported 
2 Self-reported 3,050 1,118 
 
610 29 (55) 42 (79) 
 
117 
(110) 
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Study (stratified by  gender 
when available) 
 
Methods 
Sample size 
% by which costs are higher than 
for healthy weight group 
Author Country & 
reference 
year(s) 
Costs included*** 
Source 
for costs 
Time 
horizon 
(years) 
Height and 
weight 
Cl
as
s-
I 
Cl
as
s-
II 
 
Cl
as
s-
II/
III
  
Cl
as
s-
III
  
Cl
as
s-
I 
Cl
as
s-
II 
 
Cl
as
s-
II/
III
  
Cl
as
s-
III
  
Andreyeva et 
al.,  2004(84) 
USA, 
1996,1998 & 
2000 (2002 
reference 
price) 
Hospital costs,  nursing home, 
Costs, doctor visits costs,  
dentist costs, outpatient 
surgery costs, average 
monthly, prescription drug 
costs, home health care and 
special facilities cost 
Self-
reported 
3 Self-reported 3,556 932 
 
436 25 50 
 
100 
Hu et al., 
2008 males 
(females)(96) 
Taiwan, 2002-
2004 
Inpatient, outpatients, 
emergency services and 
prescription medication. 
Database 
linkage  
3 Self-reported 
  
513 
 
Males: 
39  
Females: 
75 
Males: 
45  
Females: 
78 
  
Notes: Class-I obesity: BMI 30-34.9, Class-II obesity: BMI 35-39.9, Class-IIII obesity: BMIш40. 
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3.4 Bariatric surgery 
3.4.1 Definition 
Bariatric surgery (weight loss surgery) includes a variety of procedures performed on people who 
are obese. Weight loss is achieved by reducing the size of the stomach with a gastric band or 
through removal of a portion of the stomach (sleeve gastrectomy or biliopancreatic diversion with 
duodenal switch) or by resecting and re-routing the small intestines to a small stomach pouch 
(gastric bypass surgery) (Figure 2).  
Bariatric surgical procedures have evolved dramatically over the past 50 years. During 2011, the 
most commonly performed procedures worldwide were Roux-en-Y gastric bypass (RYGB, 46.6%), 
vertical sleeve gastrectomy (27.8%), adjustable gastric banding (17.8%), and biliopancreatic 
diversion with duodenal switch (2.2%)(97). Since the 1990s, the standard surgical technique has 
shifted from an open incisional approach to an almost exclusive minimally invasive or laparoscopic 
approach, leading to dramatic improvement in safety(98). In the USA, laparoscopic sleeve 
gastrectomy has increased drastically as a proportion of total bariatric surgery procedures between 
2008 and 2012, leading to reduced use of laparoscopic adjustable gastric banding(99). 
In 2011-12, laparoscopic adjustable gastric banding (LAGB) was the dominant bariatric surgery 
procedure performed in Australia, accounting for 67% of the 14,065 bariatric surgery episodes 
(Figure 3). A similar trend as observed in the USA has been observed with sleeve gastrectomy 
becoming more popular in financial year 2014 (8375 cases) relative to laparoscopic adjustable 
gastric banding (3817 cases)(100). 
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Figure 2: Bariatric surgery techniques 
 
Notes: Horizontal gastroplasty; (B) vertical banded gastroplasty; (C) Roux-en-Y gastric bypass; (D) transected Roux-en-Y 
gastric bypass; (E) laparoscopic adjustable gastric band; (F) biliopancreatic diversion; (G) biliopancreatic diversion with 
duodenal switch; (H) vertical sleeve. Source: Arterburn and Courcoulas(98) 
Figure 3: Bariatric surgery by surgical type in Australia, 1993 - 2013 
 
Source: Medicare Benefits Schedule, items 30511, 30512 and 30518.
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3.4.2 Eligibility 
The use of bariatric surgery globally is largely governed by a US National Institutes of Health 
ĐŽŶƐĞŶƐƵƐ ƐƚĂƚĞŵĞŶƚ ǁŚŝĐŚ ĚĞĨŝŶĞƐ ĞůŝŐŝďůĞ ƉĂƚŝĞŶƚƐ ĂƐ ƚŚŽƐĞ ǁŝƚŚ Ă D/ шϰϬ ŬŐͬŵ2 Žƌ D/ шϯϱ
kg/m2 combined with a serious obesity-related morbidity(101). The same eligibility criteria apply in 
Australia as defined in the National Health and Medical Research Council (2013) clinical practice 
guidelines for the management of overweight and  obesity in adults, adolescents and children in 
Australia (102). Many groups have described these guidelines as outdated and recommend that a 
measure of glucose impairment (rather than BMI), be used to prioritize obese patients who can 
achieve the greatest health benefits from surgery (13, 103-106). These recommendations are based 
on published bariatric surgery clinical endpoints, including remission(106) and prevention of type 2 
diabetes(107) and the prevention of cardiovascular events(105) which favor patients with impaired 
fasting glucose or diabetes at baseline. These revisions are partially reflected in the recently revised 
National Institute for Health and Care Excellence (United Kingdom) obesity guidelines(108). 
It is recommended that bariatric surgery (when indicated) should be one component of an adult 
weight management program delivered by a multidisciplinary team including surgeons, dietitians, 
nurses, psychologists and physicians which also involves long-term follow-up(78). 
3.4.3 Outcomes 
The efficiency credentials of bariatric surgery are now strong. In an Australian trial setting, surgical 
and conventional therapy groups lost a mean of 20.7% and 1.7% of initial weight, respectively, at 2 
years(109). Findings from the Swedish Obese Subjects study over twenty years find that weight loss 
is largely sustained(110). Bariatric surgery leads to improvements in a range of hard end-points, 
including mortality(17), type 2 diabetes prevention(107), type 2 diabetes remission(111-114), 
reduced cancer and reduced cardiovascular events(114). 
3.4.4 Utilisation in Australia 
Bariatric surgery treatment rates have increased dramatically over the past fifteen years from 3935 
episodes in 1999 to 14,065 episodes in 2012 (a 3.6-fold increase, Figure 4). In 2011-12͕  ๝14,000 
bariatric surgery procedures were undertaken nationally in Australia. The majority of surgeries were 
performed in private hospitals in Australia (90% of all 2011-12 episodes) (Source: National Hospital 
Morbidity database). Therefore patients typically require:  
 WƌŝǀĂƚĞŚĞĂůƚŚŝŶƐƵƌĂŶĐĞĐŽǀĞƌĂŐĞ;у AUD $1,500-$2,000 per annum for necessary coverage) 
 KƵƚŽĨƉŽĐŬĞƚĨĞĞ;у AUD $4,000) 
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Figure 4: Bariatric surgery treatment rates in Australia, 1999-2012
 
Source: National Hospital Morbidity database
3.4.5 Healthcare utilisation changes after weight loss in the severely obese 
Previous literature around healthcare utilisation changes after bariatric surgery in severely obese 
subjects is assessed in three categories corresponding to the type of healthcare utilization assessed 
(inpatient (hospitalization), outpatients and pharmaceuticals). 
Inpatient (hospitalisation). Three previous studies have explored rates of hospitalisation after 
bariatric surgery relative to a control group or pre-surgical comparator. Five hundred patients 
recruited to the bariatric surgery and control group arms of the Swedish Obesity Subjects Study 
(SOS) between 1987-1991 had cumulative hospital stays of 23.4 and 6.9 days respectively over 5 
years22. A more recent study, which analysed inpatient hospital admissions for approximately 60,000 
patients 3 years before and 3 years after undertaking Roux-En-Y Gastric Bypass (RYGB) in Californian 
hospitals (1995-2004) reported cumulative admission rates of 20.2% and 40.4% respectively23. Both 
studies reported that the majority of excess costs were related to revisional surgeries and some 
plastic surgery. In contrast, a Canadian study found lower hospital costs in surgically treated subjects 
(5y follow-up)(115). However, its control group had a much worse prognosis than in other 
studies(17) (Table 4).  
Table 4: Studies analysing hospitalization after bariatric surgery  
Study Context Design Follow up 
period (years) 
Results 
Sampalis et 
al., 2004(115) 
Canada, 
all 
bariatric 
surgery 
1,035 bariatric 
surgery 
patients and 
5,746 matched 
5 years Bariatric surgery patients had higher total costs 
for hospitalizations (per 1,000 patients) in the 
first year following cohort inception (surgery 
cohort = CDN 12,461,938 dollars; control 
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Study Context Design Follow up 
period (years) 
Results 
types controls cohort = CDN 3,609,680 dollars). At 5 years 
after cohort inception, average cumulative 
costs for operated patients were CDN 
19,516,667 dollars versus CDN 25,264,608 
dollars, for an absolute difference of almost 
CDN 6,000,000 dollars per 1,000 patients.  
Zingmond et 
al., 
2005(116) 
USA, 
Gastric 
bypass 
60,000 6 years (3 years 
before vs 3 
years after) 
In California from 1995 to 2004, 60,077 
patients underwent RYGB-11,659 in 2004 
alone. The rate of hospitalization in the year 
following RYGB was more than double the rate 
in the year preceding RYGB (19.3% vs 7.9%, 
P<.001). Furthermore, in the subset of patients 
(n = 24,678) with full 3-year follow-up, a mean 
of 8.4% were admitted a year before RYGB 
while 20.2% were readmitted in the year after 
RYGB, 18.4% in the second year after RYGB, 
and 14.9% in the third year after RYGB. The 
most common reasons for admission prior to 
RYGB were obesity-related problems (eg, 
osteoarthritis, lower extremity cellulitis), and 
elective operation (eg, hysterectomy), while 
the most common reasons for admission after 
RYGB were complications often thought to be 
procedure related, such as ventral hernia 
repair and gastric revision.  
Agren et al., 
2002 22 
Sweden, 
all 
bariatric 
surgery 
types 
481 surgical, 
455 controls 
6 years The cumulated hospital stay over 6 years was 
23.4 days in the surgical group and 6.9 days in 
the control group (p < 0.0001). The average 
hospital cost for the surgical intervention was 
USD4300. Incremental costs that could be 
attributable to obesity surgery averaged 
USD1200 per year. After exclusion of 
hospitalizations for the surgical intervention 
and conditions common after bariatric surgery, 
there were no significant differences between 
the groups in number of hospital days or 
hospitalization costs. 
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Pharmaceutical. Several previous studies have compared pharmaceutical costs before and after 
bariatric surgery(117-126) as summarised in Table 5. Previous studies assessing the impact of 
bariatric surgery on pharmaceutical utilisation and costs are from the United States and Sweden.  
Studies from the US report an overall reduction in pharmaceutical utilisation (or costs) after surgery 
(or relative to control subjects) up to six years after bariatric surgery, driven by large decreases in 
therapies to treat diabetes and cardiovascular disease(117-123, 125, 126). However, transferability 
of these results to other settings, particularly those with a universal health insurance system, is 
uncertain. Furthermore, follow-up timeframes were relatively short (range 0.5-3 years) and sample 
sizes were modest (range 50-400). 
The Swedish Obese Subjects Study (SOS) provides the only results based on prospectively collected 
data for both a bariatric surgery and a matched control group. The SOS study also observed 
ƐŝŐŶŝĨŝĐĂŶƚƌĞĚƵĐƚŝŽŶƐŝŶƚŚĞĚŝĂďĞƚĞƐ;оϲϵйͿĂŶĚĐĂƌĚŝŽǀĂƐĐƵůĂƌĚŝƐĞĂƐĞ;оϯϭйͿƚŚĞƌĂƉŝĞƐ͕ďƵƚĨŽƵŶĚ
that these were offset by increased utilisation of therapies to treat gastro-intestinal reflux disease 
and anaemia over six years(88). The SOS results relate to data collected in the late eighties and early 
nineties. Changes in bariatric surgery procedures, including the widespread adoption of arthroscopic 
techniques since this time(127), introduce uncertainty regarding the transferability of results to 
bariatric surgery today.  
Table 5: Literature summary - Pharmaceutical utilisation after bariatric surgery 
Study Context Design Follow up 
period 
(years) 
Results 
Monk 2004(121) USA, RYGB 64 patients 
Pre-post study 
design 
Not 
reported 
Mean monthly expenditure on medications 
decreased from USD $1801 to $135  
Gould 2004(125) USA, LAGB 50 patients 
Pre-post study 
design 
6 months 3.7 prescription medications before surgery, 
1.7 after surgery 
Snow 2004(117) USA, RYGB 78 patients 
Pre-post study 
design 
2 years Mean monthly expenditure on medications 
decreased from  USD $368 (pre-surgery) to 
$118 (1 year), 104 (2 years)  
Malone 
2005(122) 
USA, RYGB 114 patients 
Pre-post study 
design 
2 years Drug therapy for diabetes and hypertension 
was significantly reduced. All patients were 
required to take nutritional supplements post-
operatively.  
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Study Context Design Follow up 
period 
(years) 
Results 
Nguyen 
2006(120) 
USA, RYGB 77 patients 
Pre-post study 
design 
12 
months 
Mean monthly expenditure on medications 
decreased from $196 (pre-surgery) to $54 (1 
month). Savings over 1 year $2016. 
Gastrointestinal reflux љϴϭй͕Diabetes љϲϵй͕
hyperlipidemia љϱϯй͕ŚǇƉĞƌƚĞŶƐŝŽŶљϰϯ 
Hodo 2008(128) USA, 
Surgery 
type not 
reported 
N=? 
Pre-post study 
design 
6 months Mean 6-monthly expenditure on medications 
decreased from $221 (pre-surgery) to $158 (1 
year)  
Segato 2010(118) USA, LAGB 394 patient with 
T2D 
Pre-post study 
design 
3 years Use of diabetes medication: Increased 7.7%, 
Unchanged 23.1%, Decreased 32.7%, 
Suspended 36.5%  
Cremieux, 
2010(126) 
USA, 
bariatric 
surg 
5,502 
Pre-post study 
design 
Approx 3 
years 
Frequency of medication use decreased 
significantly for a number of conditions 
including infections, pain, respiratory, 
cardiovascular, gastroenterologic, lipidemic, 
and diabetic conditions. Anemia, however, 
increased from 3.8% to 9.9%, and use of 
nutritional supplements increased significantly. 
Makary, 
2010(123) 
USA, 
bariatric 
surg 
2,235 adults with 
diabetes and  
Pre-post study 
design 
Four years Reduction of use was observed in all classes of 
diabetes medications. The median cost of the 
surgical procedure and hospitalization was 
$29,959. In the 3 years following surgery, total 
annual health care costs per person increased 
by 9.7% ($616) in year 1 but then decreased by 
34.2% ($2,179) in year 2 and by 70.5% ($4,498) 
in year 3 compared with a preoperative annual 
cost of $6,376 observed from 1 to 2 years 
before surgery 
Segal, 2009(129) USA, 
bariatric 
surg 
6,235 bariatric 
surgery subjects  
Matched controls 
3 years By 12 months after surgery, medication use for 
diabetes, hypertension, and hyperlipidemia had 
declined by 76%, 51%, and 59%, respectively. In 
contrast, thyroid hormone, antihistamine, and 
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Study Context Design Follow up 
period 
(years) 
Results 
antidepressant use decreased by only 6%, 15%, 
and 9%, respectively. 
Potteiger, 
2004(119) 
US, RYGBP 51 subjects 1 year Preoperatively, patients were on an average of 
2.44 +/- 1.86 medications at a cost of 187.24 
USD +/- 237.41 USD per month. 
Postoperatively, the mean number of 
medications was reduced to 0.56 +/- 0.81 
agents (P<0.001) at a monthly cost of 42.53 
USD +/- 116.60 (P<0.001). Conclusions: RYGBP 
can decrease the prescription medication 
requirements, resulting in significant cost-
savings in the treatment of obesity-related 
hypertension and diabetes. This study found a 
77.3% reduction in total cost of diabetic and 
anti-hypertensive medications. 
 
Outpatient. No previous studies specifically review the impact of bariatric surgery on the utilisation 
of outpatient care. 
Total healthcare costs after bariatric surgery (return on investment). There is substantial variation 
in results from these studies ranging from a result that the costs associated to bariatric surgery are 
recouped within two years (130), through to bariatric surgery not resulting in any reduction in 
overall health care costs in the long term (131). The return on investment for bariatric surgery is 
driven by 3 factors: 
 the cost of the surgical procedures, 
 the healthcare utilisation and cost pathway of patients receiving bariatric surgery, and  
 the “hypothetical” healthcare utilisation and cost pathways for patients receiving bariatric 
surgery if they had not received the surgery.   
Results for drivers a) and b) are more visible through the analysis of claims data. However, driver c) 
is methodologically difficult to predict in the absence of a randomised trial with both an intervention 
and control group. The variability in the return on investment results is hence likely to be driven by 
different approaches to the identification of a control group. One study utilised the morbid obesity 
code as part of the criteria for selecting controls (130). This group is certainly eligible for surgery, 
however, they may be a very high risk/cost subgroup of the population eligible for bariatric surgery 
and consequently not representative of the pathways for bariatric surgery patients had they not 
undertaken the procedure (132).  
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Furthermore, it appears that the studies which match controls according to pre-surgical 
expenditures in the year before surgery lead to more favourable return on investment results. A 
future study with a stronger control group methodology is needed to provide greater certainly 
regarding the return on investment from bariatric surgery. 
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Table 6: Literature summary – studies assessing total healthcare costs after bariatric surgery 
Study Surgery patients 
profile 
Control group methods Data source Findings 
Finkelstein et 
al(132), USA, 
2013 
Mean age 44 years, 
79% female.  
9,631 LAGB, 9631 
RYGB, 9631 matched 
controls. 
 
Propensity score matched (variables: age, 
gender, type of health plan, year of 
surgery, presence of obesity related or 
highly prevalent comorbidities (diabetes, 
asthma, arthritis, hypertension, sleep 
apnea, dyslipidemia, migraines, and 
chronic obstructive pulmonary disease), 
and inpatient and total costs in each 
quarter of the match period. 
Medical claims data from a 
commercial database. 
Duration of follow-up not 
reported. 
Time to ”breakeven” 
(achieve threshold for cost 
saving) for LAGB 5.25 years 
and for  LRYGB 10 years  
Cremieux et al, 
2010, USA (130) 
3651 adult bariatric 
surgery patients and 
3651 matched 
controls. 
Demographics not 
reported. 
Bariatric surgery patients and controls 
were matched based on 
patient demographics, selected 
comorbidities (including morbidly 
obesity), and costs. 
Privately insured 
administrative claims 
database containing medical 
and drug claims from 1999 
through 2005 covering more 
than 5 million lives from 31 
large.  
The mean bariatric 
surgery investment ranged 
from approximately $17,000 
to $26,000. All costs 
recouped within 2 years for 
laparoscopic surgery patients 
and within 4 years for 
open surgery patients. 
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Study Surgery patients 
profile 
Control group methods Data source Findings 
Weiner et al, 
USA, 2013(133) 
29 820 plan 
members who 
underwent bariatric 
and a 1:1 matched 
comparison group of 
persons not 
undergoing surgery 
but with diagnoses 
closely associated 
with obesity. 
Mean age 46 years, 
80% female. 
Insurance enrolment characteristics and 
33 condition markers derived from claims 
diagnoses or medication use that were 
statistically linked with a BMI of 35 or 
higher.  
Seven BlueCross BlueShield 
health insurance plans with a 
total enrolment of more 
than 18 million persons. 
2002-2008 claims data. 
Total costs were greater in 
the bariatric surgery group 
during the second and third 
years following surgery but 
were similar in the later 
years. Bariatric surgery does 
not reduce overall health 
care costs in the long term.  
Maciejewski, 
USA, 2012 (131) 
Eight hundred forty-
seven veterans who 
were propensity 
matched to 847 
nonsurgical control 
subjects from the 
same 12 VA medical 
centres. 
Presurgical age, age squared, baseline 
comorbidity via the Diagnostic Cost 
Group score, baseline BMI, BMI squared, 
BMI cubed, sex, race, marital status, 
Veterans Integrated Service Networks, 
and numerous 2-way interactions.  
Outpatient, inpatient, and 
overall health care 
expenditures within 
Department of Veterans 
Affairs (VA) medical centres. 
 
Outpatient, inpatient, and 
total expenditures trended 
higher for bariatric surgical 
cases in the 3 years leading 
up to the procedure and 
then converged back to the 
lower expenditure levels of 
nonsurgical controls in the 3 
years after the procedure 
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Studies relating to patients with diabetes prior to surgery. Studies examining the effect of bariatric 
surgery on healthcare costs in patients with diabetes report mixed results. One study examined 
health insurance claims data for patients with diabetes receiving bariatric surgery and matched non-
surgical controls and reported cost-savings for surgery patients 4-10 years after surgery (depending 
on the surgical procedure)(132). Two previous studies assessed health insurance claims for patients 
with diabetes before and after bariatric surgery. Relative to the year prior to surgery, one study 
observed an overall decrease in health care costs over three years(123); whilst the other study 
observed similar costs in the six years after surgery(134). However, omission of a non-surgery 
comparison group means that differences relative to the alternative clinical pathway of conventional 
medical care (often associated with intensification of therapies over time(135), could not be 
quantified. No previous prospectively controlled studies have assessed long-term health care use in 
bariatric surgery patients according to their glucose status prior to intervention. 
3.5 Cost and cost- effectiveness of interventions  
Bariatric surgery is an expensive therapy costing USD15-24,0005 (136), AUD12,0006 (2), GBP 6,500-
9,3007 (137) in the first year. Cost-effectiveness analysis (CEA) is uniquely placed to analyse the 
trade-offs between the high upfront costs of bariatric surgery, its strong effectiveness results, and its 
potential to save future health care treatment costs.  
Systematic  reviews report that bariatric surgery is cost-effective relative to conventional therapy for 
treating severe obesity in the currently eligible population (1, 137, 138). However, issues across all 
studies include: 
 Assumed intervention pathways (including complication rates);  
 Reliance on “modelled” long-term health outcomes (including utility weights, mortality rates)  
 Reliance on “modelled” long-term cost offsets.  
Type 2 diabetes is remitted or improved in the majority of patients after bariatric surgery (111). To 
date, six CEAs comparing bariatric interventions to standard therapy for patients with type 2 
diabetes have been published(1, 2, 59, 62, 136, 137, 139), but no reviews have been undertaken. 
Three studies are excluded from this brief appraisal due to methodological limitations (59, 62, 139); 
either the time horizon for analysis (5 years) was considered too short to capture relevant costs and 
benefits or modelling inputs were sourced from unpublished data relating to a cohort with poor 
follow-up. A brief summary of methods for the three CEAs with more robust methods follows in 
Figure 5.  Study results are summarised in Table 7. 
 
 
5 Gastric banding, Gastric bypass, USA 2005. In 2005: 1 Euro = 1.21USD.  
6 Gastric banding, Australia 2006. In 2006: 1 Euro = 1.72AUD. 
7 Gastric banding, Gastric bypass, UK 2006. In 2006: 1 Euro = 0.69GBP 
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Figure 5: Overview of study methods (in chronological order) 
STUDY 1: Keating et al., Diabetes Care 2009 (1, 2) 
SETTING – Australia; Currency: AUD2006 
POPULATION - Recently diagnosed Type 2 Diabetes & BMI 30-40 (mean 37), mean age 49. 
COMPARATORS – Laparoscopic adjustable gastric banding (LAGB) vs conventional therapy over lifetime. 
METHODS - This study built on a Randomised Controlled Trial (RCT) by Dixon et al.(109). Observed data was 
collected for the two year trial period including: diabetes remission rates (73% LAGB & 13% conventional 
respectively), intervention pathways (including bariatric complications) and associated costs (AUD13,400 & 
AUD3,400 per patient respectively). Modelling was utilised to extrapolate results over the lifetime of the 
cohort. The durability of diabetes remission (mean 13 years), excess healthcare costs for patients with type 2 
diabetes (mean $2,860, based on age/sex/duration of disease), mortality rates and utility weights (based on 
diabetes status) were sourced from the published literature. Lifetime intervention pathways (LAGB 
maintenance and complications) were estimated based on observations during the trial and published data. 
The model estimated lifetime costs (intervention & type 2 diabetes treatment) and effectiveness (years in 
diabetes remission, life years and quality-adjusted-life years (QALYs)). Only the benefits of type 2 diabetes 
remission were captured within the analysis. Conventional therapy reflected the best available medical 
management. 
STUDY 2: Hoerger et al., Diabetes Care, 2010 (136) 
SETTING – USA, Currency: USD2005 
POPULATION – BMI>35 plus either: recent onset diabetes (aged 35-74), or established diabetes (aged 45-74). 
COMPARATORS: Gastric banding (not further defined) vs standard care for both recent & established diabetes, 
gastric bypass vs standard care for both recent & established diabetes over lifetime. 
METHODS: This study expanded the Center for Disease Control and Prevention–RTI Diabetes Cost-
Effectiveness Model (140) to incorporate bariatric surgery. The model simulated development of diabetes-
related complications on three microvascular disease paths (nephropathy, neuropathy, and retinopathy) and 
two macrovascular disease paths (coronary heart disease and stroke) and estimated disease complications, 
deaths, diabetes costs and quality-adjusted life-years (QALYs). Estimated rates of remission from diabetes after 
bariatric surgery (recent onset diabetes: banding 56.7% and bypass 80.3%, established diabetes: 40% for both 
bariatric procedures), duration of remission (mean 10 years), blood pressure and cholesterol after bariatric 
surgery and bariatric intervention costs (including complications) were sourced from the literature and 
entered into the model. Standard care was defined as tight glycemic control similar to that provided in the UK 
Prospective Diabetes Study (141). 
STUDY 3: Picot et al., Health Technology Assessment, 2009 (137) 
This study modelled the cost-effectiveness of the RCT treatment effect reported by Dixon et al. 2008. The 
study made assumptions regarding the intervention pathways based on descriptions reported in the RCT 
manuscript. Keating et al. (1, 2) had direct access to the RCT data, and therefore its intervention costings are 
more reliable. The report (60 pages) includes many analyses of bariatric surgery options, and it is difficult to 
quickly identify the data parameters utilised in the type 2 diabetes analysis.  This study estimated the mean 
duration of diabetes remission to be 10 years. 
Table Note: All three studies adopted a healthcare perspective and discounted cost and benefits at 3.0/3.5%. 
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Table 7: Study results 
Study Type 2 
Diabetes 
status 
Total 
costs 
QALYs Incremental cost-
effectiveness 
ratio (ICER), Cost 
per QALY 
Cost-
effectiveness 
threshold / 
interpretation  
Keating et al., Australia, 
AUD 2006, lifetime 
    AUD50,000 
Standard care*  Recent onset 101,376 14.5 - - 
Banding surgery  Recent onset 98,931 15.7  (ICER N/A) 
Save $2,444 
Generate 1.2 
QALYs 
Dominant 
Hoerger et al., USA, USD 
2005, lifetime 
    US50,000 
Standard care*  Recent onset 71,130 9.55 - - 
Bypass surgery  Recent onset 86,655 11.76 7,000 Very CE 
Banding surgery  Recent onset 89,029 11.12 11,000 Very CE 
Standard care* Established 79,618 7.68   
Bypass surgery  Established 99,944 9.38 12,000 Very CE 
Banding surgery  Established 96,921 9.02 13,000 Very CE 
Picot et al., UK, € 2006, 20 
years 
    £20-30,000 
Standard care*  Recent onset 31,683 10.39 - - 
Banding surgery  Established 33,182 11.49 1,367 Very CE 
Table notes: *Base case; QALY: Quality-adjusted-life-years. In mid 2006: 1 Euro = 1.72AUD, 0.69GBP, 1.28 USD, CE Cost-effective.  
All three studies found bariatric surgery to be either very cost-effective or dominant as a therapy for 
type 2 diabetes relative to standard therapy. The finding of “cost-effectiveness” indicates that health 
benefits are achieved at an acceptable price relative to country-specific cost-effectiveness 
thresholds. The “dominant” result indicates that an intervention generates both cost savings and 
health benefits over the lifetime of the cohort. This is a rare outcome and provides the most 
compelling evidence for funding based on economic criteria. 
The Hoerger et al. and Keating et al. studies only captured the benefits associated with diabetes 
remission. In other words, the benefits of weight loss on other obesity-related co-morbidities were 
excluded. Therefore results for both studies are likely to be conservative. 
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Results reported by Keating et al. were slightly more favourable than the other two studies. 
Differences are likely to be largely attributable to: 
 Keating et al. & Picot et al. adopted higher diabetes remission rates for patients receiving 
gastric banding. (Keating et al. rate: 73% as observed in associated RCT (109), Hoerger et al. 
rate: 56.3% sourced from published meta-analyses (111).) 
 Keating et al. assumed longer “durability” of diabetes remission. (Keating et al. assumption: 
13 years which was an estimate between result reported by SOS (mean 10 years) (142) & 
Greenville series (85% remain remitted at 16 years) (143); remaining studies assumed 10 
years based on the SoS study(142)). 
 Hoerger et al. and Picot et al. included cost savings related to “major complications” of type 2 
diabetes, whereas Keating et al. included “all costs” associated with type 2 diabetes. 
Therefore costs included by Keating et al were more comprehensive and includes resources 
associated to ongoing management, surveillance and medications as well as complications. 
 Picot et al. modelled results over 20 years, rather than a lifetime (Cost-effectiveness 
improves with a longer time horizon).  
The studies were undertaken based on healthcare costs and other country-specific data points from 
three different settings (USA, UK & Australia). The transferability of results is informed by whether 
CEA assumptions and data hold true in other settings. The major driver of cost-effectiveness results 
is the estimated diabetes remission rate.  Hoerger et al. sourced diabetes remission rates from a 
meta-analyses of bariatric surgery studies published between 1990–2006 (111). Keating et al. 
sourced remission rates from a RCT undertaken in 2005-06 which compared bariatric surgery to 
conventional therapy for a group of severely obese patients with recently diagnosed type 2 
diabetes(109). 
It is likely that for some settings, the remission rates adopted by Hoerger et al. may be outdated as 
the efficiency of bariatric interventions has improved over this time period. The comparison of the 
cost-effectiveness of gastric banding relative to gastric bypass undertaken by Hoerger et al. is also 
conditional upon the relevance of these data in the contemporary clinical context. This is particularly 
relevant for gastric banding which has changed from fixed to adjustable since the 1990’s.   
Keating et al. sourced costs and benefits from a RCT where patients were provided surgical therapy 
by a clinical team with many years of experience (demonstrated by short operating times and low 
complication rates). Therefore, the results reflect cost-effectiveness in best practice clinical settings, 
which may not be transferable to bariatric surgery in some settings. Results are also only 
transferable to patients with moderate obesity and recent onset type 2 diabetes. 
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In summary:  
 Bariatric interventions for treating type 2 diabetes have been reported to be (at least) very cost-
effective in the USA, UK and Australian settings.  
 An Australian study which extrapolated results from a RCT comparing surgical to conventional 
therapy for moderately obese patients with recent onset type 2 diabetes found bariatric surgery 
to be a dominant intervention. This result suggests that under best practice clinical conditions, 
bariatric interventions have the potential to save healthcare costs and generate health benefits 
over the lifetime of the cohort. 
 Bariatric interventions have been demonstrated to be very cost-effective as a therapy for 
patients with both recent onset and established type 2 diabetes. 
 There is currently insufficient evidence to recommend which bariatric procedure is the most 
cost-effective therapy for obese patients with type 2 diabetes. 
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4 Methods and Results 
4.1 Introduction 
This thesis is submitted as a PhD by publication. Therefore, to avoid duplication I wish to refer 
readers to the results and methods (including strengths and weaknesses) described in the individual 
publications. The methods and results are also summarised in Table 9. This chapter presents all of 
the publications constituting my thesis.  In total I have published: 
 8 lead author original research publications (format: 5 long format, 3 short format). These 
manuscripts are published in high quality peer-reviewed academic journals including 
International Journal of Obesity, Obesity, and JAMA Surgery.  
 2 lead author letters relating to my PhD topic in The Lancet and The Lancet Diabetes and 
Endocrinology. 
 1 manuscript directly related to my PhD topic as a co-author in Journal of the American 
Medical Association (JAMA).  
4.2 Collaborations 
During my PhD I have been fortunate enough to collaborate with 17 researchers who have provided 
critical intellectual contributions to each manuscript. Author contributions are summarised in 
Appendix 2. My co-authors span several countries and come from the following institutions: 
 Deakin University, Melbourne, Australia 
 Monash University, Melbourne, Australia 
 University of Auckland, Auckland, New Zealand 
 Baker IDI Heart and Diabetes Institute, Melbourne, Australia 
 Karolinska Institute, Stockholm, Sweden 
 Department of Healthcare, Region VastraGotaland, Gothenburg, Sweden 
 Gothenburg University, Gothenburg, Sweden 
 National Institute for Health and Welfare, Helsinki, Finland 
4.3 Data sources 
My PhD research is based on analysis of three intervention studies, one national health survey 
(multiple time points) and three healthcare utilisation administrative databases as follows: 
 The Australian Diabetes, Obesity and Lifestyle (AusDiab) study 
 Obesity Prevention in Communities (OPIC) Project (Australian context) 
 Swedish Obese Subjects (SOS) Study 
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 Australian Bureau of Statistics National Health Surveys 
 Australian Institute of Health and Welfare National Hospital Morbidity database 
 Medicare Medical Benefits Schedule (MBS) (Australian context) 
 Medicare Pharmaceutical Benefits Schedule (PBS) (Australian context) 
4.4 Publications overview 
Manuscript citations, status and other details are summarised in Table 7. Each publication is inserted 
into this chapter in its format at the time of submission of this PhD (published PDF if manuscript is 
published, MS Word document submitted if manuscript is under review). All but one of the 11 
publications are now published. Publications are presented in order of the PhD streams, to provide a 
sense of the overall PhD “story”, rather than in chronological order of publication. A table 
synthesising manuscript methods, results (technical), results (lay), significance and innovation for my 
lead author original research publications is also provided in Table 8 to provide an overview of the 
overall body of research.  
51 
 
Table 8: Summary of publications constituting PhD thesis 
No. Manuscript citation Summary 
status  
Format Data source  Stream 
1 Keating C, Backholer K, Gearon E, 
Stevenson C, Swinburn B, Moodie M, 
Carter R, Peeters A. Prevalence of class I, 
II and III obesity 1995 to 2011/12 in 
Australia, Obesity Research and Clinical 
Practice. 2015 Mar 3. pii: S1871-
403X(15)00024-1. doi: 
10.1016/j.orcp.2015.02.004. [Epub 
ahead of print] 
Published Original 
article 
(long) 
Australian 
Bureau of 
Statistics 
National 
Health 
Surveys  
1 (Prevalence) 
2 Keating C, Backholer, Peeters A. Global, 
regional, and national prevalence of 
overweight and obesity in children and 
adults during 1980—2013: a systematic 
analysis for the Global Burden of 
Disease Study 2013 (correspondence). 
The Lancet, Volume 384 , Issue 9960 , 
2107 – 2108, 
doi: http://dx.doi.org/10.1016/S0140-
6736(14)62367-9. 
Published Letter N/A 1 (Prevalence) 
3 Keating, C. L., Peeters, A., Swinburn, B. 
A., Magliano, D. J. and Moodie, M. L. 
(2013), Utility-based quality of life 
associated with overweight and obesity: 
The Australian Diabetes, Obesity, and 
Lifestyle study. Obesity, 21: 652–655. 
doi: 10.1002/oby.20290 
Published Original 
article 
(short) 
The Australian 
Diabetes, 
Obesity and 
Lifestyle study 
2 (Utility) 
4 Keating CL, Moodie ML, Richardson J, 
Swinburn BA. Utility-based quality of life 
of overweight and obese adolescents. 
Value Health. Jul-Aug 2011;14(5):752-
758. 
Published Original 
article 
(long) 
Obesity 
Prevention in 
Communities 
Project 
(Australia) 
2 (Utility) 
5 Keating, C. L., Moodie, M. L., Bulfone, L., 
Swinburn, B. A., Stevenson, C. E. and 
Peeters, A. (2012), Healthcare Utilization 
and Costs in Severely Obese Subjects 
Before Bariatric Surgery. Obesity, 
20: 2412–2419. 
doi: 10.1038/oby.2012.124 
Published Original 
article 
(long) 
Medicare 
(Australia’s 
National 
Health 
Insurer)  
3 (Healthcare 
burden) 
6 Keating CL, Peeters A, Swinburn BA, 
Carter R, Moodie ML. Pharmaceutical 
utilisation and costs before and after 
bariatric surgery.  International Journal 
of Obesity 37, 1467–1472; 
doi:10.1038/ijo.2013.24 
Published Original 
article 
(long) 
Medicare 
(Australia’s 
National 
Health 
Insurer)  
4 (Healthcare 
burden after 
treatment) 
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No. Manuscript citation Summary 
status  
Format Data source  Stream 
7 Keating CL, Ananthapavan J.  Revisional 
Surgery after Laparoscopic Adjustable 
Gastric Banding in a National Australian 
Cohort JAMA Surg. 2014;149(8):874-
875. doi:10.1001/jamasurg.2014.93 
Published Original 
article 
(short) 
Medicare 
(Australia’s 
National 
Health 
Insurer)  
4 (Healthcare 
burden after 
treatment) 
8 Neovius M, Narbro K, Keating C, 
Peltonen M, Sjöholm K, Agren 
G, Sjöström L, Carlsson L. Health Care 
Use During 20 Years Following Bariatric 
Surgery. JAMA. 2012;308(11):1132-
1141. doi:10.1001/2012.jama.11792 
Published Original 
article 
(long) 
Swedish 
Obese 
Subjects (SOS) 
Study 
4 (Healthcare 
burden after 
treatment) 
9 Keating C, Neovius M, Sjoholm K, 
Peltonen M, Narbro K, Eriksson J, 
Sjostrom L, Carlsson L. Pre-Operative 
Glucose Status and Health Care Use 
During 15 Years Following Bariatric 
Surgery, Under  review. 
Under review Original 
article 
(long) 
Swedish 
Obese 
Subjects (SOS) 
Study 
5 (Efficiency) 
10 Keating C, Peeters A, Neovius M. 
Beyond BMI: the need for new 
guidelines governing the use of bariatric 
and metabolic surgery 
(correspondence). The Lancet Diabetes 
& Endocrinology. 2014;2(6):448-9. 
Published Letter N/A 5 (Efficiency) 
11 Keating C, Backholer K, Stevenson C, 
Moodie M and Peeters A. Differences in 
the Rate of Bariatric Surgery across 
Socio-economic Groups. JAMA Surgery. 
2015 Apr 1;150(4):367-8. doi: 
10.1001/jamasurg.2014.3180. 
Published Original 
article 
(short) 
Australian 
Bureau of 
Statistics 
National 
Health 
Surveys and 
National 
Hospital 
Morbidity 
database. 
6 (Equity) 
 
 
 
53 
 
 
Table 9: Summary of first author original research publication methods, results and implications 
Manuscript title and Methods Results (technical) Results (lay) Significance Innovation  
Keating C, Backholer K, Gearon E, 
Stevenson C, Swinburn B,  Moodie 
M, Carter R, Peeters A. Prevalence 
of Class-I, II and III obesity 1995 to 
2011/12 in Australia, Obesity 
Research and Clinical Practice,  in 
press. 
Prevalence data were sourced from 
the nationally representative 
National Nutrition Survey (1995) and 
the National Health Surveys (2007-08 
and 2011-12) for the population 
aged 18 years and over. Obesity 
classifications were based on 
measured height and weight (class-I 
body mass index: 30.0-34.9 kg/m2, 
class-II: 35.0-39.9 kg/m2 and class-III: 
шϰϬ͘Ϭ ŬŐͬŵϮͿ͘ ^ĞǀĞƌĞ ŽďĞƐŝƚǇ ǁĂƐ
defined as either class-II or class-III 
obesity. 
Between 1995 and 2011-12, the 
prevalence of obesity (all classes) 
increased from 19.1% to 27.2%. 
Relative increases in Class-I, II and III 
obesity were 1.3-, 1.7- and 2.2-fold 
respectively.  
In 2011-12, out of every 100 men, 
19.4, 5.9 and 2.0 were class-I, II and III 
obese respectively. Corresponding 
figures for women were 16.1, 6.9 and 
4.2. 
The prevalence of class-I obesity 
generally decreased with decreasing 
levels of disadvantage, ranging from 
19.3% in quintile 1 (most 
disadvantaged) to 14.1% in quintile 5 
(least disadvantaged). Corresponding 
figures for class-II obesity were 8.6% 
and 5.5%; and for class-III obesity 4.8% 
and 1.7%. The relative risks of class-I, II 
and III obesity in the most 
disadvantaged group, relative to the 
least disadvantaged group were 1.4, 
1.9 and 2.8 (all p<0.05). Similar results 
were observed by education. 
Over the past two decades, the 
prevalence of obesity has continued to 
increase in Australian adults, with the 
greatest relative growth observed in 
the most severe obesity sub-classes.  
In 2011-12, one in every four people 
was obese, and one in every ten 
people was severely obese (class-II and 
III combined). Women were more 
likely to be severely obese, including 
twice as likely to be class-III obese. The 
age distribution of severe obesity was 
similar for males and females and 
generally the most substantial 
increases were observed between age 
groups 18-24 years and 35-44 years. 
In 2011-12, obesity prevalence 
increased with increasing levels of 
disadvantage, and the gradient was 
most pronounced in more severely 
obese classes, such that severe obesity 
affected 6 out of every 100 people in 
the least disadvantaged population 
and 13 out of every 100 people in the 
most disadvantaged population. 
Increases in obesity prevalence 
(particularly severe obesity) reported in 
this study, are likely to translate to high 
economic costs at both the individual 
and societal level.  
The fastest growth in obesity prevalence 
over time was observed in the more 
severely obese classes. Research to 
better understand the drivers of obesity 
prevalence patterns is urgently required 
to inform the most appropriate public 
health response. 
Continued reporting of obesity as a 
single group masks the rapid increases in 
severe obesity, a condition associated 
with greater adverse consequences 
relative to mild obesity. Future 
epidemiological studies should routinely 
stratify by obesity severity sub-classes.  
The delivery of complementary 
interventions that are tailored for, and 
targeted towards the most 
socioeconomically disadvantaged groups 
may be needed to reduce 
socioeconomic inequalities in obesity 
and future inequalities in health. 
Evaluation methodologies must evolve 
to inform decision-making based on 
equity in addition to effectiveness and 
cost-effectiveness. 
This is the first study 
to: 
(i) examine obesity 
prevalence by severity 
sub-class since 2000 in 
Australia;  
(ii) report age-sex 
stratified data for class 
I-III obesity in 
Australia; 
(iii) report relative 
differences in the 
prevalence of class I-III 
obesity according to 
socioeconomic strata 
internationally. 
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 Manuscript title and Methods Results (technical) Results (lay) Significance Innovation  
Keating, C. L., Peeters, A., Swinburn, 
B. A., Magliano, D. J. and Moodie, 
M. L. (2013), Utility-based quality of 
life associated with overweight and 
obesity: The Australian Diabetes, 
Obesity, and Lifestyle study. 
Obesity, 21: 652–655. 
doi: 10.1002/oby.20290 
 
Cross-sectional analysis of 10,959 
adults, participating in baseline data 
collection of the nationally 
representative Australian Diabetes, 
Obesity and Lifestyle (AusDiab) study 
was undertaken. Height and weight 
were measured by trained 
personnel. Bodyweight categories 
were assigned as healthy weight, 
overweight and obesity sub-classes I, 
II and III. Utility-based quality of life 
(UQoL) was assessed using the SF-
6D, which captures physical 
functioning, role limitation, social 
functioning, pain, mental health and 
vitality on a score of 0.00-1.00 
(worst-best). The relationship 
between bodyweight categories and 
UQoL was assessed using linear 
regression, adjusting for age, sex, 
education and smoking. 
 
 
 
 
 
 
 
Lower mean UQoL scores were 
observed in each higher BMI obese 
sub-class, ranging from 0.76-0.69 for 
class-I/class-III obesity respectively.  
Relative to the healthy weight group, 
mean UQoL differences (95% CIs) were 
0.001 for overweight (-0.008, 0.010), -
0.012 for class-I obese (-0.022, -0.001), 
-0.020 for class-II obese (-0.041, 0.001) 
and -0.069 for class-III obese (-0.099,  
-0.039) groups. Differences were 
significant for comparisons between 
healthy weight and both class-I and 
class-III obesity.  
Gender-stratified results were similar 
in magnitude; however confidence 
intervals were much wider for males 
such that differences were no longer 
statistically significant. 
UQoL differed by -0.002 (-0.002, -
0.001) for every one unit increase in 
BMI (p<0.001), confirming a dose-
response relationship.  
 
A strong negative relationship 
between body mass index and UQoL 
exists for the class-III obese group 
(UQoL 6.9% lower relative to the 
healthy weight group).  This compares 
to differences of 1.2% and 2.0% for the 
class-I and class-II obese groups, 
respectively.  
 
Assuming that the UQoL differences 
observed in this study are attributable to 
excess weight, the results indicate that 
class-III obese Australian adults would 
be willing to forgo 6.9% of their 
remaining life to spend it in perfect 
health. 
These results will also enable more 
sensitive cost-effectiveness analyses by 
incorporating UQoL weights which are 
specific to the sub-classes of obesity.  
 
 
This is the first study to 
publish UQoL weights 
for all three obesity 
severity categories 
defined by the World 
Health Organisation 
(WHO) for a 
representative adult 
population using 
measured height and 
weight. 
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 Manuscript title and Methods Results (technical) Results (lay) Significance Innovation  
Keating CL, Moodie ML, Richardson 
J, Swinburn BA. Utility-based quality 
of life of overweight and obese 
adolescents. Value Health. Jul-Aug 
2011;14(5):752-758. 
Data were collected from 2890 
adolescents attending 13 secondary 
schools in the state of Victoria, 
Australia. The Assessment of Quality 
of Life 6-Dimension (AQoL-6D) 
questionnaire was used to measure 
individual utility. Adolescent’s height 
and weight were measured and 
weight status categories assigned 
according to the World Health 
Organization adolescent growth 
standards. Multi-variate linear 
regression analyses were undertaken 
for the whole population and sub-
populations of boys and girls to 
estimate the mean differences in 
utility scores between 1) overweight 
and healthy weight, and 2) obese 
and healthy weight adolescents, 
whilst controlling for demographic 
and socio-economic status variables. 
A multivariate linear regression 
analysis was undertaken to estimate 
the relationship between utility and 
BMI-z scores, whilst controlling for 
the same aforementioned variables. 
 
 
The mean utility of healthy weight 
adolescents was 0.860. After 
adjustments, the overweight and 
obese groups reported significantly 
lower mean utility scores (differences: 
-0.018 and -0.059 respectively relative 
to the healthy weight group).  
A significant utility difference 
associated with overweight was only 
experienced by girls (-0.039, p=0.003). 
Both genders experienced significant 
utility differences associated with 
obesity, but the magnitude was double 
for girls (-0.084, p<0.001) relative to 
boys (-0.041, p=0.022). 
Each higher BMI z-score standard 
deviation was associated with a mean  
-0.025 utility difference. 
This study found that higher BMI 
weight status categories were 
associated with poorer utility in 
adolescents, and that this relationship 
was strongest in girls. Our study found 
that overweight and obese 
adolescents experience mean utility 
reduction of 1.8% and 5.9% 
respectively.  
A dose response relationship was 
observed between BMI z-score and 
reduced UQoL. 
If we assume that the difference in QoL 
is attributable to overweight and obesity 
(rather than vice versa), then these 
results indicate that overweight and 
obese Australian adolescents would be 
willing to forgo 1.8% and 5.9% 
respectively of a life in ‘best health’ to 
avoid the reduction in quality of life 
associated with excess weight. 
This study was not powered to examine 
the UQoL for each obesity severity class. 
However the prediction equation for the 
relationship between BMI z-score and 
UQoL should enable estimations. 
This was the first study 
internationally to 
publish utility weights 
for the overweight and 
obese adolescent 
population. 
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 Manuscript title and Methods Results (technical) Results (lay) Significance Innovation  
Keating, C. L., Moodie, M. L., 
Bulfone, L., Swinburn, B. A., 
Stevenson, C. E. and Peeters, A. 
(2012), Healthcare Utilization and 
Costs in Severely Obese Subjects 
Before Bariatric Surgery. Obesity, 
20: 2412–2419. 
doi: 10.1038/oby.2012.124 
 
This study examined healthcare 
utilisation and associated costs for a 
severely obese population prior to 
receiving bariatric surgery relative to 
an age- and sex- matched sample 
from the Australian general 
population. The nationwide 
population of severely obese 
subjects receiving Medicare-
subsidised laparoscopic adjustable 
gastric banding (LAGB) surgery in 
2009 (n=11,769) were identified. 
Utilisation of medical services and 
pharmaceuticals in the 3.5 years 
prior to surgery were ascertained for 
each severely obese subject through 
linkage with Medicare, Australia’s 
universal health insurance scheme. 
Equivalent data were retrieved for 
each subject from the matched 
general population sample 
(n=140,000). 
Severely obese subjects utilised 
significantly more medical services 
annually compared to the general 
population (mean: 22.8 vs. 
12.1/person, standardised incidence 
ratio (SIR): 1.89 [95%CI 1.88- 1.89]), 
translating to 2.0-fold higher mean 
annual costs (Australian $ 1,140 vs. 
$567/person).  
The greatest excess costs in the obese 
related to consultations with general 
practitioners, psychiatrists/ 
psychologists and other specialists, 
investigations for obstructive sleep 
apnoea and in-vitro fertilisation.  
Severely obese subjects also utilised 
significantly more pharmaceutical 
prescriptions annually (mean: 11.4 vs. 
5.3/person, SIR 2.18 [95%CI: 2.17-
2.19]), translating to 2.2-fold higher 
mean annual costs (AUD595/person 
vs. AUD270/person). The greatest 
excess costs in the obese related to 
diabetes drugs, lipid modifying agents, 
psychoanaleptics, acid-related disorder 
drugs, agents acting on the renin-
angiotensin system, 
immunosuppressants and obstructive 
airway disease drugs. 
 
Overall, healthcare costs in the 
severely obese population were more 
than double those incurred by the 
general population.  
Cost differences were largely driven by 
greater annual healthcare costs 
relating to treating diabetes, 
cardiovascular disease and depression 
in the severely obese subjects. 
 
In settings where universal access to 
healthcare is available, as is provided in 
Australia, healthcare utilisation data 
provides a proxy measure for morbidity 
and morbidity change. Therefore, results 
from the study assessing health care 
utilisation in the severely obese relative 
to the general population can be 
interpreted as markers of morbidity 
expanding the evidence on the health 
profile of the severely obese in Australia.  
Results can also be utilised to quantify 
the burden of severe obesity and as 
potential “cost offsets” for adoption 
within economic evaluation if severe 
obesity is successfully prevented or 
treated. 
 
This is the first study 
internationally to 
quantify the cost of 
severe obesity based 
on observed data 
which stratifies results 
by therapeutic 
categories (previous 
studies reported global 
costs). 
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 Manuscript title and Methods Results (technical) Results (lay) Significance Innovation  
Keating CL, Peeters A, Swinburn BA, 
Carter R, Moodie ML. 
Pharmaceutical utilisation and costs 
before and after bariatric surgery.  
International Journal of Obesity 
37, 1467–1472; 
doi:10.1038/ijo.2013.24 
This study examined healthcare 
utilisation and associated costs for 
the total population of Australians 
receiving Medicare-subsidised 
laparoscopic adjustable gastric 
banding (LAGB) in 2007 (n = 9,542). 
Computerised data linkage with 
Medicare, Australia’s universal tax-
funded health insurance scheme was 
undertaken. Pharmaceuticals 
relating to obesity-related disease 
and post-surgical management were 
assigned to therapeutic categories 
and analysed. The mean annual 
numbers of pharmaceutical 
prescriptions for each category were 
compared over the four year period 
from the year before LAGB (2006) to 
two years after LAGB (2009) using 
utilization incidence rate ratios 
(IRRs). 
 
Utilisation rates decreased significantly 
after LAGB in the following therapeutic 
categories: diabetes (IRR 0.51, 95%CI 
0.50 - 0.53, mean annual cost 
differences per/person -$30), 
cardiovascular (0.81, 0.80 - 0.82, -$29), 
psychiatric (0.95, 0.93 - 0.97, -$13), 
rheumatic and inflammatory disorders 
(0.51, 0.49 - 0.53, $-10) and asthma 
(0.78, 0.75 - 0.81, $-9).  
In contrast, significantly greater 
utilisation was observed in the pain 
(1.28, 1.23-1.32, $12), gastrointestinal 
tract disorder (1.04, 1.02 - 1.07, -$5) 
and anemia/vitamins (2.34, 2.01 - 2.73, 
$4) therapeutic categories.  
When the defined categories were 
combined, a net reduction in 
pharmaceutical utilisation was 
observed, from 10.5 to 9.6 
pharmaceuticals prescribed per 
person/year and costs decreased from 
AUD517 to AUD435 per year in 2009 
prices 
Mean total pharmaceutical costs 
associated with obesity-related 
disease and post bariatric surgery 
management were reduced by 7%, 
19% and 16% in the year of LAGB, year 
one after LAGB and year two after 
LAGB respectively, relative to the year 
prior to LAGB. The greatest absolute 
cost reductions in year two after LAGB 
(relative to the year before LAGB) 
were observed in pharmaceuticals to 
treat diabetes ($30 per/person 
annually, 47% reduction) and 
cardiovascular disease ($29 
per/person, 17% reduction). However 
these savings were partially offset by 
increases in the use of selected 
therapeutic categories including 
nutrition/anemia and pain 
medications.  
 
Relative to the year before LAGB, overall 
pharmaceutical utilisation was reduced 
in the two years after the year of LAGB 
surgery, demonstrating that bariatric 
surgery can lead to reductions in 
pharmaceutical utilization in the “real 
world” setting. The greatest absolute 
cost reductions were observed in the 
therapies to treat diabetes and 
cardiovascular disease. 
Importantly, these reductions were 
observed for the entire population 
receiving bariatric surgery. Absolute cost 
reductions per patient would be far 
greater if the population analysed was 
restricted to subjects with type 2 
diabetes or other metabolic conditions 
because the health benefits attributable 
to weight loss are likely to be larger for 
these patients. Cost data presented in 
the current study which quantify the 
impact of bariatric surgery on short-
term pharmaceutical expenditure can be 
adopted within future CEAs. 
This is the first study to 
assess healthcare costs 
before and after 
bariatric surgery in a 
universal health 
insurance setting 
based on 
contemporary surgery 
procedures (thus 
excludes SOS study 
wherein the 
procedures used are 
now outdated). 
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Keating CL, Ananthapavan J.  
Revisional Surgery after 
Laparoscopic Adjustable Gastric 
Banding in a National Australian 
Cohort JAMA Surg. 2014;149(8):874-
875. doi:10.1001/jamasurg.2014.93 
The population of Australians 
undergoing LAGB subsidized by the 
government tax-funded insurance 
program (known as Medicare) in the 
year 2005-06 (n=6,037) was 
identified. Identification was based 
on utilization of Medicare Benefits 
Schedule item (i.e. billing code) 
30511 (gastric reduction or 
gastroplasty for morbid obesity), 
which is primarily utilized for 
LAGB(144).  
Medical utilization data from the 
date of LAGB until 3.5 years after 
surgery were retrieved for each 
subject from an administrative 
database (145) maintained by 
Medicare. Medicare funds 
approximately 3,800 medical 
services (145). Selected pre-defined 
items directly related to bariatric 
surgery, were analysed.  
 
During the3 years after LAGB, the rate 
of revisional surgery was 18.9 events 
per 100 patients, comprising 11.4 
intra-abdominal and 7.5 subcutaneous 
surgeries. The majority of revisional 
surgeries were repeat/revisional LAGB 
(8.3 events per 100 patients) and 
repair/revision of the LAGB reservoir 
(7.5 events per 100 patients). 
Conversion to another bariatric 
procedure (1.3 events per 100 
patients) and LAGB reversal (1.9 
events per 100 patients) were 
uncommon. 
Almost one in five patients undergoing 
LAGB required some revisional surgery 
within three years. 
The benefits of surgery must be 
compared to the risk of adverse events, 
need for reoperations and associated 
costs for each patient. 
This is the first study to 
report revisional 
surgery rates for a 
national wide 
population of people 
receiving bariatric 
surgery 
internationally). 
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Keating C, Neovius M, Sjoholm K, 
Peltonen M, Narbro K, Eriksson J, 
Sjostrom L, Carlsson L. Pre-
Operative Glucose Status and 
Health Care Use During 15 Years 
Following Bariatric Surgery, draft 
manuscript 
Design, Setting, and Participants: The 
Swedish Obese Subjects study is an 
ongoing, prospective, 
nonrandomized, controlled 
intervention study conducted in the 
Swedish health care system that 
included 2010 adults who underwent 
bariatric surgery and 2037 
contemporaneously matched 
controls recruited between 1987 and 
2001.  
Main Outcome Measures: Total 
hospital days (follow-up years 1-15; 
and nonprimary care outpatient 
visits (follow-up years 2-15) were 
retrieved from the Swedish National 
Patient Register. Prescription drug 
costs were retrieved from 
questionnaire data and from the 
Swedish Prescribed Drug Register 
(follow-up years 1-15). Register 
linkage was complete for >99% of 
patients (4040/4047). Mean 
differences were adjusted for 
baseline age, sex, smoking, BMI, 
inclusion period, and (for inpatient 
care) hospital days the year prior to 
the index date.  
During years 1-15, in normo-glycemic 
patients, mean imputed total hospital 
days were 30.3 in the surgery group 
and 16.9 in the control group (adjusted 
difference, 12.9; 95%CI, 9.9-15.9; 
P<.001) and comparable figures in 
glucose-impaired patients were 32.5 
and 21.8 (adjusted difference, 12.5; 
95%CI, 5.6-19.4; P<.001). In patients 
with diabetes, no difference between 
the surgery and control group was 
observed (38.7 vs 36.7; adjusted 
difference, 3.4; 95%CI, -6.4 to 13.3; 
P=.49).  
During years 2-15, there was no 
difference between treatment groups 
in imputed nonprimary outpatient care 
use for any glucose category).  
During years 1-15, mean imputed total 
drug costs did not differ between the 
surgery and control group in normo-
glycemic patients (USD $10,264 vs 
$10,635, adjusted difference -$40; 
95%CI, -$2190 to $1310; P=.62). In 
contrast, mean imputed total drug 
costs were lower for the surgery group 
in glucose-impaired patients (USD 
$10,048 vs $12,845, adjusted 
difference -$2911; 95%CI, -$5605 to -
$218; P=.034), and in patients with 
diabetes (USD $14,245 vs $19,488, 
adjusted difference -$5597; 95%CI, -
$8631 to -$2563, P<.001).  
During years 1-15, surgery patients 
with normal and impaired fasting 
glucose accumulated higher mean 
total hospital days relative to controls, 
whilst no between-group difference 
was observed in patients with type 2 
diabetes. During years 2-15, there was 
no difference in mean total 
nonprimary care outpatient visits 
between treatment groups. During 
years 1-15, total prescription drug 
costs did not differ between treatment 
groups in patients with normal 
glucose, whilst lower mean drug costs 
were observed in surgery patients with 
impaired fasting glucose and type 2 
diabetes. 
The current study presents for the first 
time, that long-term economic 
outcomes also favour the glucose-
impaired and diabetes sub-groups, 
adding further evidence to support the 
prioritization of these sub-groups to 
receive bariatric surgery. 
It is likely that economic evaluations 
published for the “total” eligible 
population underestimate the economic 
benefits of bariatric surgery for glucose-
impaired and diabetes sub-groups and 
overestimate the benefits for normo-
glycemic patients. 
This study presents for 
the first time, observed 
health care use over 15 
years by obese 
patients treated 
conventionally or with 
bariatric surgery 
stratified by baseline 
glucose categories. 
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Keating C, Backholer K, Stevenson C, 
Moodie M and Peeters A. 
Differences in the Rate of Bariatric 
Surgery across Socio-economic 
Groups. JAMA Surgery. 2015 Apr 
1;150(4):367-8. doi: 
10.1001/jamasurg.2014.3180. 
Custom data relating to all bariatric 
surgery episodes undertaken in 
Australian adults during 2011-12 
(n=14,056) were sourced from the 
National Hospital Morbidity 
database and provided by the 
Australian Institute of Health and 
Welfare(146). Bariatric surgery 
episodes were selected based on 
three Australian Refined Diagnosis 
Related Groups codes (K04A-S, K04B-
S, K07Z-S). Customized data relating 
to the annual estimated number of 
adults with severe obesity in 
Australia were provided by the 
Australian Bureau of Statistics based 
on results from the nationally-
representative 2011-12 Australian 
Health Survey. All data were 
stratified by an area-level measure of 
socioeconomic position (SEP), where 
a lower quintile represents greater 
disadvantage. Bariatric surgery 
treatment rates were calculated as 
“the observed annual number of 
bariatric surgery episodes” / “the 
estimated annual number of adults 
with severe obesity” for each SEP 
strata. 
Bariatric surgery treatment rates 
increased with increasing level of 
socioeconomic position. The lowest 
treatment rates were observed in the 
most disadvantaged quintiles (quintiles 
1/2: 7.9/8.1 episodes per 1,000 
severely obese per year), whilst the 
highest treatment rates were observed 
in the least disadvantaged quintiles 
(quintiles 4/5: 13.6/12.6 episodes per 
1,000 severely obese per year) 
Socioeconomic inequalities in the use 
of bariatric surgery exist in Australia. 
Between 2011 and 2012, severely 
obese people in the two most 
disadvantaged quintiles were 
approximately 40% less likely to 
receive bariatric surgery relative to 
severely obese counterparts in the two 
least disadvantaged quintiles.  
Inequalities in treatment for severe 
obesity may further increase existing 
inequalities in the prevalence of severe 
obesity. 
This suggests the need to move towards 
treatment and care which is 
proportionate to the socioeconomic 
distribution of obesity.  
 
This is the first study to 
quantify 
socioeconomic 
inequalities in bariatric 
surgery using a 
comparison of the 
eligible versus the 
treated population in 
Australia (second 
internationally to a 
USA study). 
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Summary
Objective:  To  compare  the  prevalence  of  class-I,  II  and  III  obesity  in Australian  adults
between 1995,  2007—08  and  2011—12.
Methods: Prevalence  data  for  adults  (aged  18+  years)  were  sourced  from  cus-
tomised data from  the  nationally  representative  National  Nutrition  Survey  (1995),
the National  Health  Survey  (2007—08),  and  the  Australian  Health  Survey  (2011—12)
conducted by  the  Australian  Bureau  of  Statistics.  Obesity  classiﬁcations  were based
on  measured  height  and  weight  (class-I  body mass  index:  30.0—34.9  kg/m2, class-II:
35.0—39.9 kg/m2 and  class-III:  ≥40.0 kg/m2). Severe  obesity  was  deﬁned  as  class-II
or class-III  obesity.
∗ Corresponding author at: Baker IDI Heart and Diabetes Institute, Level 4, 99 Commercial Road, Melbourne, VIC 3004, Australia.
Tel.: +61 03 8532 1866; fax: +61 03 8532 1928.
E-mail address: anna.peeters@bakeridi.edu.au (A. Peeters).
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Results:  Between  1995  and  2011—12,  the  prevalence  of  obesity  (all classes  combined)
increased  from  19.1%  to  27.2%.  During  this  17  year period,  relative  increases  in  class  I,
II and  III  obesity  were  1.3,  1.7  and  2.2-fold  respectively.  In  2011—12,  the  prevalence  of
class  I,  II  and  III  obesity  was  19.4,  5.9  and  2.0  per  cent  respectively  in  men,  and  16.1,
6.9  and  4.2  per  cent respectively  in women.  One  in  every  ten  people  was  severely
obese,  increasing  from  one  in twenty in 1995,  and women were disproportionally
represented  in  this  population.  Obesity  prevalence  increased  with  increasing  levels
of  area-level  socioeconomic  disadvantage,  particularly  for the  more  severely  obese
classes. Severe  obesity  affected  6.2%  and 13.4% in the  least  and  most  disadvantaged
quintiles  respectively.
Conclusion:  Over  the  last  two  decades,  there  have  been substantial  increases  in  the
prevalence  of  obesity,  particularly  the  more  severe  levels  of  obesity.  This  study  high-
lights high  risk groups  who  warrant  targeted  weight  gain  prevention  interventions.
©  2015  Asian  Oceanian  Association  for the  Study  of  Obesity.  Published  by  Elsevier
Ltd.  All  rights  reserved.
Introduction
The  World  Health  Organisation  deﬁnes  three  sub-
classes of  obesity  severity  (class-I  body  mass  index
(BMI): 30.0—34.9  kg/m2, class-II:  35.0—39.9  kg/m2
and  class-III:  ≥40.0  kg/m2)  [1].  Severe  obesity  is
deﬁned as  class-II  or class-III  obesity.  We have
previously reported  that  between  1980  and  2000,
the prevalence  of  obesity  (all  classes)  increased
from 10.6  to 17.2% in men  and  8.8  to  19.3%  in
women aged  25—65  in Australia  [2].  Increases  were
greatest in the  more severe  obesity  sub-classes.
During this  period,  the  prevalence  of  class-III obe-
sity increased  4.8-fold  in  women  and  2.5-fold  in
men, whilst  comparable  increases  in class-I obesity
were 1.8-fold  and  1.5-fold  respectively  [2].  Simi-
lar observations  were  reported  in  other  developed
countries during  the  same  period  [3—5].  During  the
last decade,  the  prevalence  of  obesity  has  contin-
ued to  increase.  The Australian  Bureau  of Statistics
report that  27.3% of  Australians  were obese (all
classes) in 2011—12,  an  increase  from  24.0% in
2007—08 [6].  To the best  of  our  knowledge,  recent
obesity trends  by  severity  sub-class  have  not  been
examined in Australia  [2].
An exponential  increase  in  the risk  of  adverse
health outcomes  is  observed  with increasing  sever-
ity of  obesity.  For  example,  it has  been  estimated
that the risk  of  developing  type 2  diabetes  is
increased 93-fold  in women  and  42-fold  in men who
are severely  obese,  relative  to  healthy weight  coun-
terparts [7,8].  Similarly,  a  body  mass  index  greater
than 40  is  associated  with between  6.5  and 13.7
years of life lost [9].  Consequently,  small  increases
in the  prevalence  of  severe  obesity  will  probably
have a  similar impact  on adverse  health  outcomes
as large  increases  in the prevalence  of  class-I obe-
sity. Therefore,  understanding  the  composition  of
the obese  population  is  critical  to  determining
the associated  morbidity  and  mortality  burden  of
recent trends.
A socioeconomic  gradient  in  obesity,  where
greater prevalence  of  obesity  is observed  in more
disadvantaged groups,  has  been  reported  in  most
high income  countries  [10]. Two  previous  stud-
ies have  reported  a  greater  risk of  severe  obesity
in more  socioeconomically  disadvantaged  groups
[11,6]. However  to  the best  of  our  knowledge,
no previous  study has  explored  differences  in the
prevalence of  obesity  classes  I,  II  and  III  [1], across
socioeconomic strata.
In the current  study,  we analysed  nationally
representative data  to compare  the  prevalence
of class-I,  II  and III  obesity  in Australian  adults
between 1995, 2007—08  and  2011—12.  Obesity  clas-
siﬁcations were  based  on measured  height  and
weight. We  also  examined  the age,  sex and  socio-
economic proﬁle  for each obesity  severity  sub-class
in 2011—12.
Methods
Data  sources
Prevalence  data  for the  population  aged  18  years
and over were  sourced  from  customised  data,
provided for  the  purposes  of this  research,  from
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the  National  Nutrition  Survey  (1995),  the National
Health Survey  (2007—08),  and  the  Australian  Health
Survey (2011—12)  each  conducted  by  the  Australian
Bureau of  Statistics  (ABS).  Each  survey  was  selected
to provide  a  representative  sample  of  the  Australian
population.
In 2011—12,  a  total  of  30,721  households  were
approached to  participate  in  the Australian  Health
Survey, of which  25,080 households  participated
in the  survey.  The  sample  included  31,837  par-
ticipants, of  whom 83.5% (26,577)  participated  in
height and  weight  measurement  [6].  The sam-
ple was  24,910  after  people aged  less  than 18
years were excluded  (personal  communication,
ABS, 26/05/14).
In 2007—08,  a  total  of  19,979  private  dwellings
were selected  in the  sample  for  the  National  Health
Survey, reducing  to  an  active  sample  of  17,426
dwellings after  sample  loss  in the  ﬁeld  stage.  The
sample included  15,779 participants  aged 18  years
and over  [12],  of  whom  71.4%  (11,266)  participated
in height  and weight  measurements  (personal  com-
munication, ABS,  26/05/14).
In 1995,  a  total  of  57,633 people were  inter-
viewed by the  National  Health  Survey.  Of this
sample, 22,562  people  were  selected  to  also
participate in the  National  Nutrition  Survey.
Approximately 13,800  (61%)  people  completed  the
survey, of  whom 98.2% participated  in height
and weight  measurements  [13].  The  sample  was
reduced to  10,281  after  people aged  less  than
18 years  were  excluded  (personal  communication,
ABS, 26/05/14).
The process  for  collecting  physical  measures
was similar  for  all  surveys.  Interviewers  used  dig-
ital scales  to  measure  weight  (maximum  weight
measured by  scales  was  150  kg in 2011—12  and
2007—08 and  140  kg  in 1995) and  a  stadiometer
to measure  height (maximum  210  cm).  Interview-
ers encouraged  respondents  to  remove  shoes  and
heavy clothing,  prior  to  measurement.  Weight  (kilo-
grams) and  height  (centimetres)  were  recorded  to
one decimal  point.  BMI  was calculated  as  weight
(kg) divided  by  height  (m)2.
In the  2011—12  survey,  highest  educational
attainment was  reported  by  participants  and  cat-
egorised into  three mutually  exclusive  categories:
‘did not  complete  secondary  school’,  ‘completed
secondary school’,  ‘completed  degree/diploma’
(reﬂecting most  to  least  disadvantaged  socioecono-
mic position  (SEP)).  Survey  participants  were  also
categorised into  Index  of  Relative  Socio-Economic
Disadvantage (IRSD)  quintiles.  IRSD  is  an  area-
level SEP  indicator  developed  by  the  Australian
Bureau of  Statistics.  This  index  represents  a  sum-
mary measure  from  a  group  of  20  variables  (related
to education,  income,  employment,  family compo-
sition, housing  beneﬁts,  car  ownership,  ethnicity,
English language  proﬁciency  and  residential  over-
crowding). A lower  quintile  indicates  an  area with
relatively greater  disadvantage.
Analysis
The  Australian  Bureau  of  Statistics  provided  cus-
tomised data  on the  prevalence  of  obesity  and
associated uncertainty  statistics  (95%  conﬁdence
intervals and standard  errors)  for individuals  aged
18+. Survey  participants  excluded  from  this  data-
set included  females  who  indicated  during  the
interview that  they  were  pregnant  and  a  very  small
group of  people  whose  weight  exceeded  the  maxi-
mum weight  the  scales  would measure  (140/150  kg
depending on survey  year).  Sampling  weights  were
utilised to  adjust  results  from  the  sample survey
to infer results  for the  in-scope  total  population.
Prevalence data  for  class-I,  class-II  and  class-III
obesity were  provided,  stratiﬁed  by  gender  and
ten-year age  groups  for  each  of  the  three  surveys.
Prevalence rates  age-standardised  to  the 2011—12
population were  also  provided.  For  the  most  recent
2011—12 survey,  obesity  prevalence  data  were  also
stratiﬁed by  educational  attainment  and  IRSD.
Age-standardised prevalence  rates  were  com-
pared over the long-term  (1995  vs 2011—12, 17
years) and  short-term  (2007—08  vs  2011—12,  5
years). Age-standardised  prevalence  was also  com-
pared between  the  most  and least  disadvantaged
groups for education  level  (‘did not  complete  sec-
ondary school’  vs  ‘completed  degree/diploma’)  and
IRSD (quintile  1  vs  quintile  5).  The  statistical  signif-
icance of  these  comparisons  was  assessed  using  a
z score  and associated  p value.  The  z score  was
calculated as  the  difference  between  the  preva-
lence estimates  divided  by  the standard  error  of
this difference,  with  this standard  error  calculated
as the square  root  of the  sum of  the squares  of  the
individual prevalence  standard  errors.  Associated
p values  were  derived  using  the  standard  normal
probability distribution.  A  p  value  less than 0.05
was interpreted  as  statistically  signiﬁcant.
Results
Age  and sex  proﬁle  of  the obese  population
in  2011/12
In 2011—12,  the  total  prevalence  of  obesity  was
27.2% (27.3%  for males  and  27.2%  for  females).  In
2011—12, out  of  every  100  men,  19.4 were  class-I
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Table  1  Prevalence  of class-I,  class-II  and  class-III  obesity  in Australian  adults,  1995, 2007—08  and  2011—12.
Prevalence* Change p  value
1995  2007—08 2011—12 2011—12  vs 2007—08
(5 years)
2011—12 vs  1995
(17 years)
2011—12 vs
2007—08
2011—12  vs
1995
%  95%  CI  %  95% CI  %  95% CI  Relative
change**
Absolute
change
Relative
change**
Absolute
change
Males
Obese  class-I 15.4 (14.5,  16.3) 18.1 (16.7,  19.5) 19.4 (18.5,  20.3) 1.07 1.3 1.26  4.0 0.129 <0.001
Obese  class-II  2.9 (2.4,  3.4)  5.4 (4.5,  6.3) 5.9  (5.4,  6.4)  1.09 0.5 2.03  3.0 0.336 <0.001
Obese  class-III  0.7 (0.4,  1.0)  1.7 (1.3,  2.1) 2.0  (1.6,  2.4)  1.18 0.3 2.86  1.3 0.306 <0.001
Females
Obese  class-I  12.7 (11.9,  13.5)  14.7 (13.4,  16) 16.1  (15.3,  16.9)  1.10 1.4 1.27  3.4 0.063 <0.001
Obese  class-II  4.4 (3.8,  5.0)  6.0 (5.1,  6.9) 6.9  (6.2,  7.6)  1.15 0.9 1.57  2.5 0.116 <0.001
Obese  class-III  2.1 (1.7,  2.5)  2.7 (2.1,  3.3) 4.2  (3.6,  4.8)  1.56 1.5 2.00  2.1 0.001 <0.001
People
Obese  class-I 14.0 (13.5,  14.5)  16.4 (15.4,  17.4)  17.7  (17.1,  18.3)  1.08 1.3 1.26  3.7 0.044 <0.001
Obese  class-II 3.7 (3.3,  4.1)  5.8 (5.2,  6.4) 6.4  (6.0,  6.8)  1.10 0.6 1.73  2.7 0.091 <0.001
Obese  class-III  1.4 (1.2,  1.6)  2.2 (1.8,  2.6) 3.1  (2.8,  3.4)  1.41 0.9 2.21  1.7 <0.001  <0.001
Source: Australian National Health Surveys (2011—12 and 2007—08) and the National Nutrition Survey (1995).
* Age-standardised to the  2011/12 population.
** A  1.07 relative change is equivalent to  a  1.07-fold or 7% increase in  prevalence.
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Figure  1  Prevalence  of  class-I,  class-II/II  (combined)  obesity  in  Australian  adults  by  age  group  and  sex,  2011—12.
obese,  5.9  were  class-II  obese  and  2.0  were  class
III-obese (Table  1).  Equivalent  ﬁgures for  women
were 16.1,  6.9  and  4.2. Relative  to  men,  women
were 1.2-  and  2.1-fold  more  likely  to  be  class-II
and class-III  obese  respectively.  For  men  and  women
combined, one  in every four  people  was  obese,  and
one in  every  ten  people  was severely  obese  (Fig.  1).
In women,  the  prevalence  of  class-I  obesity
increased with age  (starting  at  18—24  years) and
peaked in  the  55—64  year  age  group (21.1%)  before
decreasing with older age.  The  prevalence  of  severe
obesity was  approximately  8%  in  the  age  groups
18—24/25—34 years,  11—12%  in the  age  groups
35—44/45—54 years  and  14—15%  in  the  age  groups
55—64/65—74 years.
In men,  the  same  pattern  for  class-I  obesity  was
observed, with the  highest  prevalence  of  class-
I obesity  (27.8%)  also  observed  in the age  group
55—64 years.  The  prevalence  of  severe  obesity
increased from 4.7% in the  age  group  18—24  years
to 9.7%  in the  age  group  35—44  years  and then
remained roughly  steady  until  the  age  group  65—74
years (Fig.  1).
Socioeconomic position  of  the obese
population  in  2011/12
In  2011—12,  the prevalence  of  obesity  (all  sever-
ity sub-classes)  in  Australian  adults  decreased  with
increasing level  of  educational  attainment  (‘did
not complete  secondary  school’:  32.5%,  ‘com-
pleted secondary  school’:  22.7%  and  ‘completed
degree/diploma’: 19.3%)  (Fig.  2).
Class-I  obesity  prevalence  estimates  were  19.7%,
15.7% and  13.3% in  the  least  to  most  educated  sub-
groups. Corresponding  ﬁgures  for class-II  obesity
were 8.6%,  4.8% and 4.3%;  and  for  class-III  obesity
4.2, 2.3  and  1.7%.  The  relative  risks of class-I,  II
and III  obesity  in the  least  educated  group, rela-
tive to  the most  educated  group  were  1.5,  2.0 and
2.5 respectively  (all  p  <  0.05  for  prevalence  compar-
ison between  least  and  most  educated).  For  men,
the relative  risks  of  class-I,  II  and  III  obesity  in the
least educated  group,  relative  to  the  most  edu-
cated group  were  1.5,  2.3  and 3.3  respectively.  For
women, corresponding  ﬁgures were  1.5,  1.8  and  2.4
(all p  < 0.05)  (Fig.  2).
Similar trends  were  observed  according  to  area-
level SEP  (IRSD).  A SEP  gradient  was observed  for
all obesity  class  and  gender  sub-groups,  with the
exception of  class-I  obese men,  where  a  non-linear
trend was  observed  with prevalence  being  rela-
tively stable  across  the  middle  SEP  groups  (Fig.  3).
Changes in  prevalence  over  time
Between  1995  and 2011—12, the prevalence  of  obe-
sity (all  severity  sub-classes  combined)  increased
from 19.1% to  27.2%.  In 1995,  the  age-standardised
prevalence of  class-I,  II  and  III  obesity  were
15.4, 2.9  and 0.7  per cent  respectively  in  men
and 12.7,  4.4  and  2.1 per cent  respectively  in
women (Table  1).  The  changes  in  obesity  prevalence
between 1995  and 2011—12  represented  relative
increases of  1.3-,  2.0-  and 2.9-fold  respectively
in men  and  1.3-,  1.6-  and  2.0-fold  respectively  in
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Figure  2  Prevalence  of  class  I, II  and  III  obesity  by  education  level in  Australia,  2011—12.  *p < 0.05.  A  tabular  version
of  this  ﬁgure  providing  data  points  is  provided  as  an  online  supplementary  table.
women.  Increases  in age-standardised  prevalence
were statistically  signiﬁcant  for each  obesity  sub-
class in  both  men and  women  (all  p  <  0.001).
In  2007—08,  the  age-standardised  prevalence  of
class-I, II  and III  obesity  were  18.1,  5.4  and  1.7
per cent  respectively  in men and  14.7,  6.0 and  2.7
per cent  respectively  in women  (Table  1).  Over  this
short time  horizon,  the increase  in class-III  obe-
sity in  women  alone  was  statistically  signiﬁcant
(p < 0.001).  In all  obesity  class  and gender  sub-
groupings, the  2007/8  prevalence  was  intermediate
to the  1995  and  2012  prevalence.
Discussion
Key ﬁndings
In  the  current  study,  we  compared  the preva-
lence of  class-I,  II  and  III  obesity  in Australian
adults between  1995  and  2011—12.  Nationally  rep-
resentative population  samples  were  assessed  and
obesity classiﬁcations  were  based  on  measured
height and  weight.  We observed  that  over  the  past
two decades,  the prevalence  of  all obesity  sub-
classes has  increased,  with  the  greatest  relative
growth in the more severe  obesity  sub-classes.  In
2011—12, one  in  every four  adults  was  obese  and
one in  every  ten  adults  was  severely obese.  Women
were more  likely to  be severely  obese,  including
twice as  likely  to  be  class-III  obese.  Severe  obesity
prevalence as  high  as  15.5% was  observed  in women
aged 64—74  years  and  10.1%  in  men  aged  55—64
years. On  a  population-level,  we  estimate  that  in
2011—12, 2.6  million  adults  were  class-I  obese  and
1.4 million  adults  were  severely  obese and poten-
tially required  treatment.
We also  found  that  class-I,  II  and  III  obe-
sity prevalence  increased  with  increasing  levels
of disadvantage  based  on  both education  and
an area-level  marker  of  socioeconomic  position.
Figure  3 Prevalence  of  class  I,  II  and  III  obesity  by  area-level  socioeconomic  status (IRSD)  in  Australia,  2011—12.
*p  <  0.05.  A  tabular  version  of  this  ﬁgure  providing  data points  is  provided  as  an  online  supplementary  table.
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The  gradient  was  most  pronounced  in the  more
severely obese  sub-classes,  such that  severe obesity
affected 6  out  of  every  100  people  in the least  dis-
advantaged (IRSD)  quintile  of  the population  and  13
out of  every  100  people  in the most  disadvantaged
quintile of the  population.  The  prevalence  of  obe-
sity was  higher  in the  most  disadvantaged  group,
relative to  the least  disadvantaged  group,  for  both
men and  women  in  all  obesity  severity  sub-classes
according to  education  level,  and all except  class-I
obese men  according  to  area-level  SEP.
Strengths  and limitations
To  the  best  of  our  knowledge,  this is  the  ﬁrst  study
to examine  obesity  trends  by  severity  sub-class  for
a large  nationally  representative  sample  popula-
tion in  Australia.  In contrast,  our previous  study
for the  period  1980—2000  [14]  was  limited  to  the
urban population  aged 25—65. Height  and  weight
were measured,  survey  methods  were  similar across
all time  points  and  response  rates  were  generally
high. Prevalence  measures  were age-standardised
to ensure  changes  in population  adiposity  over  time
were not  confounded  by  changes  to  the  population
age structure.  This  is  also  the  ﬁrst  Australian  study
to describe  prevalence  for  each obesity  severity
sub-class stratiﬁed  by  age,  sex  and socioeconomic
position (previously  not  feasible  due  to  small  sam-
ple sizes).
The  three  Health  Surveys  measured weight  up
to a  maximum  of  140  kg in  1995  and  150  kg  in
2011—12 and  2007—08.  Weight was  not  recorded
for a  small number  of  participants  with  very high
apparent weight  exceeding  these maximum  meas-
ures, and  these  participants  were excluded  from
the health  survey  weight  data.  It  is  possible  that
as the  population  became  heavier  over  time,  the
number of  participants  exceeding  the  maximum
measure increased,  hence the  prevalence  of  class-
III obesity  at  later  time  points  reported  herein  may
be conservative.  However  this  effect  will  have  been
diluted due to  increases  in  the  maximum  weight
which could  be  measured  by  the  scales  over  time.
Overall, the  Australian  Bureau  of  Statistics  have
advised that the  prevalence  estimates  were  not
seriously affected  by  this issue  (personal  commu-
nication, ABS,  26/05/14).
Response rates  for  the  1995  National Nutrition
Survey were relatively  low. Potential  non-response
bias was  reduced  via  the adjustment  of  sample
weights to  reﬂect  nationally  representative  data.
It is  possible  that  obese  people were  less  willing
to participate  in  surveys at  all time  points,  lead-
ing to  an underestimation  in  prevalence  rates.  It
is also  possible  that  lower  response  rates  in 1995
could have  led to  an  over-estimation  in  the  increase
in obesity  prevalence  between  1995  and  later  time
points.
With regards  to the  analysis  of  severe obesity
prevalence according  to  socioeconomic  position,  to
the best  of  our knowledge,  one  previous  Australian
study has  published  in this theme  area.  Howard
et al. reported  that  the odds  ratio  of  severe  obe-
sity (class  II/III  combined)  was  2.3  fold  higher  in
the most  disadvantaged  quintile  (IRSD),  relative
to the two least  disadvantaged  quintiles  in  South
Australia [11].  We observed  similar  results  with the
relative risk of  class  II  and  class  III  obesity  in the
most vs  least  disadvantaged  quintile  as  1.9  and 2.8
respectively. Therefore  our  results  support  previous
ﬁndings for  a  nationally  representative  sample.
Signiﬁcance
Historically,  severe obesity  affected  a  small  pro-
portion of  the  population  in Australia  (e.g.  1—2%
in 1980)  and  has  received  little  attention.  We
now demonstrate  that  severe  obesity  affects  a
substantial proportion  of  the  adult population
(10%). Similarly  large  prevalence  (15%)  has  been
reported for  US  adult populations  in  2010  [15].  The
adverse health  and  quality  of  life  consequences
of severe  obesity  for  the  individual  are  widely
accepted [16,17]. However  with  increasing  preva-
lence, adverse  consequences  are  also  becoming
increasingly large at  the  societal  level. We have
previously demonstrated  that  the  healthcare  costs
borne by  the Australia  government  through  Medi-
care are  greater  than double in  the  severely obese
population relative  to the  general population  [18].
We have  also  demonstrated  that  the risk of  disabil-
ity in the highest  BMI  quintile  is 2—4-fold  greater
relative to  the  lowest  quintile  [19],  suggesting
a strong  relationship  between  increasing  BMI  and
the need  for  disability-related  services  and  care.
Therefore, increases  in obesity  prevalence  (partic-
ularly severe  obesity)  reported  in this  study,  are
likely to translate  to  large economic  costs  at  both
the individual  and  societal  level.
The fastest  growth  in obesity  prevalence  over
time was  observed  in the  more severely  obese
classes. One  possible explanation  for  this trend
is that  there  is variation  in vulnerability  to  the
obesogenic environment  across  the population.
Consequently, as  our  environment  becomes  more
obesogenic [20],  the  Australian  population  at risk
of excess  weight gain  is likely  to  gain  more weight
today than its  counterparts  twenty  years  ago.  A fur-
ther explanation  may be  that  for  individuals  with
excess weight  early  in life,  several  vicious  cycles
occur whereby  obesity  begets  obesity,  leading
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to  disproportionally  larger  weight  gain  over time
[21]. Importantly,  our  analysis  of  multiple  cross-
sectional surveys  does  not  enable  conclusive  results
regarding cohort  changes  over  time.  Finally,  while
the observation  of  greater  relative  increases  for
severe obesity  may also  in  part be  due  to  the  fact
that it  is easier  to  have  a greater  relative  increase
from a  lower baseline prevalence,  prior research
has also  demonstrated  greater  absolute  differences
in BMI  over  time  with increasing  level  of  BMI  [14].
Research to  better  understand  the  drivers  of  obesity
prevalence patterns  is  urgently  required  to inform
the most appropriate  public  health  response.
The age  distribution  of  severe obesity  was sim-
ilar for  males  and  females  and  generally  the  most
substantial increases  were  observed  between  age
groups 18—24  years  and 35—44  years.  This  sug-
gests that targeting  interventions  in settings  with
young adults  will  be important  for  prevention.  For
women, the prevalence  of  severe obesity  had  two
notable increases:  between  the  age  groups  25—34
and 35—44  years,  as  well  as  between  age  groups
45—54 and  55—64  years.  These  increases  likely  coin-
cide with  key life  phases  of  child-bearing  and  the
onset of menopause,  highlighting  these  as  key risk
periods for weight  gain  in women,  and hence  ideal
windows for  targeted  intervention.  Importantly  the
data assessed  is  cross-sectional  rather  than  cohort
data, so we  cannot  provide  conclusive  statements
about critical  periods  of  life.  These  results  high-
light the  need  to  understand  the drivers  of  the  rapid
increases in severe  obesity  better  so  that  we  can
conﬁrm key  risk periods and  sub-groups.
Policy responses  to  the obesity  epidemic  will
have a  direct  impact  on socioeconomic  disparities
in obesity  prevalence  reported  herein.  A recent
review reported  that  the effectiveness  of  obesity
prevention programs  can differ by  SEP,  with some
programs (those  focussed  on  education  delivery)
realising beneﬁts  primarily  for  high  SEP  popula-
tions [13].  It is  foreseeable  that  if delivered  in
isolation, these  types  of  interventions  may  increase
the already  large  socioeconomic  differences  in  obe-
sity. It  is  important  that  we  continue  to  implement
universal interventions  to  reduce  population-wide
weight gain.  However,  the  delivery  of  comple-
mentary interventions  that are  tailored  for,  and
targeted towards  high  risk low  SEP groups  may
also be  needed  to  reduce  socioeconomic  inequal-
ities in  obesity  and  future  inequalities  in health.
Evaluation methodologies  must  evolve  to  inform
decision-making based  on equity in  addition  to
effectiveness and cost-effectiveness.
The current  study  demonstrated  the  greatest
relative socioeconomic  inequalities  in the  more
severely obese  groups.  Therefore,  policy  responses
to reduce  inequalities  in severe obesity  are  partic-
ularly important.  For  this group,  currently  bariatric
surgery is the  primary  available  option  which  fos-
ters large  sustained  weight  loss  [22].  We have
recently quantiﬁed  socioeconomic  inequalities  in
access to  bariatric surgery  treatment  in Australia
[23], which  risks  further widening  the  inequalities
in severe obesity  reported  herein.  With  increasing
rates of  severe  obesity,  proven  treatments  such  as
bariatric surgery  [22],  must  be  more  accessible  to
Australians from  all socioeconomic  groups  if  we  are
to reduce  the future  associated  morbidity  burden.
Increasing funding  to treat  severe obesity  using
bariatric surgery  in  public  hospitals  is one  tangible
step which  could  be  taken to  address  socioeconomic
inequalities in severe  obesity.
We observed  signiﬁcant  increases  in the  preva-
lence of  class  I,  II  and  III  obesity  between  1995
and 2011—12,  with  the  greatest  relative  increases
in class-III  obesity  (which  more than doubled).
However, during the  more  recent  time  period
assessed (2011—12  vs 2007—08),  the increase  in
obesity prevalence  reached  statistical  signiﬁcance
for class-III obese  women  only.  However,  the  short-
time period  assessed  (5 years),  combined  with  small
samples for  the  more  severely  obese  categories
means that  it is  not  possible  to  identify  whether
lack of  statistical  signiﬁcance  is  due  to  insufﬁcient
power, or a  plateauing  in prevalence.
In the  most  recent  decade,  studies  from  the
USA (2003—2012)  [24]  and  the UK  (1992—2010)
[25] have  reported  a  plateauing  in the overall
prevalence of  obesity.  However,  it  appears  that
the results for  overall  prevalence  mask  ongoing
large increases  at the  extreme  levels  of  obesity
in both  settings  [15,25].  This highlights  the  impor-
tance of  stratifying  by  obesity  severity  sub-classes
in epidemiological  studies.  It  also  highlights  that
continued growth  in  the  most  severe  end  of  the  obe-
sity spectrum  in adults  appears  to  be a  consistent
pattern across many  countries,  including  Australia
over the last  decade.  Understanding  the drivers  for
ongoing increases  in severe  obesity  should  be  priori-
tised in  future  research  to  assist  with  the targeting
of interventions  to  stem  current  trends.
Over the past  two decades,  the  prevalence  of
obesity has  continued  to  increase  in  Australian
adults, with the  greatest  relative  growth  observed
in the  most  severe  obesity  sub-classes.  One  in  every
ten Australians  is  now severely  obese,  and  even
higher rates  are  observed  in  women,  older  adults
and people from  the  most  disadvantaged  socioeco-
nomic groups.  Continued  reporting  of  obesity  as  a
single group  masks  the  rapid  increases  in severe
obesity, a  condition  associated  with  greater  adverse
consequences relative  to  mild obesity.  Universal
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efforts  are  required  to  prevent  and  treat mild and
severe obesity  in  all age, sex  and socioeconomic
sub-groups. This  study  highlights  high  risk groups
who also  warrant  targeted  interventions.
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preliminary evidence suggests that 
this has not been shared across all 
socioeconomic levels.3 Obesity is 
one of the few preventable risk factors 
with increasing prevalence world-
wide. Reduction of socioeconomic 
inequalities in obesity is an opportunity 
to reduce future social disparities 
in health. Routine monitoring of 
obesity trends by socioeconomic 
position should be introduced to make 
inequalities central to policy making. 
Second, the composition of the 
obese population should be described 
with respect to the degree of severity. 
During the past three decades, 
increases have been reported in overall 
obesity prevalence, with the largest 
increases in the most severe obesity 
subgroups.4,5 Consequently, cases 
of severe obesity (body mass index 
[BMI] more than 35 kg/m²) account 
for an increasingly large proportion 
of the obese population over time. 
One in seven Americans are now 
severely obese, and the total obesity 
prevalence is 35% in the USA.6 Severe 
obesity is associated with  greater 
adverse consequences than mild 
obesity (BMI between 30·0 and 
34·9 kg/m²). Monitoring trends in 
the severity composition of the obese 
population is essential to predict the 
associated disease burden and inform 
options for intervention. 
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known effectiveness have almost 
disappeared from the debate on 
tobacco control.
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The debate on electronic 
cigarettes
We were surprised to read in 
The Lancet (Nov 1, p 1576),1 
Lorien Jollye’s criticisms of the 
public health community for, as 
she alleges, insulting and ignoring 
the supporters  of  electronic 
cigarettes (e-cigarettes). A recent 
Lancet–London School of Hygiene & 
Tropical Medicine Global Health Lab 
(held in London, on Nov 4, 2014) 
debating the tobacco endgame, 
that was widely advertised, was an 
opportunity to engage on this issue. 
Yet rather than put forward their 
arguments, advocates of e-cigarettes 
instead chose to remain silent in the 
lecture theatre while insulting the 
participants on twitter. Two things 
are now clear. First, the advocates 
of e-cigarettes seem only willing to 
engage on their own terms. Second, 
anyone with the temerity to suggest 
that e-cigarettes are anything other 
than the game changing solution 
to the problem of tobacco will be 
subject to grossly offensive attacks,2 
with growing evidence that these 
are being orchestrated.3 One recent 
example, a tweet directed at two of 
us, contained a picture of a noose 
with the caption “your days are 
numbered”. The public health 
community has listened, but it 
has also systematically reviewed 
the evidence.4 Numerous national 
and international organisations 
have reached the conclusion that 
it is possible that these products 
might help some people who 
are heavily addicted to nicotine 
but there are many very serious 
concerns about their effectiveness, 
safety, and potential to renormalise 
smoking.5 Moreover, there are 
real concerns that they are intro-
ducing non-smoking adolescents to 
nicotine addiction,6 so it is certainly 
premature to encourage their 
use. However, the very effective 
campaign waged by their supporters 
has ensured that other measures of 
Prevalence of 
overweight and obesity 
in children and adults
The global burden of overweight 
and obesity study by Marie Ng and 
colleagues (Aug 30, p 766)1 will be 
crucial to drive political change. We 
emphasise two important additional 
steps in global obesity surveillance to 
inform action.
First, obesity trends should be 
reported stratiﬁ ed by socioeconomic 
position. A socioeconomic gradient 
in obesity has been reported in most 
developed countries; greater prevalence 
of overweight and obesity is seen in 
more disadvantaged groups.2 Although 
levelling off of the obesity epidemic 
has been reported in some countries, 
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Education of health 
professionals in China
 With great interest I  read 
Jianlin Hou and colleagues’ Review 
(Aug 30, p 819).1 I applaud the initiative 
of China’s Ministry of Education to 
provide previously unreleased data 
on the number of health professional 
graduates and faculty by school. 
I respectfully request this information 
to be made publicly available: improved 
data can drive research on the quality 
of schools and their graduates, both 
in China and worldwide. We recently 
reported an overview of the world’s 
medical schools,2 and identiﬁ ed many 
challenges associated with counting 
schools and tracking information at 
school level. Nevertheless, to help 
meet the projected demand for health 
professionals in China, its government 
must pay attention, not only to the 
number and capacity of their training 
institutions, but also to their quality.
Hou and colleagues provide 
observations on the quality of health 
professional education, but do not 
comment on the availability of out-
come measures, such as government 
recognition and oversight, licensure and 
test scores, or process measures, such 
as qualifications of faculty staff. The 
absence of standard setting processes, 
accreditation, and licensing processes 
poses a real threat to the quality of 
the educational institutions of health 
professionals in China. 
Rigid and static educational methods 
are prevalent—incorporation of adult 
learning principles coupled with 
state-of-the-art assessment and 
evaluation are urgently needed to 
bring the education of China’s health 
professionals into the 21st century. What 
China needs are health professionals 
with the knowledge and skills to bring 
major educational reform and create 
meaningful and sustainable advances. 
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Authors’ reply
We welcome the Correspondence 
from Catherine Keating and colleagues 
commenting on our recent Article1 
and thank them for their suggested 
steps to improve the quality of global 
obesity surveillance.
We agree that stratiﬁ cation of trends 
by socioeconomic status is important 
and relevant to understanding the 
obesity epidemic. In our study, we 
have focused mainly on estimating 
the national trends and revealing the 
intercountry similar ities and diﬀ erences. 
Intracountry variation was not studied. 
To address this limitation, the Global 
Burden of Disease Study is gradually 
incorporating sub-national analysis in 
some countries to generate the most 
policy-relevant results. One challenge, 
however, is the scarcity of reliable data 
for subpopulations. Surveillance and 
surveys are often designed to be nation-
ally represen tative. To capture sub-
national and subpopulation infor mation, 
a compre hensive monitoring system 
should be developed to allow gathering 
of data at a more localised level.
Regarding the authors’ second 
point, we agree that it is important to 
examine the composition of the obese 
population according to severity. Again, 
the scarcity of data is  a substantial 
challenge in the estimation process.
Obesity is a pressing health issue 
worldwide. Eﬀ ective monitoring and 
surveillance are crucial to inform action 
and trace success.
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We read with interest the Review 
by Jianlin Hou and colleagues on 
the progress and challenges of 
transformation of the education of 
health professionals in China.1 We 
are concerned about the training of 
nurses. We are worried by the fact 
that most nurses did not receive 
standard nursing training. According 
to ﬁ gure 1 in the Review,1 in 2012, only 
30 000 out of 186 000 graduate nurses 
earned standard bachelor degrees or 
above. Most nurses received diplomas 
associated with brief training. Based on 
the supplementary materials,1 more than 
80% of nurses working in the Chinese 
medical system received a diploma 
or lower and lack adequate training. 
With a 1:1 ratio between doctors and 
nurses1 and stressful working conditions, 
inadequately trained nurses could make 
mistakes during their medical service. 
The Review1 on education 
transformation was accompanied 
by three pieces of Correspondence2–4 
about violence against doctors in 
China. Although we agree that stronger 
punishments and other measures 
should be implemented to reduce 
violence against health professionals, 
we also believe that the education of 
nurses in China could also participate 
to some degree to the issue of 
violence against medical personnel.5 
Nurses are intermediates between 
doctors and patients. In our practice, 
we have seen misunderstanding 
and mistrust between patients and 
doctors most probably due to of the 
inadequate training of nurses. A more 
comprehensive training system for 
nurses is needed.
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The association between high BMI and low health-related 
quality of life (QoL) is well established (1). However, few stud-
ies have employed utility-based QoL (UQoL) instruments to 
assess this relationship in population samples. UQoL instru-
ments are similar to general health profiling scales (e.g., 
SF-36), in that they assess multiple QoL dimensions, but they 
differ because their scoring captures the relative importance 
of each QoL dimension, as judged by a reference population 
(2). During the construction of UQoL instruments, reference 
subjects are required to reveal their willingness to trade quan-
tity and quality of life, and this information is utilized to weigh 
health states (2). Consequently, a strength of the UQoL met-
ric is that scores reflect the subjects’ willingness to forgo life 
expectancy.
Significant reductions in UQoL associated with obesity in 
the general population have previously been reported (range: 
2–11.0% relative to healthy weight) (3–5). However, body 
weight categories were based on self-reported height and 
weight which are often unreliable, particularly in obese per-
sons (6). Furthermore, few studies stratify by obesity subclasses 
(I–III) defined by the World Health Organisation (WHO).
Quantifying UQoL for subclasses of obesity is increasingly 
relevant due to the rapidly rising prevalence of more severe  levels 
of obesity. The prevalence of class-III obesity (BMI ≥40 kg/m2) 
is rising twice as fast as the prevalence of class-I obesity (BMI 
30–34.9 kg/m2) in the United States (7). More severe levels of 
obesity are associated with much greater increases in health 
risks (8). Information on the UQoL for subclasses of obesity 
can inform the prioritization of obesity prevention and man-
agement strategies and more sensitive economic evaluations of 
these interventions.
The present study analyzed data for adults participating in 
the Australian Diabetes, Obesity, and Lifestyle (AusDiab) Study. 
The hypothesis that UQoL is inversely associated with BMI was 
tested. UQoL differences between healthy weight and excess body 
weight categories were calculated, with and without adjustments 
for markers of metabolic obesity-related disease.
METHODS
This study analyzed UQoL, anthropometry, biochemical, and sociode-
mographic data collected in AusDiab, a nationwide,  representative study 
designed to investigate diabetes and related risk factors in the Australian 
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Utility-Based Quality of Life Associated 
With Overweight and Obesity: The Australian 
Diabetes, Obesity, and Lifestyle Study
Catherine L. Keating1, Anna Peeters2,3, Boyd A. Swinburn4, Dianna J. Magliano2,3 
and Marjory L. Moodie1
This study aimed to estimate utility-based quality of life (UQoL) differences between healthy body weight and excess 
body weight categories. Cross-sectional analysis of 10,959 adults, participating in baseline data collection of the 
nationally representative Australian Diabetes, Obesity, and Lifestyle (AusDiab) Study was undertaken. Height and 
weight were measured by trained personnel. Body weight categories were assigned as healthy weight, overweight, 
and obesity subclasses I, II and III. UQoL was assessed using the SF-6D, which captures physical functioning, role 
limitation, social functioning, pain, mental health, and vitality on a score of 0.00–1.00 (worst-best). The relationship 
between body weight categories and UQoL was assessed using linear regression, adjusting for age, sex, education, 
and smoking. Relative to the healthy weight group (mean UQoL score 0.77), mean adjusted UQoL differences (95% 
confidence intervals) were 0.001 (−0.008, 0.010) for overweight, −0.012 (−0.022, −0.001) for class-I obese, −0.020 
(−0.041, 0.001) for class-II obese, and −0.069 (−0.099, −0.039) for class-III obese groups. Adding metabolic syndrome 
markers to the covariates had little impact on these differences. Results confirmed an inverse dose–response 
relationship between body weight and UQoL in this study of Australian adults. This highlights the need to incorporate 
UQoL measures which are sensitive to the subclasses of obesity when evaluating obesity interventions.
Obesity (2012) doi:10.1038/oby.2012.151
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population. The population, methods, and response rates for the 
AusDiab Study are detailed elsewhere (9). In brief, it was a population-
based study of 11,247 individuals aged ≥25 years, from 42 randomly 
selected urban and rural areas of Australia, conducted in 1999–2000.
Fasting plasma glucose was determined by the glucose oxidase 
method using an Olympus-AU600 automated analyzer (Olympus 
Optical, Tokyo, Japan). Serum triglycerides and high-density lipopro-
tein cholesterol were measured by standard enzymatic methods. Blood 
pressure was measured using a Dinamap monitor (GE Medical Systems 
Information Technologies, Milwaukee, WI). Height and weight were 
measured by trained personnel with subjects in light clothing. BMI 
was calculated as weight in kilograms divided by the square of height 
in meters. Information on sociodemographic variables and smoking 
were obtained through interview (9).
Body weight categories were defined according to WHO BMI cut-
points (10): underweight (<18.5 kg/m2), healthy weight (18.5–25 kg/m2), 
overweight (25.0–29.9 kg/m2); class-I obesity (30.0–34.9 kg/m2); class-II 
obesity (35.0–39.9 kg/m2); and class-III obesity (≥40.0 kg/m2).
QoL was assessed using the SF-36 QoL Scale (version 1; Medical 
Outcomes Trust, Lincoln, RI). Scores were converted to utility-based 
SF-6D scores using an algorithm developed by Brazier et al. (11). The 
SF-6D captures six dimensions: physical functioning, role limitation, 
social functioning, pain, mental health, and vitality. Scoring is 0.00–1.00 
(worst-best), and incorporates health state preference weights from a 
general population sample from the United Kingdom (11), considered 
transferable to the general Australian population.
Subjects with incomplete QoL or anthropometry data, or categorized 
as “underweight” were removed from the sample. To account for cluster-
ing and stratification of the survey design, and adjust for non-responses, 
the data were weighted to match the age- and sex-distribution of the 1998 
residential population of Australians aged ≥25 years.
Two multivariate regression models were used to estimate the mean 
differences in UQoL scores between the healthy weight and each excess 
body weight category. In model 1, differences for the whole population 
and subpopulations of males and females were estimated adjusting for 
age, sex, education, and smoking. In model 2, metabolic syndrome mark-
ers (triglycerides, high-density lipoprotein cholesterol, systolic blood 
pressure, and fasting plasma glucose) were added to the covariates in an 
attempt to remove the effects of metabolic obesity-related morbidity on 
UQoL. Model 1 was also repeated with BMI replacing the body weight 
category. Statistical significance was defined P < 0.05.
RESULTS
The population analyzed (n = 10,959) is profiled in 
Supplementary Table S1 online. The mean age was 48.1 years 
and 45.3% were male. Females and subjects with lower educa-
tion levels were over-represented in the obese subclasses, par-
ticularly class-III obese. Biochemical markers of the metabolic 
syndrome worsened with each higher BMI category. The mean 
UQoL score for the sample was 0.77.
Lower mean UQoL scores were observed in each higher 
BMI obese subclass, ranging from 0.76 to 0.69 for class-I/class-
III obese respectively. Relative to the healthy weight group, 
mean UQoL differences (95% confidence intervals) were 
0.001 for overweight (−0.008, 0.010), −0.012 for class-I obese 
(−0.022, −0.001), −0.020 for class-II obese (−0.041, 0.001), and 
−0.069 for class-III obese (−0.099, −0.039) groups, after model 
1 adjustments. Differences were significant for comparisons 
between healthy weight and both class-I and class-III obesity. 
Gender-stratified results were similar in magnitude; however, 
confidence intervals were much wider for males such that dif-
ferences were no longer statistically significant. Adjusting for 
markers of the metabolic syndrome (model 2) had little impact 
on differences for the whole sample. UQoL differed by −0.002 
(−0.002, −0.001) for every one unit increase in BMI (P < 0.001), 
confirming a dose–response relationship (Figure 1).
DISCUSSION
This national, population-based study of Australian adults 
found an inverse dose–response relationship between BMI 
and UQoL. Controlling for metabolic syndrome markers had 
little impact on these differences, suggesting that lower UQoL 
scores in the general overweight and obese adult population 
are not driven by metabolic disturbance.
A strong negative relationship between BMI and UQoL 
was demonstrated for the class-III obese group (UQoL 6.9% 
0.001
Model 1
O
ve
rw
e
ig
ht
Cl
as
s 
1 
ob
es
e
Cl
as
s 
2 
ob
es
e
Cl
as
s 
3 
ob
es
e
O
ve
rw
e
ig
ht
Cl
as
s 
1 
ob
es
e
Cl
as
s 
2 
ob
es
e
Cl
as
s 
3 
ob
es
e
O
ve
rw
e
ig
ht
Cl
as
s 
1 
ob
es
e
Cl
as
s 
2 
ob
es
e
Cl
as
s 
3 
ob
es
e
O
ve
rw
e
ig
ht
Cl
as
s 
1 
ob
es
e
Cl
as
s 
2 
ob
es
e
Cl
as
s 
3 
ob
es
e
Model 2 Model 1 (females) Model 1 (males)
0.012
0.020
0.069
0.005
0.006
0.015
0.062
0.005
0.020
0.023
0.066
0.008
0.003
0.014
0.092
M
ea
n 
SF
6D
- a
dju
ste
d d
iffe
re
n
ce
 r
e
la
tiv
e
 to
 h
ea
lth
y 
we
ig
ht
Figure 1 Mean difference in baseline utility-based quality of life scores according to body weight category: the AusDiab Study. Labels on bars 
denote adjusted differences relative to the healthy weight group. Model 1 adjusted for age, sex, education, and smoking. Model 2 adjusted for the 
same characteristics, plus triglycerides, HDL cholesterol, systolic blood pressure, and fasting plasma glucose. Lines on bars indicate 95% confidence 
intervals; lines which cross the x-axis were not statistically significant. P values for model 1 were 0.794, 0.028, 0.064, and <0.001 for overweight 
and class I–III obesity respectively. HDL, high-density lipoprotein.
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lower relative to the healthy weight group). This compared to 
differences of 1.2 and 2.0% for the class-I and class-II obese 
groups, respectively. This observation is consistent with the 
previously reported exponential relationship between BMI 
and morbidity (8). The UQoL differences for obesity sub-
classes-I/II/III were similar in magnitude to those attribut-
able to glaucoma (1.3%), asthma (2.1%), and depression 
(6.3%) determined using the EQ-5D UQoL instrument (12). 
Our study also found that UQoL scores were significantly 
lower for obese females, but not males. This result is mir-
rored in the disability literature where significant disability 
is reported in obese females, but not males (13), suggesting 
body weight-related disability may be a mediating factor for 
reduced UQoL in obese females.
The key strengths of this study were the use of measured 
height and weight, analysis of a national population-based sam-
ple enabling transferability of results to the general overweight/
obese population, stratification by obesity subclasses, and the 
step-wise controlling for rigorously collected covariates.
Causal directions in the relationship between excess weight 
and UQoL could not be determined due to the analysis of 
cross-sectional data. The SF-6D is not an obesity-specific 
UQoL instrument and therefore some impacts of obesity 
may not have been captured. However, correlations in QoL 
estimated using the SF-6D and the obesity-specific IWQoL-
Lite have been reported (14). The analysis which adjusted 
for obesity-related comorbidity only included markers of 
the metabolic syndrome; the effects of other obesity-related 
disease such as obstructive sleep apnea and osteoarthritis, 
which may be more symptomatic and thus more likely to 
impact on UQoL, were not captured. The population data 
was collected in 1999–2000, therefore it is possible that due 
to increasing levels of overweight and obesity over the last 
decade the relationship between excess weight and BMI has 
changed.
The key strength of the UQoL metric is that scores reflect 
the subjects’ willingness to forgo life expectancy. Assuming 
that the UQoL differences observed in this study are attribut-
able to excess weight, the results indicate that class-III obese 
Australian adults would be willing to forgo 6.9% of their 
remaining life to spend it in best health.
While UQoL measurement is imperfect, there is no supe-
rior methodology for the inclusion of QoL within cost-
 effectiveness analysis (CEA). UQoL and survival are combined 
to estimate quality-adjusted-life-years, the outcome measure 
recommended by many national regulatory authorities for 
adoption in CEA (15). Our results can be utilized to inform 
CEA of obesity interventions, such that the effects of obesity 
per se (rather than simply obesity-related morbidity) can be 
captured in UQoL modeling. Results will also enable more 
sensitive CEA by incorporating UQoL data which are specific 
to the subclasses of obesity.
Previously published population-based studies (using self-
reported height and weight) report UQoL differences of 4% 
(5) and 7% (3) between healthy weight and class-II obese 
subjects and a UQoL difference of 11% (4) between healthy 
weight and class-III obese subjects. Although UQoL differ-
ences vary by study, regardless of the methods or participants, 
each study found an inverse relationship between BMI and 
UQoL. The current study confirms this relationship utilizing 
measured anthropometric data. UQoL differences estimated 
by this study may be lower than estimated by previous stud-
ies because the study population was adjusted to represent a 
national sample. To our knowledge, this is the first study to 
publish UQoL weights for all excess body weight categories 
defined by the WHO for a representative adult population 
using measured height and weight. This study confirms that 
UQoL is inversely associated with BMI. It also found that 
adjusting for the metabolic syndrome does little to attenuate 
this relationship.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper at http://
www.nature.com/oby
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A B S T R A C T
Objective: To explore the relationship between overweight/obesity
and utility in adolescents. Methods: Data were collected from 2890
adolescents attending 13 secondary schools in the state of Victoria,
Australia. The Assessment of Quality of Life 6-Dimension (AQoL-6D)
questionnaire was used to measure individual utility. Adolescent’s
height and weight were measured and weight status categories as-
signed according to the World Health Organization adolescent growth
standards. Multivariate linear regression analyseswere undertaken for
the whole population and subpopulations of boys and girls to estimate
the mean differences in utility scores between 1) overweight and
healthy weight and 2) obese and healthy weight adolescents, while
controlling for demographic and socioeconomic status variables.
Results: Themean age of adolescents was 14.6 years, 56.2%were boys,
22.2% were overweight, and 9.4% were obese. The mean utility of
healthy weight adolescents was 0.860. After adjustments, the over-
weight and obese groups reported signiﬁcantly lower mean utility
scores (differences: 0.018 and 0.059, respectively, relative to the
healthyweight group). This can be interpreted as equivalent to a stated
willingness to sacriﬁce 1.8% and 5.9% of a life in perfect health or 2.3%
and 6.8% of a life at healthy weight. A signiﬁcant utility difference
associated with overweight was only experienced by girls (0.039, P 
0.003). Both sexes experienced signiﬁcant utility differences associated
with obesity, but the magnitude was double for girls (0.084, P 0.001)
relative to boys (0.041, P  0.022). Conclusion: Utility is lower among
overweight and more so among obese adolescents.
Keywords: adolescents, obese, overweight, utility.
Copyright © 2011, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.
Background
Obesity is emerging as themost important preventable risk factor for
morbidity andmortality inmany high-income countries [1]. Govern-
ment policymakers must make decisions regarding the optimal mix
of interventions to tackle obesity in the context of their health-care
budgets and the evolving evidence base. Many countries already use
cost-effectiveness analysis (CEA) approaches to compare the cost-
effectiveness of single or multiple [2] interventions.
Some authorities have indicated their preference for a special-
ized stream of CEAs known as cost-utility analyses (CUAs); for
example, the US Public Health Service Panel on Cost-Effectiveness
in Health and Medicine [3], the UK National Institute for Health
and Clinical Excellence [4], the Canadian Common Drug Review [5],
and the Australian Pharmaceutical and Medical Service Advisory
Committees [6]. CUA compares the costs and beneﬁts of alternative
interventions with the beneﬁts expressed as quality-adjusted life-
years (QALYs). QALYs are an outcome measure that combines the
duration and quality of survival and can therefore be used to com-
pare interventions targetingdiversediseaseareas.QALYsareusually
calculated as the utility index for a particular health statemultiplied
by the length of time (in years) spent in that state [7].
Utility indexes are often elicited through multiattribute utility
(MAU) instruments. These are similar to general health proﬁle
(GHP) instruments because they include questions relating tomul-
tiple dimensions of health-related quality of life (QoL). MAU in-
struments differ from GHPs because their scoring takes into ac-
count the relative importance of each area of QoL as judged by a
reference population. Utility indexes are scored between 0.00 and
1.00 (worst to best). A utility loss of 0.05 can be interpreted as
meaning that to avoid the poorer health state, an individual would
be willing to forgo 5% of a life expectancy in the best health state,
i.e., U  1.00 [8]. Similarly, a 5% reduction in utility from one state
(e.g., healthy weight) to a second (e.g., obesity) is interpretable as a
willingness to give up 5% of remaining life expectancy at healthy
weight to avoid being obese.
Four published studies have assessed the relationship between
excess weight and utility in population samples [9–12]. These are
summarized in Table 1. Half of the studies controlled for obesity-
relatedmorbidity, and therefore reportedutility scores capturedonly
the impacts of obesity per se, not obesity-related morbidity. Each
study reported a signiﬁcant reduction inutility (range 3.2–5.0%) asso-
ciated with obesity (excludes studies targeting morbid obesity). Re-
sults were less consistent for the relationship between overweight
andutility;most studiesdidnot ﬁnda signiﬁcant difference inutility.
All these studies, however, were based on self-reportedmeasures of
height and weight, which have been reported as unreliable [13]. Ad-
ditionally, all the studies were limited to adult populations.
This study analyzed utility and anthropometry data for adoles-
cents participating in the Australian arm of the Paciﬁc Obesity
Prevention in Communities (OPIC) Project [14]. To our knowledge,
* Address correspondence to: Catherine Keating, Deakin Health Economics, Deakin University, 221 Burwood Highway, Burwood, Victoria
3125, Australia.
E-mail: catherine.keating@deakin.edu.au.
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Table 1 – Previous studies assessing the relationship between overweight/obesity and utility: population samples.
Study
(chronological)
Methods Results
Study sample Height and
weight
data
MAU
instrument(s)
Comorbidities
controlled for
Impact of
overweight*
Impact of obesity* Sex impacts*
Trakas et al.,
2001, Canada
N  38,151; age range
20-64 years
Self-reported HUI-III None Not signiﬁcant Signiﬁcant mean utility
loss; 4% for morbidly
obese
Utility losses signiﬁcant for
both sexes but greater in
females (mean utility
loss for morbid obesity:
females. 6%; males: 2%).
Jia and Lubetkin,
2005, USA
N  13,646 adults,
age range
unspeciﬁed
Self-reported EuroQol EQ-
5D and EQ-
VAS
Asthma, hypertension,
diabetes, heart disease,
stroke, emphysema
Signiﬁcant mean utility
losses on 1/2
measures; 1.3%
according to the EQ-
5D
Signiﬁcant mean utility
loss on both
measures; 3.3% for
BMI 30–35 and 7.3%
for BMI 35 (EQ-5D)
and 3.2% for BMI 30–
35, 4.8% for BMI 35
and (EQ-VAS)
Not reported
Kortt and Clarke,
2005,
Australia
N  12,767, age range
18–79 years
Self-reported SF-6D None for primary analysis.
Secondary analysis:
diabetes, coronary heart
disease,
musculoskeletal
disorders, depression
and cancer
Not reported Not reported For males (females), the
marginal effect of a one-
unit increase in BMI was
associated with a 0.0024
(0.0034) decrement in
utility
Sach et al., 2007,
UK
N  1612, age range
45–99 years
Self-reported EQ-5D, EQ-
VAS and
SF-6D
Back pain, hip pain, knee
pain, heart disease,
stroke, asthma, cancer,
diabetes, rheumatoid
arthritis, osteoarthritis
Not signiﬁcant Signiﬁcant mean utility
loss on all measures;
4% (EQ-5D), 3.8% (SF-
6D), and 5.0% (EQ
VAS)
Not reported
BMI, body mass index; HUI-III, Health Utilities Index Mark 3; MAU, multiattribute utility.
* Where raw results and results controlling for potential confounders are presented, the latter are included in table.
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this is the ﬁrst study to report the relationship between over-
weight/obesity and utility in a general adolescent population. The
results will inform a CEA of the Australian arm of the OPIC Project.
These utility weights can also be adopted within other future
CUAs of obesity interventions.
Methods
Sample
The Paciﬁc OPIC Project was an obesity prevention project tar-
geting secondary school–age adolescents. The Australian arm of
the study was located in the Barwon-South West region in the
state of Victoria, Australia. The intervention site was located
over ﬁve secondary schools in the East Geelong/Bellarine re-
gion. The comparison group was a stratiﬁed, random selection
of eight secondary schools across the rest of the Barwon-South
West region. Participants were recruited for the study from
years 7 to 10 (typically age range 12–15 years) from each of the
schools. The sample for analysis comprised adolescents from
all 13 schools. Anthropometry, QoL, and sociodemographic data
were collected by a research team from Deakin University in
2005 to 2006 from adolescents who provided both self and pa-
rental written consent.
Weight status classiﬁcation
Adolescent’s height and weight were measured by trained ﬁeld
workers. Adolescents removed bulky clothing before measurement.
Heightwasmeasured to thenearest 0.1 cmusingaportable stadiom-
eter (Surgical and Medical PE87, Novel Figure Finder, Novel Products
Inc., Rockton, IL). Weight was measured to the nearest 100 g using a
TANITA Body Composition Analyzer (Model BC 418, Wedderburn,
Australia). Body mass index (BMI) was calculated as weight (in kilo-
grams) divided by the square of height (inmeters). Adolescentswere
classiﬁed into four weight status categories: thin, healthy weight,
overweight, and obese according to the World Health Organization
(WHO) growth reference standards for school-age children and ado-
lescents [15]. In a subsequent analysis, adolescents were also classi-
ﬁed into the same categories according to the International Obesity
Task Force (IOTF) BMI cut points for children [16]. Standardized BMI
z-scoreswere calculated by subtracting themedianBMI for theWHO
reference population from each observed value and dividing by the
SD for the same WHO reference population (a BMI z-score of 0 is
equivalent to the median WHO reference population BMI).
Measurement of utility
TheAssessment of Quality of Life 6-Dimension (AQoL-6D)wasused
to measure utility and was completed by students using hand-held
computers in the classroom. The AQoL-6D questionnaire comprises
20 items across 6 dimensions: physical ability, social and family re-
lationships, mental health, coping, pain, and vision, hearing, and
communication [17]. Weighted item scores were combined into di-
mensions using the multiplicative function recommended by Deci-
sionAnalytic Theory [18].Weighted dimensionswere similarly com-
bined into a single multiplicative score. The initial AQoL was
validated against four other utility instruments [19] and theAQoL-6D
against independently derived time trade-off (TTO) scores [20]. As
part of the OPIC project AQoL-6D multiplicative scores were recali-
brated for Australian adolescents with utility scores derived using
the TTO technique,which asked the adolescents to indicate the time
in best health that they would be willing sacriﬁce to avoid being in a
series of health state scenarios described to them.Detailed recalibra-
tion methods and results are described in Moodie et al. [21].
Socioeconomic quartile
The Socioeconomic Index for Areas published by the Australian
Bureau of Statistics [22] was used as an indicator of relative socio-
economic status (SES) advantage/disadvantage. The index is
Table 2 – Characteristics of the study population.
No. (%) by WHO weight status categories
Thin Healthy
weight
Overweight Obese Total P
value*
Sex
Boys 8 (0.5) 1107 (68.1) 348 (21.4) 162 (10.0) 1625 (100.0) 0.458
Girls 8 (0.6) 853 (67.4) 294 (23.2) 110 (8.7) 1265 (100.0)
Age in years
11 0 (–) 6 (54.5) 2 (18.2) 3 (27.3) 11 (100.0) 0.003
12 3 (0.8) 237 (61.2) 99 (25.6) 48 (12.4) 387 (100.0)
13 5 (0.7) 452 (64.1) 159 (22.6) 89 (12.6) 705 (100.0)
14 3 (0.5) 439 (68.3) 148 (23.0) 53 (8.2) 643 (100.0)
15 5 (0.8) 419 (70.9) 119 (20.1) 48 (8.1) 591 (100.0)
16 0 (–) 298 (73.4) 85 (20.9) 23 (5.7) 406 (100.0)
17 0 (–) 106 (73.6) 30 (20.8) 8 (5.6) 144 (100.0)
18 0 (–) 3 (100.0) 0 (–) 0 (–) 3 (100.0)
Age group
15 11 (0.6) 1134 (64.9) 408 (23.4) 193 (11.1) 1746 (100.0) 0.001
15 5 (0.4) 826 (72.2) 234 (20.5) 79 (6.9) 1144 (100.0)
SES quartile (most-least disadvantaged)
25th 3 (0.4) 447 (62.5) 192 (26.9) 73 (10.2) 715 (100.0) 0.027
25th–50th 3 (0.7) 320 (69.4) 92 (20.0) 46 (10.0) 461 (100.0)
50th-75th 8 (0.7) 773 (69.8) 221 (19.9) 106 (9.6) 1108 (100.0)
75th 2 (0.3) 398 (69.5) 130 (22.7) 43 (7.5) 573 (100.0)
Total 16 (0.0) 1960 (0.7) 642 (0.2) 272 (0.1) 0 (100.0)
WHO, World Health Organization.
* P values indicate signiﬁcant differences in distribution of weight status categories across demographic variables.
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based on data collected from the 2001 Australian Census of Popu-
lation and Housing and incorporates variables such as income,
education, occupation, living conditions, access to services, and
wealth. The index is based on geographic postal area, and a higher
score on the index indicates that an area has a relatively high
proportion of people with high incomes or a skilled work force
(national mean 1000, SD 100). Scores were assigned based on ad-
olescent’s home postal code and categorized into SES quartiles
based on the population distribution in the state of Victoria.
Analysis
Summary statistics were used to describe the characteristics of
the sample including the prevalence of weight status catego-
ries. The thin category was excluded from all subsequent anal-
ysis. Mean utility scores were calculated for each weight status
category. Multivariate linear regression analyses were under-
taken for the whole population and subpopulations of boys and
girls to estimate the mean differences in utility scores between
1) overweight and healthy weight and 2) obese and healthy
weight adolescents while controlling for demographic and SES
variables. Mean AQoL utility scores were calculated for each BMI
z-score SD category to conﬁrm a linear relationship. A multivar-
iate linear regression analysis was undertaken to estimate the
relationship between utility and BMI z-scores while controlling
for the same aforementioned variables. Mean differences be-
tween healthy weight and overweight/obese adolescents were
Table 3 – Adjusted mean differences in utility scores by weight status, age, SES, and sex.
WHO classiﬁcation IOTF classiﬁcation
Coefﬁcient P  t* Coefﬁcient P  t*
All adolescents
Weight status
Healthy weight Ref Ref Ref Ref
Overweight 0.018 0.035 0.023 0.007
Obese 0.059 0.001 0.058 0.000
Age
15 years Ref Ref Ref Ref
15 years 0.014 0.040 0.012 0.079
SES (most-least disadvantaged)
25th Ref Ref Ref Ref
25th–50th 0.017 0.116 0.017 0.115
50th–75th 0.020 0.024 0.019 0.028
75th 0.017 0.108 0.017 0.108
Gender
Boys Ref Ref Ref Ref
Girls 0.035 0.001 0.035 0.000
Boys
Weight status
Healthy weight Ref Ref Ref Ref
Overweight 0.000 0.248 0.013 0.248
Obese 0.041 0.022 0.043 0.022
Age category
15 years Ref Ref Ref Ref
15 years 0.011 0.274 0.010 0.274
SES (most-least disadvantaged)
25th Ref Ref Ref Ref
25th–50th 0.008 0.604 0.008 0.604
50th–75th 0.011 0.408 0.010 0.408
75th 0.005 0.749 0.004 0.749
Girls
Weight status
Healthy weight Ref Ref Ref Ref
Overweight 0.039 0.003 0.035 0.009
Obese 0.084 0.001 0.077 0.001
Age
15 years Ref Ref Ref Ref
15 years 0.016 0.139 0.013 0.225
SES (most-least disadvantaged)
25th Ref Ref Ref Ref
25th–50th 0.029 0.084 0.030 0.078
50th–75th 0.030 0.028 0.031 0.025
75th 0.033 0.046 0.034 0.041
IOTF, International Obesity Task Force;WHO,World Health Organization; P t, Ref, reference population for each variable; SES, socioeconomic.
* This column shows the 2-tailed p-values used in testing the null hypothesis that the coefﬁcient (parameter) is 0.
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calculated for each utility dimension score. Analysis was under-
taken using STATA version 9 (StataCorp, College Station, TX)
and a statistical signiﬁcance value of 0.05.
Results
Participant characteristics
Approximately half of all students enrolled in the sample
schools participated in OPIC data collection. Of 3040 adoles-
cents for whom data were collected, 150 were excluded due to
incomplete information on weight status or utility, leaving a
sample of 2890 for analysis (Table 2). The mean age was 14.6
years (SD 1.4), and the majority of the sample were boys (56.2%).
The proportions in the WHO (IOTF) weight status categories
were 0.6% (2.9%) thin, 67.8% (70.7%) healthy weight, 22.2%
(20.2%) overweight, and 9.4% (6.3%) obese. No sex distribution
differences between healthy weight and overweight/obese ad-
olescents were observed across weight categories (P  0.458).
The proportion of overweight/obese adolescents decreased
with age in years (P  0.003). The proportion of healthy weight
individuals was the lowest in the most disadvantaged SES quar-
tile and vice versa.
Weight status categories and utility
Utility scores were inversely associated with BMI; mean scores for
healthy weight, overweight, and obese adolescents were 0.860,
0.842, and 0.805, respectively. After adjusting for age, sex, and SES
status, the overweight and obese groups reported mean utility
differences of0.018 (95% conﬁdence interval [CI]0.034 to 0.001)
and 0.059 (95% CI 0.083 to 0.035), respectively, relative to the
healthy weight group. Obesity had the strongest association with
utility of all variables in the regression model. Signiﬁcant utility
differences were also observed between age groups (P  0.040)
(older adolescents reported lower scores) and sex (P  0.001) (girls
reported lower scores).
Relative to healthy weight peers, overweight girls reported a
signiﬁcant0.039 (95% CI0.065 to 0.014) difference in mean util-
ity, whereas overweight boys did not report a signiﬁcant utility
difference. Both obese girls and boys reported signiﬁcant utility
differences, however the magnitude of the difference was double
for girls (0.084, 95% CI 0.122 to 0.046) relative to boys (0.041,
95% CI 0.071 to 0.011) (Table 3).
The greatest utility difference for obese adolescents relative to
their healthyweight peers was in the coping dimension (Fig. 1). All
results were similar when the IOTF weight status classiﬁcations
were adopted.
BMI z-scores and utility
Themeanutility scores by BMI z-score SDs are illustrated in Figure 2.
Utility scores were lower with each higher BMI z-score category.
Regression analysis indicated that, if all other variables in the
model were held constant, each BMI z-score SD was associated
with a 0.025 utility reduction.
Discussion
This study found that higher BMI weight status categories were
associatedwith poorer utility in adolescents and that this relation-
ship was strongest in girls. The key strengths of this study were
the use of measured height and weight for the calculation of BMI,
the adoption of WHO BMI cutoff points for adolescents to assign
weights status categories, and the use of a validated utility con-
struct (AQoL-6D), which was completed by adolescents.
Our study found that overweight and obese adolescents experi-
ence mean utility differences of 0.018 and 0.059, respectively. If
we assume that the difference in QoL is attributable to overweight
and obesity (rather than vice versa), then these results indicate that
overweight and obese Australian adolescents would be willing to
forgo 1.8% and 5.9%, respectively, of a life in best health to avoid the
reduction in QoL associated with excess weight. Because the mean
utility score forhealthyweightadolescent is 0.860, this indicateswill-
ingness for overweight andobeseadolescents to sacriﬁce2.1% (0.018/
0.860) and 6.9% (0.059/0.860), respectively, of their life in exchange for
the improvedQoLassociatedwithhealthyweight (theseﬁgureswere
calculated as mean utility loss for overweight/obese/mean utility
score for healthy weight). These magnitudes are similar to those re-
ported by Sullivan and Ghushchyan [23] for asthma (2.1%) and de-
pression (6.3%), respectively.
Our study also found that each higher BMI z-score SD is asso-
ciated with a mean 0.025 utility difference. Again, based on the
assumption that excess weight leads to a reduction in utility, for a
girl aged 14.5 years and 162 cm tall (the mean for girls in our
sample), our results predict that moving from a healthy median
weight to the minimum BMI threshold for obesity (52.2–72.7 kg) is
associated with a willingness to sacriﬁce 4.6 years to live the re-
mainder of her life at a healthy weight (assumes life expectancy of
82.4 years). This is equivalent to a willingness to sacriﬁce approx-
imately 2.7 months per kilogram gained. Importantly, this exam-
Fig. 1 – Mean difference in utility scores relative to healthy
weight, by the Assessment of Quality of Life (AQoL)
dimension.
Fig. 2 – Mean utility scores by body mass index (BMI)
z-score categories. WHO, World Health Organization.
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ple assumes constant BMI and utility losses for the lifetime and
excludes the impacts of future obesity-related morbidity.
This study assessed baseline data for adolescents participating in
the Australian arm of the OPIC Project. The sample overrepresented
several groups relative to averages from the state of Victoria: 1) ado-
lescents who lived in higher SES areas; 2) boys, and 3) adolescents
from regional areas and centers. Furthermore, the participation rate
in OPIC baseline data collection as a proportion of all students en-
rolled in the sample schools was approximately 50%. Therefore, the
transferability of results to the general population of overweight and
obese adolescents in Australia is uncertain.
This research presents results from a single time point and
therefore causal directions in the relationship between excess
weight and QoL cannot be determined. Whether poorer QoL
causes overweight/obesity or overweight/obesity causes poorer
QOL, each causes the other (i.e., bidirectional) or both are caused
by a third independent factor is the topic of debate.
Our study did not collect data on obesity-related morbidities.
The two previous adult studies that adopted this approach [9,11]
found that the mean utility difference between healthy weight
and obese adults approximately halved after controlling for co-
morbidities. Such adjustments are unlikely to inﬂuence results for
pediatric populations because most obesity-related morbidity
does not manifest until adulthood [24]. Furthermore, obesity pre-
vention or alleviation will affect both obesity and obesity-induced
morbidity. Therefore, it is arguable that if the morbidity is attrib-
utable to obesity, then utility weights that capture both obesity
and its consequent morbidity are more appropriate for use in eco-
nomic evaluation. It is, however, possible that overweight/obesity
is caused by pediatric diseases and syndromes in a small propor-
tion of participants, and therefore utility score differences attrib-
utable to weight may be overestimated in these adolescents. Our
study also did not control for stage of puberty within the analysis
because no relevant data were collected.
The measurement of utility is imperfect, and the results cited
here should not be overinterpreted. QALYs are based on stated
preferences and the calculations presented here assume a contin-
uation of the loss of utility through time. Nevertheless, there is no
superior methodology for the inclusion of QoL, and this is the
accepted approach in economic evaluation studies generally and
has been endorsed by national regulatory authorities. This study
uses a recently developed instrument designed speciﬁcally for
health states close to full health.
Longitudinal studies for utility donot exist that demonstrate how
theutility of theoverweight andobese changesover time.On theone
hand, adaptation is possible. Offsetting this, however, obesity is in-
creasingly likely to result in other chronic problems, which may in-
crease the utility reductions over time. On balance, therefore, the
assumption of a constant loss of utility is likely to be conservative.
The mean utility reductions associated with overweight and
obesity estimated by our study are greater than the comparable
results reported for adults in Table 1. This may suggest a stronger
negative association between overweight/obesity and utility for
adolescents. Alternatively, the results may indicate the greater
sensitivity of the AQoL-6D compared to the utility instruments
used in previous studies. This is likely because the AQoL-6D was
developed speciﬁcally to increase measurement sensitivity in
health states close to normal health [20]. Studies exploring the
relationship between overweight/obesity and utility dimensions
for adults [9–12] consistently report the greatest reductions in pain
and mobility. In contrast, our study found the greatest utility re-
duction to be in the coping dimension followed by the same di-
mensions as adults. This may again be attributed to instrument
sensitivity because the AQoL-6D was the ﬁrst MAU instrument to
introduce a coping dimension. The two adult studies that strati-
ﬁed their analysis by sex [9,11] reported a greater utility reduction
for obese females. Our study found the same trend.
Conclusion
This is the ﬁrst study to report utility weights for an overweight
and obese adolescent population. It demonstrates that these con-
ditions are associated with a signiﬁcant reduction in QoL for ado-
lescents and a quantitatively large reduction in utility. Our results
therefore permit the economic evaluation of an adolescent obesity
prevention and treatment program, which may be compared to
the results of economic evaluations of other health-related pro-
grams. The magnitude of the lost utility due to obesity also indi-
cates the magnitude of the likely effect of the unfolding obesity
epidemic and therefore the need for, and potential beneﬁts from,
interventions to mitigate this problem.
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INTRODUCTION
The prevalence of BMI ≥40 kg/m2 is increasing twice as fast 
as that for BMI 30–34.9 kg/m2 in the United States (1), with similar 
trends reported in other Western countries (2). As BMI increases 
above the healthy range (BMI 18.5–25 kg/m2), health risks increase 
exponentially (3). Three out of four adults with a BMI ≥40 kg/m2 
have at least one obesity-related morbidity (4), with the risk of type 2 
diabetes particularly high (up to 93/42-fold higher for women/men 
relative to healthy-weight adults) (5,6). The population with either a 
BMI ≥40 kg/m2 or BMI 35–39.9 kg/m2 with an obesity-related mor-
bidity is described as severely obese.
Increased relative morbidity in the severely obese is asso-
ciated with increased healthcare costs, reported as 65–113% 
higher relative to healthy-weight subjects (7–13). Previous 
studies examining the healthcare costs in the severely obese 
have been limited by a reliance on patient self-reported health-
care utilization data; which is often under-reported, particu-
larly by those receiving more therapies (14), or by an absence 
of data stratified by therapeutic categories.
Quantifying the healthcare costs attributable to severe obes-
ity is increasingly relevant to healthcare payers owing to the 
rapidly rising prevalence of the condition. This information 
can also be utilized to inform the economic evaluation of 
interventions targeting the prevention or treatment of severe 
obesity.
This study compares the utilization of healthcare resources 
and associated costs for a large Australian population of 
severely obese subjects, before undergoing laparoscopic adjust-
able gastric banding (LAGB), with an age- and sex-matched 
general population group. Detailed healthcare data maintained 
by the Australian government, covering a period of 3.5 years, 
were analyzed.
METHODS AND PROCEDURES
Subjects
Two Australian population samples to be compared—a severely 
obese sample and a sample from the general population, were 
identified by Medicare, which administers Australia’s universal 
tax-funded health insurance scheme. Severely obese subjects were 
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identified based on their utilization of LAGB in Australia in 2009 
(n = 11,769). For simplicity, this group is hereafter referred to as the 
“severely obese” population. For the general population sample, a 
random sample of 140,000 subjects was selected from the popula-
tion subscribing to Medicare (which comprises Australian citizens 
and persons with permanent residency status). These were selected 
as samples of 10,000 males and 10,000 females from each of the fol-
lowing 2009 age groups: 15–24, 25–34, 35–44, 45–54, 55–64, 65–74, 
and 75–84 years in order to generate data which were age- and sex-
matched to the severely obese sample as described below (Table 1). 
Medicare expenditure was not a criterion for selection. For simplic-
ity, this group is hereafter referred to as the “general population”.
Measures
Healthcare utilization and cost data for each of the samples were sourced 
from medical and pharmaceutical administrative databases maintained 
by Medicare.
Medicare funds ~3,800 medical services (15) including the follow-
ing outpatient services: consultations provided by general practitioners 
and specialists, radiology, pathology services, dental surgery, optometry, 
and selected allied health services. Many inpatient services provided to 
patients treated in private hospitals are also funded. Data are categorized 
into ten “service type” categories, such as professional attendances and 
therapeutic procedures, as shown in Table 2.
Medicare also funds ~2,100 pharmaceutical therapies (16), ~80% of 
all prescription medications dispensed in Australia. Data are classified 
according to the Anatomical Therapeutic Chemical (ATC) Drug Clas-
sification System maintained by the WHO Collaborating Center for Drug 
Statistics (17). In this system, pharmaceuticals are classified at five dis-
crete levels. This study analyzes pharmaceutical data to the second level 
(therapeutic main group).
Healthcare data capturing all services and therapies funded by Medi-
care were retrieved for each subject in both population samples by Medi-
care. For privacy reasons, de-identified, aggregate data were provided to 
the research team by Medicare. For the severely obese subjects, data were 
retrieved for the 3.5-year period before subjects received LAGB. For the 
general population sample, data were retrieved for the 3.5 years from July 
2005 to December 2008. Data for the obese population was provided as a 
single data-set and the age/gender distribution was provided separately. 
Data for the general population was provided stratified by each requested 
age/gender group.
Analysis
Healthcare utilization “incidence rates” (mean annual number of medi-
cal services and pharmaceutical prescriptions utilized per person) were 
calculated by dividing the observed population incidence for each unique 
medical/pharmaceutical item by the sample sizes and the number of 
years for data retrieval (3.5). The expected incidence rates in the severely 
obese group if the general population incidence rates had applied were 
calculated as the sum of the observed population incidence rate in each 
age-sex group multiplied by the proportion of the severely obese group 
in each age-sex group. The same methods were applied to cost data.
Comparison of incidence rates between the severely obese and general 
population samples were undertaken using standardized incidence ratios 
(SIRs) (18). SIRs were calculated as the ratio of the observed incidence 
rate in the severely obese group divided by the expected incidence rate in 
the general population sample. A SIR equal to one implies no difference 
in the incidence rate between the two samples. Standard methods were 
applied to calculate SIR confidence intervals and to test whether the SIRs 
were statistically significantly different (18). All reported P values are two-
sided and P < 0.05 was considered to be statistically significant.
Medical and pharmaceutical costs for the severely obese were retrieved 
for the period from 3.5 years to 1 day before LAGB surgery and there-
fore are likely to include some costs related to LAGB preparation. On 
the basis of advice from LAGB surgeons, an assumption was made that 
each patient in the severely sample received two consultations with a 
specialist surgeon/physician and six pathology tests before surgery. These 
assumed “LAGB preparation” costs were deducted from the gross costs 
in the obese population. Costs are reported in Australian 2007 dollars (1 
AUD: 0.86 USD: 0.43 GBP).
RESULTS
Severely obese sample characteristics
The age and sex distribution of the severely obese sample is 
illustrated in Figure 1. Within the sample, age was approxi-
mately normally distributed, with the majority of subjects aged 
35–54 years; females were over-represented (78.2%).
Medical services
Severely obese subjects utilized statistically significantly more 
medical services annually relative to the general population 
subjects (mean: 22.8 vs. 12.1/person). The utilization SIR across 
all medical services was 1.89 (95% confidence interval (CI): 
1.88–1.89, P < 0.001). Mean annual medical costs were 2.01-fold 
higher in the severely obese ($1,140/person) relative to the gen-
eral population ($567/person), whereas the mean unit cost of 
medical services utilized was similar across the samples ($49.2 
and $46.8, respectively) (Table 2). It thus appears that cost dif-
ferences are largely driven by greater utilization of services rather 
than by a shift towards services with higher unit prices.
The mean annual number of medical services per person 
were statistically significantly higher in the severely obese sub-
jects in all Medicare medical categories (P < 0.001) except two 
dental/oral categories (no. 4, 10) which were seldom utilized. 
For the medical categories where utilization was statistically sig-
nificantly higher in the severely obese, utilization SIRs ranged 
from 1.38 to 2.86, with the highest SIRs (reported along with 
95% CIs) observed in diagnostic procedures and investigations 
Table 1 Data request to Medicare Australia
Populations for data retrieval
Timeframe for data retrieval (year and 6-month period)
2005 2006 2007 2008 2009
2 1 2 1 2 1 2 1 2
Severely obese before bariatric 
surgery
Data retrieval period: 3.5 years to 1 day before gastric banding 
surgery for each subject
Select population using Medicare gastric 
bandinga in 2009
General population (similar 
demographic characteristics to 
severely obese sample)
Data retrieval period: from July 2005 to December 2008 for each 
subject
Randomly selected subjects from the 
general population based on age and sex 
in July 2009b
aIndicated by Medicare Beneﬁts Schedule item number 30511. bRefer to demographic speciﬁcations under the methods section.
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(2.86, 2.78–2.95), therapeutic procedures (2.03, 2.00–2.06), 
and miscellaneous services (2.22, 2.17–2.27) (Table 2).
The greatest differences in mean annual costs per person 
were observed in professional attendances ($239), therapeutic 
procedures ($112), and pathology services ($91). The twenty 
medical services with the greatest absolute cost differences 
between samples are presented in Table 3. Mean costs for the 
severely obese subjects were higher for each of these services. 
Services relating to consultations with general practitioners, 
psychiatrists/psychologists and other specialists, as well as for 
investigations for obstructive sleep apnea and in vitro fertiliza-
tion services, dominated the list.
Pharmaceutical therapies
The mean number of pharmaceutical prescriptions utilized annu-
ally was statistically significantly higher in the severely obese 
subjects relative to the general population (mean: 11.4 vs. 5.2/
person). The utilization SIR across all pharmaceutical therapies 
was 2.18 (95% CI: 2.17–2.19; P < 0.001). Mean annual pharma-
ceutical costs were 2.2-fold higher in the severely obese subjects 
($595) relative to the general population subjects ($270), whereas 
the mean unit cost of pharmaceutical therapies utilized was simi-
lar across samples ($52.2 and $50.9, respectively). It thus appears 
that cost differences are driven by greater utilization of therapies 
rather than by a shift towards therapies with higher unit prices.
The mean annual number of pharmaceutical prescriptions 
dispensed per person was statistically significantly higher in 
the severely obese in all (P < 0.001) but two of the fifteen level-
one ATC therapeutic categories (Table 4). Costs associated 
with pharmaceutical use, stratified to ATC level-two therapeu-
tic categories, are presented for each sample in Figure 2. The 
largest mean annual cost differences per person between the 
samples (reported along with cost ratios and utilization SIRs) 
were observed in: drugs used in diabetes ($67, 7.85, 5.58 (95% 
CI: 5.43–5.73)), lipid-modifying agents ($61, 2.56, 2.43 (95% CI 
2.39–2.47)), psychoanaleptics ($51, 3.20, 2.81 (95% CI: 2.77–
2.85)), drugs for acid-related disorders ($29.8, 2.48, 2.01 (95% 
CI: 1.97–2.04)), agents acting on the renin–angiotensin system 
($23, 2.81, 2.64 (95% CI: 2.59–2.69)), immunosuppressants 
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Figure 1 Age and sex distribution of severely obese sample. Source: 
Medicare Australia. Sample is an annual cohort of all Australians 
receiving gastric banding surgery (Medicare Medical Benefits Schedule 
item number 30511) in 2009 (n = 11,769).
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($14, 1.94, 2.07 (95% CI: 1.9–2.25)), and drugs for obstructive 
airway diseases ($13, 1.87, 4.72 (95% CI: 4.58–4.89)). Costs 
were higher in the severely obese in each scenario.
DISCUSSION
This study found that severely obese subjects utilized approx-
imately double the number of medical services and phar-
maceutical prescriptions annually, compared to an age- and 
sex-matched general population sample. Mean annual health-
care costs (comprising medical and pharmaceutical costs) 
were more than double in severely obese subjects before 
receiving LAGB surgery ($1,735) relative to general popula-
tion subjects ($837). Excess medical costs in the severely obese 
were driven by greater utilization of professional attendances, 
therapeutic procedures, pathology, and diagnostic imaging, 
whereas excess pharmaceutical costs were driven by greater 
use of drugs in the metabolic, cardiovascular, and nervous 
system categories.
The key strengths of this study are related to the data source 
employed. Data analyzed were actual healthcare consump-
tion data maintained by the Australian government (rather 
than self-reported), therefore reliability is high. The data 
were extremely detailed (capturing over 6,000 unique medi-
cal services and pharmaceutical therapies), enabling an in-
depth analysis of healthcare utilization trends. The severely 
obese sample comprised over 11,000 subjects, fivefold greater 
Table 4 Pharmaceutical therapies–annual pharmaceutical utilization and costs for the general population and severely obese 
samples
Utilization incidence rate  
(mean number of prescriptions/person/year)
Annual cost per person AUD  
(Medicare benefit paid)a
General 
population
Severely 
obese
Standardized 
incidence ratio  
(95% CI) P value
General 
population
Severely 
obese Difference
Cost 
ratio
Pharmaceutical therapeutic category
 Alimentary tract  
 and metabolism
0.77 2.25 2.92 (2.88–2.96) P < 0.001 35.34 134.02 98.68 3.79
 Anti-infectives for  
 systemic use
0.43 0.65 1.52 (1.49–1.55) P < 0.001 13.14 18.77 5.64 1.43
 Antineoplastic and  
 immunomodulating 
 agents
0.08 0.11 1.27 (1.22–1.33) P < 0.001 54.60 69.52 14.93 1.27
 Antiparasitic  
 products,  
 insecticides, and  
 repellants
0.00 0.00 1.19 (0.81–1.77) 0.356 0.02 0.02 0.00 1.00
 Blood and  
 blood-forming  
 organs
0.12 0.26 2.15 (2.08–2.23) P < 0.001 5.80 14.04 8.24 2.42
 Cardiovascular  
 system
1.40 3.50 2.50 (2.47–2.52) P < 0.001 60.27 154.96 94.69 2.57
 Dermatologicals 0.07 0.11 1.44 (1.38–1.52) P < 0.001 2.49 3.96 1.47 1.59
 Genitourinary  
 system and sex  
 hormones
0.18 0.28 1.55 (1.50–1.59) P < 0.001 6.32 13.39 7.07 2.12
 Musculoskeletal  
 system
0.26 0.51 1.94 (1.89–1.98) P < 0.001 9.10 13.58 4.48 1.49
 Nervous system 1.42 2.86 2.02 (2.00–2.04) P < 0.001 61.95 134.67 72.72 2.17
 Respiratory system 0.31 0.57 1.82 (1.77–1.86) P < 0.001 15.69 28.92 13.23 1.84
 Sensory organs 0.12 0.14 1.18 (1.13–1.23) P < 0.001 2.60 3.95 1.35 1.52
  Systemic hormonal 
preparations, 
excluding sex 
hormones and 
insulins
0.07 0.14 1.90 (1.81–1.99) P < 0.001 1.96 3.38 1.42 1.72
 Unclassified 0.00 0.00 0.92 (0.73–1.17)    0.484 0.07 0.06 −0.01 0.86
 Various 0.01 0.03 2.18 (1.97–2.42) P < 0.001 1.04 1.74 0.70 1.67
Total 5.24 11.41 2.18 (2.17–2.19) P < 0.001 270.39 594.98 324.59 2.20
AUD, Australian dollars; CI, conﬁdence interval.
aOut-of-pocket contributions by subjects were not captured.
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than the maximum sample size reported in previous costing 
studies focusing on severe obesity (7–13). No exclusion crite-
ria were applied when identifying subjects, therefore, results 
reflect healthcare utilization in contemporary practice rather 
than under clinical trial conditions. Data for both samples 
were sourced from identical time periods; therefore, clinical 
and pricing contexts were directly comparable.
The Medicare healthcare data analyzed was also subject to 
limitations. First, utilization of services provided to patients 
admitted to public hospitals are not captured. However, 40% 
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Pituitary and hypothalamic hormones and analogues
Pancreatic hormones
Corticosteroids for systemic use
Clacium homeostasis
Sensory organs
Otologicals
Ophthalmologicals
Ophthalmological and otological preparations
Drugs for obstructive airway diseases
Cough and cold preparations
Antihistamines for systemic use
Psycholeptics
Psychoanaleptics
Anti-parkinson drugs
Antiepileptics
Analgesics
Antipsoriatics
Antipruritics, including antihistamines, anesthetics, etc.
Antifungals for dermatological use
Antibiotics and chemotherapeutics for dermatological use
Anit-acne preparations
Peripheral vasodilators
Lipid modifying agents
Diuretics
Cardiac therapy
Calcium channel blockers
B-blocking agents
Antihypertensives
Agents acting on the renin-angiotensin system
Blood substitutes and perfusion solutions
Antithrombitic agents
Antihemorrhagics
Antianemic preparations
Ectoparasiticides
Antiprotozoals
Anthelmintics
Immunosuppressants
Immunostimulants
Endocrine therapy
Antineoplastic agents
Vaccines
Vitamins
Stomatological preparations
Mineral supplements
Laxatives
Drugs used in diabetes
Drugs for functional gastrointestinal disordes
Drugs for acid-related disorders
Digestives, including enzymes
Bile and liver therapy
Appetite stimulants
Antiemetics and antinauseants
Antidiarrheals, intestinal antiinflammatory, antiinfective agents
Anabolic agents for systemic use
0 10 20 30 40 50
Annual cost per person AUD
General population Severely obese
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Antivirals for systemic use
Antimycotics for systemic use
Antibacterials for systemic use
Antimycobacterials
Muscle relaxants
Drugs for treatment of bone diseases
Antiinflammatory and antirheumatic products
antigout preparations
Urologicals
Sex hormones and modulators of the genital system
Other gynecologicals
Other dermatological perarations
Corticosteroids, dermatological perarations
Emollients and protectives
Other nervous system drugs, including parasympathomimetics
Figure 2 Pharmaceutical costs for severely obese and general population subjects by therapeutic subcategories. Notes: Excludes “various”  
and “unclassified” categories, data available upon request. ATC, Anatomical Therapeutic Chemical; AUD, Australian dollars.
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of all hospital admissions and 64% of all surgeries occur in 
private hospitals (19). Medicare subsidizes the majority of 
medical services provided in private hospitals (i.e., the major-
ity of investigations, therapies, surgeries, etc) and therefore 
these items were captured, however, services not subsidized 
by Medicare (i.e., most nontherapeutic services, for example, 
the “hotel” component of inpatient care, salaries for nonclini-
cal staff, etc.) are not captured by this study. Second, Medicare 
funding is based on average costs for medical services pro-
vided to the Australian population. However, obesity is asso-
ciated with increased operating times for common surgical 
procedures (20) and a requirement for additional speciality 
equipment (21). Therefore, it is likely that Medicare unit costs 
underestimate the actual cost to provide healthcare to the 
severely obese. As a consequence of the aforementioned issues, 
absolute healthcare costs estimated by this study are likely to 
be underestimated, as is the magnitude of the cost differences 
between the general population and severely obese.
Healthcare data were provided in aggregate form, therefore it 
was not possible to calculate standard errors for the mean costs 
or undertake hypothesis tests of differences between the sam-
ples. However, given the large sample sizes in both groups, the 
relatively large cost differences between samples are unlikely 
to have arisen by chance. The aggregate nature of the data also 
meant that we could neither test for, nor adjust for, any lack of 
independence. The SIR analyses assume statistical independ-
ence of events. Since each person in the sample may have had 
multiple events, this may have compromised the statistical 
independence. This may have led to some underestimation of 
the associated confidence intervals and P values. It was also 
not possible to analyze the number of subjects in the general 
population sample with zero costs.
A further limitation of this study was the absence of detailed 
BMI information for each of the samples. An analysis of a 
large database of Australian patients receiving LAGB between 
1994–2000 (22) reported a mean presurgical BMI of 45 ± 
7 kg/m2, which was essentially unchanged (43.2 ± 7.3 kg/m2) 
when assessed in 2009 (P. O’Brien, personal communication). 
Australian eligibility guidelines for LAGB procedures (23), 
describe indications as BMI ≥40 kg/m2 or BMI 35–39.9 kg/m2 
with an obesity-related morbidity, therefore all subjects met the 
criteria for severe obesity. Ideally, the comparator group used in 
this study would have been a healthy-weight (BMI ≤25 kg/m2) 
sample. However, as BMI data are not captured in the Medicare 
database this was not feasible. Based on Australian prevalence 
trends, it is assumed that ~32.0 and 19.4% of the general popula-
tion sample were overweight (BMI >25 kg/m2) and obese (BMI 
>30 kg/m2) respectively (24). The inclusion of the full BMI dis-
tribution in the comparator group is a further reason that the 
excess costs attributable to severe obesity reported by this study 
are likely to be underestimated. However, the prevalence of BMI 
≥40 kg/m2 in the general population was likely very low (<2%) 
and the mean BMI ~26 kg/m2, therefore the general population 
comparator group still provides a comparator group which is 
substantially leaner (24). Individual subject level data indicat-
ing characteristics such as ethnicity, income, education or other 
health risk factors (e.g., alcohol consumption, smoking) were 
also not available. Therefore, it was not possible to adjust for any 
differences between samples relating to these variables.
The therapeutic categories with the greatest excess healthcare 
costs in the severely obese observed by this study align with the 
diseases with the highest obesity-related relative risks for mor-
bidity (24). These included type 2 diabetes (diabetes drugs costs 
were eightfold higher), cardiovascular disease (lipid-modifying 
drugs costs were 2.6-fold higher, agents acting on the renin–
angiotensin drug costs were 2.8-fold higher), obstructive sleep 
apnea (obstructive sleep apnea investigations costs were 11-fold 
higher), and depression (psychoanaleptic drugs costs were 2.2-
fold higher). These estimates are based on analysis of cross-sec-
tional data, therefore the relationship between severe obesity and 
excess healthcare costs cannot be confirmed as causal. However, 
a causal relationship between obesity and morbidity has been 
clearly demonstrated in the medical literature (24,25).
Previous studies report that costs in the severely obese are 
65–113% higher relative to healthy-weight samples (7–13). Costs 
are unlikely to be directly comparable across studies due to dif-
ferent inclusion criteria (i.e., inclusion of one or more of pharma-
ceutical, inpatient, and outpatient costs), healthcare settings, and 
analytical methods. Nevertheless, there is a consistent relation-
ship reported across these studies for far greater healthcare costs 
in the severely obese relative to healthy-weight or general popu-
lation samples. The current study found costs were 107% higher 
(2.1-fold) in the severely obese relative to the general population 
utilizing observed healthcare utilization data. The excess costs 
attributable to severe obesity would have been even higher if the 
comparator group had been a healthy-weight sample.
The most methodologically similar previous study was con-
ducted by the Swedish Obese Subjects (SOS) study. In this 
study, pharmaceutical costs for a severely obese sample (mean 
BMI 41 kg/m2) were compared to a randomly selected general 
population sample (mean BMI 25 kg/m2). Key findings were 
that the annual cost of all prescribed medications was 77% 
higher in the obese individuals, with the use of diabetes medi-
cations nine times more common and use of cardiovascular 
disease medications four times more common relative to the 
general population (11). The costs of pharmaceuticals in the 
current study were similar, as highlighted above. Greater rela-
tive drug costs for the management of asthma, psychiatric, and 
gastrointestinal conditions were also documented in the obese 
populations in both studies (see Table 4) (11). The SOS study 
did not analyze medical services.
An important issue in undertaking economic evaluation of 
new therapies is to ascertain the degree to which the costs of the 
therapy can be offset by reductions in the future use of health-
care services and pharmaceuticals. Results from this study can 
be utilized to inform more sensitive cost-effectiveness analy-
sis of obesity interventions, particularly those targeting severe 
obesity or be combined with prevalence data to estimate the 
economic burden of obesity.
The severely obese sample was a cohort seeking and sub-
sequently receiving bariatric surgery. Therefore, the general-
izability of results to the entire population of severely obese 
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is uncertain. It is possible that the severely obese population 
analyzed may have had more obesity-related morbidity, lead-
ing to an increased likelihood of obesity treatment-seeking. 
Alternatively, it is possible that this group were healthier 
because surgery is contraindicated if patients are too unwell. 
No register of severe obesity exists in Australia, therefore selec-
tion of a cohort of patients seeking treatment for obesity was 
considered to be the best available approach for the current 
study. The age and sex distribution of the severely obese sam-
ple analyzed was demographically similar to a representative 
sample of Australian severely obese (26).
This analysis was based on healthcare utilization and costs 
for the severely obese before LAGB in the Australian set-
ting. Australian eligibility guidelines for the LAGB procedure 
describe indications as BMI ≥40 kg/m2 or BMI 35–39.9 kg/m2 
with an obesity-related morbidity (23). The same eligibility 
guidelines are adopted in other settings, for example Europe 
(27) and the United States (28), therefore results are likely 
transferable to severely obese before bariatric surgery in other 
settings. The pharmaceutical therapeutic categories reported 
in this study are based on the WHO ATC system (17). This 
system is adopted by many countries and will therefore allow 
comparison of results to studies in other settings. In countries 
such as Australia, where universal healthcare exists, healthcare 
utilization provides a crude proxy for morbidity and morbid-
ity change. Therefore the relative utilization results reported in 
this study are likely to reflect the health risks and health sys-
tem burden associated to severe obesity in developed country 
settings.
This study found that annual healthcare costs in severely 
obese subjects before receiving bariatric surgery were over 
double the equivalent costs relative to age- and sex-matched 
subjects from the general population. The excess costs attrib-
utable to severe obesity would have been even higher if the 
comparator group had been a healthy-weight sample. Cost 
differences were largely driven by greater annual healthcare 
costs relating to treating diabetes, cardiovascular disease, and 
depression in the severely obese subjects.
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ORIGINAL ARTICLE
Pharmaceutical utilisation and costs before and after bariatric
surgery
CL Keating1, A Peeters2, BA Swinburn3, R Carter1 and ML Moodie1
OBJECTIVE: To determine whether pharmaceutical utilisation and costs change after bariatric surgery.
SUBJECTS: Total population of Australians receiving Medicare-subsidised laparoscopic adjustable gastric banding (LAGB) in 2007
(n¼ 9542).
DESIGN: Computerised data linkage with Medicare, Australia’s universal tax-funded health insurance scheme. Pharmaceuticals
relating to obesity-related disease and postsurgical management were assigned to therapeutic categories and analysed. The mean
annual numbers of pharmaceutical prescriptions for each category were compared over the 4-year period from the year before
LAGB (2006) to 2 years after LAGB (2009) using utilisation incidence rate ratios (IRRs).
RESULTS: The population was mainly female (77.7%) and age was normally distributed with the majority (60.7%) of subjects aged
between 35–54 years. Utilisation rates decreased signiﬁcantly after LAGB in the following therapeutic categories: diabetes (IRR 0.51,
IRR 95% CI 0.50–0.53, mean annual cost differences per person $30), cardiovascular (0.81, 0.80–0.82, $29), psychiatric (0.95,
0.93–0.97, $13), rheumatic and inﬂammatory disorders (0.51, 0.49–0.53, $10) and asthma (0.78, 0.75–0.81, $9). In contrast,
signiﬁcantly greater utilisation was observed in the pain (1.28, 1.23–1.32, $12), gastrointestinal tract disorder (1.04, 1.02–1.07, $5)
and anaemia/vitamins (2.34, 2.01–2.73, $4) therapeutic categories. When the deﬁned categories were combined, a net reduction in
pharmaceutical utilisation was observed, from 10.5 to 9.6 pharmaceuticals prescribed per person/year, and costs decreased from
$AUD517 to $AUD435 per year in 2009 prices.
CONCLUSION: Relative to the year before LAGB, overall pharmaceutical utilisation was reduced in the 2 years after the year of LAGB
surgery, demonstrating that bariatric surgery can lead to reductions in pharmaceutical utilisation in the ‘real world’ setting. The
greatest absolute cost reductions were observed in the therapies to treat diabetes and cardiovascular disease.
International Journal of Obesity advance online publication, 5 March 2013; doi:10.1038/ijo.2013.24
Keywords: cost; economic; healthcare; pharmaceutical; bariatric surgery; gastric banding
INTRODUCTION
In Australia, the prevalence of individuals with body mass index
(BMI) of X40 kgm 2 is increasing twice as fast as that for the
cohort with a BMI between 30–34.9 kgm 2,1 with similar trends
reported in the United States (US)2 and European countries.3 As
BMI increases above the healthy range (BMI 18.5–25 kgm 2),
health risks increase exponentially.4 Three out of four adults with a
BMIX40 kgm 2 have at least one obesity-related morbidity.5 The
risk of type 2 diabetes in the severely obese population is 93-fold
higher in women6 and 43-fold higher in men7 relative to the
healthy weight population. The population with either a BMI of
X40 kgm 2 or a BMI between 35–39.9 kgm 2 with an obesity-
related morbidity is described as severely obese.
Lifestyle and pharmacological interventions facilitate very
modest and often poorly sustained weight loss in the severely
obese.8,9 In contrast, bariatric surgery is associated with signiﬁcant
and sustained weight reduction,10,11 leading to associated
reductions in the incidence of diabetes,12,13 cardiovascular
disease14 and selected cancers,15 improved quality of life16,17
and extended life expectancy.18 While these outcomes for
bariatric surgery are well recognised, in the context of limited
healthcare budgets, authorities around the world consider the
associated costs of intervention as well as efﬁcacy when making
healthcare priority-setting decisions.19–21
Previous studies assessing the impact of bariatric surgery on
pharmaceutical utilisation and costs in the population eligible for
surgery are from the US and Sweden. Studies from the US report
an overall reduction in pharmaceutical utilisation (or costs) after
surgery, (relative to the preprocedural costs or to a control group)
up to 6 years after bariatric surgery. This is driven primarily by the
large reduction in prescriptions to treat diabetes and cardiovas-
cular disease after surgery.22–30 However, the transferability of
these results to other countries, particularly those with a universal
health insurance system, is uncertain. Limitations in these studies
also included small sample sizes (no400) or short duration of data
capture before surgery (o90 days). The Swedish Obese Subjects
Study (SOS) provides the only prospectively collected database for
pharmaceuticals utilised by both a bariatric surgical group and a
matched control group. The SOS also observed signiﬁcant
reductions in diabetes and cardiovascular therapies, but found
that these were offset by increased utilisation of therapies to treat
gastrointestinal tract disorders (GIDs) and anaemia/vitamin
deﬁciency, resulting in similar overall costs over 6 years.31 The
SOS results relate to data collected in the late eighties and early
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nineties. Changes in bariatric surgery procedures, including the
widespread adoption of laparoscopic techniques since this time,32
may limit the transferability of results to bariatric surgery today.
This study aims to determine whether pharmaceutical utilisa-
tion and the associated costs change in the short-term after
bariatric surgery. Pharmaceutical data maintained by the Austra-
lian government were analysed for the total annual population of
severely obese Australians undergoing Medicare-subsidized
laparoscopic adjustable gastric banding (LAGB).
MATERIALS AND METHODS
Subjects
The population of Australians undergoing LAGB in 2007 (n¼ 9542) was
identiﬁed by Medicare, which administers Australia’s universal tax-funded
health insurance scheme. Identiﬁcation was based on the utilisation of
Medicare Beneﬁts Schedule item 30511 (gastric reduction or gastroplasty
for morbid obesity, by any method), which is primarily utilised for LAGB.33
Measures
Pharmaceutical utilisation (number of prescriptions dispensed, comprising
both original and repeat scripts) and cost data for the population before
and after LAGB was sourced from an administrative database34 maintained
by Medicare for the period 2006–2009, capturing the year before surgery
(2006), the year of surgery (2007) and years 1 and 2 after surgery (2008,
2009). Medicare funds B1500 prescription pharmaceutical therapies,
covering 80% of all prescription medications dispensed in Australia.34 Data
are classiﬁed according to the Anatomical Therapeutic Chemical Drug
Classiﬁcation System maintained by the World Health Organisation
Collaborating Centre for Drug Statistics.35 Medicare provided
pharmaceutical data covering all Anatomical Therapeutic Chemical
categories stratiﬁed by year. For privacy reasons, de-identiﬁed, aggregate
data were provided to the research team by Medicare. The 4-year time
horizon was the maximum available from Medicare Australia.
Analysis
Pharmaceutical data were classiﬁed into eight therapeutic categories
corresponding to obesity-related disease (diabetes, cardiovascular disease,
asthma, psychiatric, rheumatic and inﬂammatory disorders), and post
bariatric surgery management (pain, anaemia and vitamin supplementa-
tion and GIDs for analysis. Therapeutic categories were based on the
Anatomical Therapeutic Chemical second level (therapeutic main group)
categories (Table 1).
Pharmaceutical utilisation ‘incidence rates’ (mean annual number of
pharmaceutical prescriptions dispensed per person) were calculated by
dividing the observed population incidence for each pharmaceutical item
by the study population size for each separate year. Comparison of
incidence rates between the year before LAGB (2006) and year 2 after
LAGB (2009) were undertaken using incidence rate ratios (IRRs).36 An IRR
equal to one implies no difference in the incidence rate between the two
time points; an IRR greater than one indicates greater use after LAGB and
vice versa. Standard methods were applied to calculate IRR conﬁdence
intervals and to test whether the differences in IRRs were statistically
signiﬁcant.36
Pharmaceutical costs were also analysed. Mean annual costs per person
were calculated by dividing the observed population cost for each
pharmaceutical item by the study population size for each separate year.
Cost differences and ratios between 2006 (the year before surgery) and
2009 (year 2 after surgery) were also calculated. A government healthcare
payer perspective was adopted, and therefore the unit cost paid by
Medicare listed within the Pharmaceutical Beneﬁts Schedule was
analysed.34 Costs relating to consultation with doctors to prescribe
pharmaceuticals, as well as copayments for pharmaceuticals by patients,
were not captured in the data, and were therefore not analysed. Health
sector deﬂators from the Australian Institute of Health and Welfare were
utilised to inﬂate costs to the 2009 reference year37 (1AUD: 0.99USD:
0.63GBP).
Validation analyses
An ‘other’ category, comprising all prescribed pharmaceuticals not
captured in the eight deﬁned therapeutic categories, was analysed to
conﬁrm that no important trends were missed. The nomination of a pre-
post study design enabled subjects to be utilised as their own controls,
thereby avoiding potential selection bias associated with identifying non-
intervention control subjects. However, changes in clinical guidelines or
pharmaceutical availability/pricing over the time are potential confounders
in the longitudinal analysis of healthcare utilisation and costs. To overcome
this potential issue, pharmaceutical data were also analysed for two
additional populations—a severely obese sample before receiving LAGB
and a similar population after receiving LAGB. Medicare identiﬁed the
before-LAGB and after-LAGB populations based on their utilisation of LAGB
in Australia in 2009 (n¼ 11 769) and between July 2005–June 2006
(n¼ 6040), respectively. Data were retrieved for each population for the
years 2005–2009, enabling pharmaceutical usage data to be compared at
identical time periods, and thus identical clinical and pricing contexts
(Table 2).
RESULTS
Sample characteristics
The age and sex distribution of the pre-post LAGB population
adopted in the primary analysis, as well as the validation
populations (pre-LAGB, post-LAGB) are depicted in Table 3. All
populations were dominated by females (77.7, 78.2 and
80.4%, respectively) and age was normally distributed with the
Table 1. Pharmaceutical therapeutic categories
Therapeutic categorya Anatomical therapeutic chemical categories includedb
Diabetes Drugs used in diabetes mellitus (A10)
Cardiovascular disease Agents acting on the renin-angiotensin system (C09), antihypertensives (C02), beta blocking agents (C07),
calcium channel blockers (C08), cardiac therapy (C01), diuretics (C03), lipid modifying agents (C10) and peripheral
vasodilators (C04)
Asthma Drugs for obstructive airway diseases (R03)
Psychiatric Psycholeptics (N05), psychoanaleptics (N06)c
Rheumatic and inﬂammatory
disorders
Antiinﬂammatory and antirheumatic products (M01)
Pain Analgesics (N02), muscle relaxants (M03)
Anaemia and vitamin
supplementation
Vitamins (A11), antianemic preparations (B03)
Gastrointestinal tract
disorders
Antidiarrheals/intestinal/antiinﬂammatory/ antiinfective agents (A07), antiemetics and antinauseants (A04), bile
and liver therapy (A05), drugs for acid related disorders (A02), drugs for functional gastrointestinal disorders,
laxatives (A03)
aAn ‘other’ category comprising all remaining pharmaceuticals was also deﬁned and analysed within the validation analysis. bBracketed information is
Anatomical Therapeutic Chemical code. cPsycholeptics include: antipsychotics, anxiolytics, hypnotics and sedatives. Psychoanaleptics include: antidepressants;
psychostimulants, agents used for Attention Deﬁcit and Hyperactivity Disorder and nootropics; psycholeptics and psychoanaleptics in combination; and
anti-dementia drugs.
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majority of cases in the 35–54 age group (60.7, 57.5 and 61.0%,
respectively).
Therapeutic categories
Over the 4-year period assessed (from the year before LAGB to
year 2 after LAGB), utilisation rates decreased signiﬁcantly after
LAGB in the following therapeutic categories: diabetes (IRR 0.51,
IRR 95% CI 0.50–0.53, annual cost differences $30), cardiovascular
(0.81, 0.80–0.82, $29), psychiatric (0.95, 0.93–0.97, $13), rheumatic
and inﬂammatory disorders (0.51, 0.49–0.53, $10) and asthma
(0.78, 0.75–0.81, $9) (all utilization, Po0.001). In contrast,
signiﬁcantly greater utilisation was observed in the pain (1.28,
1.23–1.32, $12), GIDs (1.04, 1.02–1.07, $5) and anaemia/vitamins
(2.34, 2.01–2.73, $4) therapeutic categories.
Steady decreasing trends over the 4 years (either a decrease
each year or decreasing then stable) were observed in the
diabetes, cardiovascular, asthma and rheumatic/inﬂammatory
categories. Steady increasing trends (either an increase each year
or increasing then stable) were observed for the pain and the
anaemia/vitamins categories. Trends over time were less consis-
tent for the psychiatric and GID categories.
When all of the predeﬁned therapeutic categories were
combined, an overall reduction in pharmaceutical use was
observed after LAGB. Over the 4-year period assessed, the mean
pharmaceutical utilisation rate decreased from 10.5 to 9.0
pharmaceutical prescriptions per person/year. The utilisation IRR
was 0.86 (95% CI: 0.85–0.87). Associated mean annual pharma-
ceutical costs over the same time horizon decreased by 16%, or
the equivalent of $82 (Table 4).
Validation analyses
After the data analysed were expanded to include the ‘other’
therapeutic category (and therefore all available pharmaceutical
data were analysed), the IRR increased to 0.90 (95% CI: 0.89–0.92),
driven by an increase of pharmaceuticals in the antineoplastic and
immunomodulating agents category over the 4 years. Analysis of
the alternative comparator populations (the validation; pre-LAGB
and post-LAGB populations; different populations compared over
the same timeframe) conﬁrmed key results. For example, large
reductions were observed for diabetes (IRR 0.51, 95% CI
0.50–0.52) and cardiovascular drugs (IRR 0.90, 95% CI 0.89–0.91)
over the 3.5 year time horizon after LAGB relative to the 3.5 years
before LAGB. Other utilisation results all trended in the same
direction as the primary analysis, with the exception of the
psychiatric category where greater utilisation was observed after
LAGB (IRR 1.3).
DISCUSSION
Summary
This study found that, relative to the year before LAGB, mean
annual pharmaceutical utilisation was reduced in the 2 years
after LAGB. The greatest differences in utilisation were observed
in therapies to treat obesity-related disease, particularly diabetes
and cardiovascular disease, where marked reductions were obser-
ved, although these reductions were partially offset by greater
utilisation of therapies related to post bariatric surgery
management.
Decreased utilisation in selected therapeutic categories after
bariatric surgery
Statistically signiﬁcant reductions in the utilisation of therapies to
treat diabetes, cardiovascular disease, asthma, psychiatric condi-
tions and rheumatic/inﬂammatory disorders were observed by
this study. These reductions are likely explained by a decrease in
obesity-related morbidity mediated by surgically-induced weight
loss. Previous studies report that bariatric surgery facilitates impro-
vements in each of the aforementioned conditions.12,13,16,17,38–42
The current study suggests that these improvements translate to
rapid reductions in pharmaceutical healthcare utilisation in the
‘real world’ setting. Reduced pharmaceutical utilisation was
replicated in all of the aforementioned categories in the
validation analyses, with the exception of the psychiatric
therapeutic category, where an increase was observed during
the 3.5 years after LAGB relative to the same time horizon
before LAGB. Previous studies report a reduction in psychiatric
symptoms in the vast majority of bariatric surgery subjects after
surgery,16,17,43–47 however, there is less consistency regarding the
impact of bariatric surgery on the utilisation of psychiatric phar-
maceuticals. Previous studies report an increase/no
difference16,48–50 or a decrease22,51,52 after bariatric surgery, inclu-
ding gastric bypass. This is an area requiring further research.
Increased utilisation in selected therapeutic categories after
bariatric surgery
Increased pharmaceutical utilisation in therapies in the anaemia/
vitamins category, to treat pain and to a lesser extent GID, were
observed by this study. Increased utilisation of anaemia/vitamins
medications is unsurprising, given that supplementation is
recommended for patients post bariatric surgery.53 The increase
Table 2. Data request to Medicare Australia
Population for data retrieval Year of bariatric surgery Timeframe for data retrieval
Primary analysis Before and after bariatric surgery populationa 2007 January 2006–December 2009
Validation analysis Before bariatric surgerya 2009 July 2005–December 2009a
After bariatric surgerya July 2005/June 2006 July 2005–December 2009a
Populations were annual cohorts of all Australians receiving Medicare item 30511 (gastric reduction or gastroplasty). aUnique 3.5 year data retrieval within the
nominated timeframe for each patient depending on the date of surgery.
Table 3. Age and sex distribution of populations
Primary analysis Validation analysis
Before and after
bariatric surgery
population
(n¼ 9542)
Before bariatric
surgery
(n¼ 11 769)
After bariatric
surgery
(n¼ 6040)
Female
(%)
Male
(%)
Female
(%)
Male
(%)
Female
(%)
Male
(%)
0–24 5.8 4.5 6.3 4.7 6.8 5.4
25–34 16.3 11.5 17.9 11.6 17.8 11.0
35–44 31.6 27.8 29.4 26.4 31.5 28.9
45–54 29.5 31.5 28.3 30.6 29.3 32.7
55–64 15.3 20.6 15.8 21.6 13.1 19.2
65–74 1.5 4.1 2.3 5.0 1.5 2.9
75–84 0.0 0.0 0.0 0.1 0.0 0.0
Source: Medicare Australia.
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in pain medication is potentially explained by several factors.
These include: (i) pain caused by the index bariatric surgery54 and
(ii) a shift from non-steroidal anti-inﬂammatory drugs, which are
frequently stopped after gastric banding, because they exacerbate
gastrointestinal side-effects, to less effective pain medications
(personal communication, John Dixon, 6 September 2012). For the
GID therapeutic category, total utilisation and costs trended in
opposite directions. Analysis at the drug item level revealed that
this was due to a decrease in the unit price of selected drugs for
peptic ulcer and gastro–oesophageal reﬂux disease over the time
horizon assessed.
Implications
In the context of limited healthcare budgets, authorities around
the world19–21 consider both intervention effectiveness and ‘costs’
when making healthcare priority-setting decisions. An important
issue in undertaking cost-effectiveness analysis of new
interventions is to ascertain the degree to which the costs of
the intervention can be offset by reductions in the future use of
healthcare resources. Previous cost-effectiveness analysis
consistently report that bariatric surgery is cost-effective relative
to conventional therapy (diet and exercise with or without
pharmacotherapy) for treating severe obesity.55,56 However,
reliance on patient-reported and/or modelled (rather than
observed) healthcare costs introduces signiﬁcant uncertainty.
Mean total pharmaceutical costs associated with obesity-related
disease and post bariatric surgery management (categories
deﬁned for current study, and which would typically be included
in a cost-effectiveness analysis) were reduced by 7, 19 and 16% in
the year of LAGB, year 1 after LAGB and year 2 after LAGB,
respectively, relative to the year before LAGB. The greatest
absolute cost reductions in year 2 after LAGB (relative to the year
before LAGB) were observed in pharmaceuticals to treat diabetes
($30 per person annually, 47% reduction) and cardiovascular
disease ($29 per person, 17% reduction). Importantly these
reductions were observed for the entire population receiving
bariatric surgery. Absolute cost reductions per patient would be
far greater if the population analysed was restricted to subjects
with type 2 diabetes or other metabolic conditions, because the
health beneﬁts attributable to weight loss are likely to be larger for
these patients. Cost data presented in the current study, which
quantify the impact of bariatric surgery on short-term pharma-
ceutical expenditure can be adopted within future cost-effective-
ness analysis.
This study only examined the 2-year period following the year
of bariatric surgery. A longer time horizon and expansion of costs
to include outpatient and hospital costs are required to determine,
if, and to what extent bariatric surgery costs are offset by the
prevention of downstream obesity-related healthcare. Healthcare
costs increase with the duration of obesity,57,58 therefore it is also
necessary to compare a bariatric surgery population with a
matched population receiving conventional obesity treatment.
This is afﬁrmed by previous studies from the US, which suggest
that healthcare ‘savings’ are achieved in bariatric surgery subjects
due to the prevention of escalating costs in obese-control
subjects, rather than a net reduction in healthcare costs in the
bariatric surgery subjects.59
Comparisons and transferability
The SOS examined pharmaceutical utilisation and costs after
bariatric surgery in a universal health insurance setting. The SOS
observed lower mean annual costs in the diabetes ( 69%) and
cardiovascular disease ( 31%) therapies relative to matched
conventionally-treated controls over 6 years.31 These ﬁgures
compare with reductions of 49 and 19%, respectively, for the
same therapeutic categories in the current study. The smaller
differences observed in the current study are most likely explained
by the different comparator populations adopted; the SOS study
compared bariatric surgery subjects to control subjects receiving
conventional therapies, while the current study compared
subjects before and after bariatric surgery. The current study
also analysed trends over a shorter time frame. The SOS study
found that reductions in the metabolic therapies were offset by
greater costs in the surgical group in drugs to treat
gastrointestinal tract disorders, anaemia and pain. The current
study also observed greater utilisation in these latter therapeutic
categories after LAGB, however, to a much lesser degree than the
SOS, likely due to advances in surgical methods leading to
decrease in the need for postsurgery therapies.
This analysis was based on healthcare utilisation data for
severely obese subjects before and after LAGB in the Australian
setting. Australian eligibility guidelines for bariatric surgery
(including LAGB) describe indications as BMI of X40 kgm 2 or
a BMI between 35–39.9 kgm 2 with an obesity-related morbid-
ity.60 The same eligibility guidelines are adopted in other settings,
for example, Europe61 and the US.62 Therefore, before the surgery,
the populations analysed in the current study are likely to meet
bariatric surgery eligibility criteria elsewhere. However, all subjects
in the current study received LAGB. Other bariatric surgery
procedures, particularly gastric bypass are utilised more frequently
globally.32 Weight loss outcomes and clinical outcomes (such as
resolution of type 2 diabetes) differ slightly between bariatric
procedures;63 therefore, results from this study may not be directly
transferable to subjects receiving other bariatric procedures. The
Table 4. Pharmaceutical therapies—annual utilisation and costs before and after bariatric surgery
Utilisation incidence rate (mean number of scripts per person/year) Annual cost per person AUD (2009$)
2006
(year
before
surgery)
2007
(year of
surgery)
2008
(year 1
after
surgery)
2009
(year 2
after
surgery)
Difference
(2006 vs
2009)
Incidence rate
ratio (2006 vs
2009)
(95% CI)
2006
(year
before
surgery)
2007
(year of
surgery)
2008
(year 1
after
surgery)
2009
(year 2
after
surgery)
Difference
(2006 vs
2009)
Cost
ratio
(2006 vs
2009)
Therapeutic categories
Diabetes 0.90 0.76 0.49 0.46  0.44 0.51 (0.50–0.53) 64.41 59.48 34.97 33.97  30.44 0.53
Cardiovascular 3.79 3.50 3.06 3.06  0.73 0.81 (0.80–0.82) 170.35 159.41 139.61 140.90  29.45 0.83
Asthma 0.59 0.56 0.45 0.46  0.13 0.78 (0.75–0.81) 33.72 31.34 25.28 24.69  9.03 0.73
Psychiatric 2.55 2.23 2.18 2.42  0.12 0.95 (0.93–0.97) 143.58 128.60 123.52 130.19  13.38 0.91
Rheumatic and
inﬂammatory
disorders
0.69 0.42 0.39 0.35  0.34 0.51 (0.49–0.53) 19.00 10.27 9.77 8.70  10.29 0.46
Pain 0.65 0.74 0.77 0.83 0.18 1.28 (1.23–1.32) 16.91 19.82 23.93 28.74 11.83 1.70
Anaemia and
vitamins
0.03 0.03 0.05 0.06 0.03 2.34 (2.01–2.73) 3.07 6.94 7.68 7.31 4.23 2.38
Gastrointestinal
tract disorders
1.33 1.42 1.16 1.38 0.06 1.04 (1.02–1.07) 65.49 62.28 52.10 60.37  5.13 0.92
Total 10.52 9.66 8.54 9.03  1.48 0.86 (0.85–0.87) 516.54 478.14 416.86 434.87  81.67 0.84
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pharmaceutical therapeutic categories reported in this study are
based on the WHO Anatomical Therapeutic Chemical system.35
This system is widely adopted and will therefore allow
international comparisons.
Strengths and limitations
A key strength of this study was the data source and large
populations. Data analysed were observed prescription pharma-
ceutical dispensation data maintained by the Australian govern-
ment (rather than self-reported), therefore reliability is assumed to
be high. Data were sourced via linkage with the national
databases; therefore complete data were retrieved for all subjects
(no loss to follow-up). The population analysed was the entire
population of Australians receiving Medicare-subsidized LAGB in
2007, meaning that there was no selection bias. The population
reﬂects LAGB as delivered in the ‘real world’ setting, rather than in
clinical trials, which are likely to represent interventions delivered
in best-practice settings. The Australian universal health insurance
setting, where pharmaceuticals are accessible to all, enabled
healthcare utilisation to be analysed as a proxy for morbidity and
morbidity change. The validation analysis enabled potential
confounders relating to the impact of changes in the clinical
context on healthcare to be eliminated.
The longitudinal analysis of pharmaceutical data for the
population before and after surgery enabled subjects to be
utilised as their own controls, thereby reducing a potential
selection bias associated with adopting a retrospectively identiﬁed
non-intervention control population as the comparator. However,
this study design was also subject to limitations. As with any
longitudinal study, the mean age of subjects increased over the
4-year time horizon assessed. Older age is associated with
increasing healthcare costs.64 However, most subjects were in
the age range 35–54, where an age difference of 4 years is unlikely
to be associated with a marked increase in healthcare utilisation. If
anything, savings estimated by this study will have been
underestimated, particularly for the metabolic categories where
there is a strong correlation between age and pharmaceutical
utilisation.65 Ageing is also a potential explanation for the minor
increase in the utilisation of pharmaceuticals in the antineoplastic
and immunomodulating agents category observed in the
validation analyses. A further explanation is that cancer is a
contraindication for bariatric surgery, therefore a very low rate
would be expected in the year before bariatric surgery.
The key limitation of this study was the absence of BMI
information for the population assessed. Therefore, it was not
possible to calculate differences in BMI or weight loss outcomes
after LAGB, or to determine whether there was a dose-response
relationship between weight loss and reduced pharmaceutical costs.
Pharmaceutical data were provided in aggregate form, there-
fore it was not possible to calculate s.e. for the mean costs, or
undertake hypothesis tests of cost differences between the
populations. However, given the large sample sizes in both
groups, the relatively large cost differences at the therapeutic
category level between populations are unlikely to have arisen by
chance. The aggregate nature of the data also meant that it was
not possible to test for, nor adjust for any lack of independence.
The IRR analyses assume statistical independence of events. As
each person in the sample may have had multiple events, this may
have compromised the statistical independence, and led to some
underestimation of the associated conﬁdence intervals.
Conclusion
This study analysed pharmaceutical data maintained by the
Australian government for the total population of Australians
receiving Medicare-subsidized LAGB in 2007 within a contempor-
ary universal health insurance setting. Relative to the year before
LAGB, overall pharmaceutical utilisation was reduced in the
2 years after LAGB, demonstrating that bariatric surgery leads to
reductions in pharmaceutical utilisation in the ‘real world’ setting.
The greatest absolute cost reductions were observed in pharma-
cotherapy used to treat diabetes and cardiovascular disease.
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Letters
RESEARCH LETTER
Revisional Surgery After Laparoscopic Adjustable
Gastric Banding in a National Australian Cohort
A recent systematic review reported wide-ranging long-
term revision or reversal rates after laparoscopic adjustable
gastric banding (LAGB) of between 8% and 60%.1 The
marked variability is likely due to different definitions of
revisional surgery, different follow-up durations, and the
different “eras” of the surgical cohorts. The studies
reviewed provided little detail regarding the types of revi-
sional procedures performed.1 Two recent studies1,2 have
significantly advanced evidence in this area. The Longitudi-
nal Assessment of Bariatric Surgery2 in the United States
reported that of 610 patients undergoing LAGB, the rate of
revisional surgery was 17.5 events per 100 patients over 3
years, primarily for band removal, revision to another bar-
iatric procedure, or port revision. O’Brien et al1 reported
that of 1370 patients undergoing LAGB at an Australian bar-
iatric center, the rate of revisional surgery was 15.3 events
per 100 patients over 3 years, primarily for repositioning of
the gastric band or port revisions. The present study reports
revisional surgery rates for the national population of Aus-
tralians undergoing LAGB between July 1, 2005, and June
30, 2006.
Methods | The population of Australians undergoing LAGB
subsidized by Australia’s government tax-funded insurance
program (known as Medicare) between July 1, 2005, and
June 30, 2006, was identified (N = 6037). Identification was
based on utilization of Medicare Benefits Schedule item (ie,
billing code) 30511 (gastric reduction or gastroplasty for
morbid obesity), which is primarily used for LAGB.3
Medical utilization data from the date of LAGB until 3.5
years after surgery was retrieved for each patient from an ad-
ministrative database4 maintained by Medicare. Medicare
funds approximately 3800 medical services.4 Selected pre-
defined items directly related to bariatric surgery, as speci-
fied in the Table, were analyzed. For privacy reasons, de-
identified, aggregatedataonmedicalutilizationwereprovided
to the research teambyMedicare. Theearliest and latest dates
for data capture were July 1, 2005, and December 30, 2009,
respectively.
Observed frequencies over 3.5 years were converted to
3-year rates for each revisional surgery item. The Medicare
item relating to LAGB reversal (item 30514) is used when the
initial gastric banding procedure is repeated (item 30511)
and when a conversion to another bariatric procedure is
undertaken (items 30512 and 30518). Therefore, gastric
banding reversals performed in association with other pro-
cedures were excluded from the data to remove the risk of
double counting.
Results | The age and sex distribution of the LAGB population
analyzed is provided in the Figure. During the 3 years after
LAGB, the rate of revisional surgery was 18.9 events per 100
patients, comprising 11.4 intra-abdominal and 7.5 subcuta-
neous surgical procedures. The majority of revisional proce-
Table. Data on Revisional Procedures
Summary
Description
Medicare Item
No. of Observed
Events Over
3.5 Years
(N = 6037)a
Events per
100 Persons
Over 3.5 Years
Events per
100 Persons
Over 3 YearsbDescription Item No.
Repeated or
revisional LAGB
Gastric reduction or
gastroplasty for
morbid obesity, by any
method
30511 583 9.7 8.3
Conversion to
gastric bypass
Gastric bypass for
morbid obesity, by any
method, including
anastomosis
30512 40 0.7 0.6
Conversion to
gastrectomy
Partial gastrectomy 30518 46 0.8 0.7
LAGB reversal Surgical reversal for
morbid obesity, by any
method
30514 131 2.2 1.9
Subtotal of
intra-abdominal
surgical procedures
800 13.3 11.4
Port repair
of replacement
Repair, revision, or
replacement of
long-term implanted
reservoir associated
with the adjustable
gastric band
31441 528 8.7 7.5
Total 1328 22.0 18.9
Abbreviation: LAGB, laparoscopic
adjustable gastric banding.
a The 3.5-year time horizon was the
maximum available at the time of
data request fromMedicare
Australia.
bData are presented over 3 years to
enable comparison with 2 recent
studies1,2 reporting LAGB revisional
surgery rates.
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dures were repeated or revisional LAGB procedures (8.3
events per 100 patients) and repairs or revisions of the LAGB
reservoir (7.5 events per 100 patients). Conversions to
another bariatric procedure (1.3 events per 100 patients) and
LAGB reversals (1.9 events per 100 patients) were uncom-
mon (Table).
Discussion |Thepresent study found that almost 1 in 5 patients
undergoing LAGB require some revisional surgery within 3
years. These results from our national cohort study are simi-
lar, albeit slightlyhigher, than the results fromprevious single-
center (15.3%ofpatients)1 andmulticentercohortstudies (17.5%
of patients).2
There are 2 key strengths of our study. First, the data
analyzed are observed health care utilization data main-
tained by the Australian government; therefore, the level of
reliability is high, and the data set is complete (no loss to
follow-up). Second, the entire population of Australians
who received Medicare-subsidized LAGB was analyzed,
thus providing results reflective of LAGB as delivered in a
“real-world” setting.
Bariatric surgery is associated with dramatic weight loss
and improvements in many clinical end points.2 The ben-
efits of surgery must be compared with the risk of adverse
events, the need for reoperations, and the associated costs
for each patient.
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Figure. Age and Sex Distribution of the Annual Cohort of Patients
Receiving Gastric Banding in 2005-2006 (N=6037)
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The source for the data is Medicare Australia. Identification was based on
utilization of Medicare Benefits Schedule item 30511 (gastric reduction or
gastroplasty for morbid obesity, by anymethod), which is primarily used for
laparoscopic adjustable gastric banding in Australia.3
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OVER THE LAST 3 DECADES,the prevalence of obesitygreatly increased. Themostsignificant increases have
occurred among patients with a body
mass index [BMI] of 35 or higher (BMI
is calculated as weight in kilograms di-
vided by height in meters squared).1,2
Such individuals, who are eligible for
bariatric surgery, represent 15% of the
adult population,3 incur a dispropor-
tionate share of health care costs rela-
tive to moderately obese individuals
(BMI, 30-34.9),4 and have greater risk
of premature death.5
Bariatric surgery reduces weight
and improves diabetes, hyperlipid-
emia, hypertension, and obstructive
sleep apnea.6 Long-term outcomes
for surgically induced weight loss
from the Swedish Obese Subjects
study have demonstrated sustained
weight loss, reduced incidence of
diabetes, cardiovascular events, and
cancer, as well as improved 10- to
15-year survival.7-12 Although there
are many benefits from bariatric sur-
gery, it is not known whether these
translate to reduced long-term health
care use.
The Swedish study is a long-term
prospective, matched cohort study that
tracks the effects of bariatric surgery and
For editorial comment see p 1160.
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Context Bariatric surgery results in sustained weight loss; reduced incidence of dia-
betes, cardiovascular events, and cancer; and improved survival. The long-term effect
on health care use is unknown.
Objective To assess health care use over 20 years by obese patients treated con-
ventionally or with bariatric surgery.
Design, Setting, and Participants The Swedish Obese Subjects study is an on-
going, prospective, nonrandomized, controlled intervention study conducted in the
Swedish health care system that included 2010 adults who underwent bariatric sur-
gery and 2037 contemporaneouslymatched controls recruited between 1987 and 2001.
Inclusion criteria were age 37 years to 60 years and body mass index of 34 or higher
in men and 38 or higher in women. Exclusion criteria were identical in both groups.
Interventions Of the surgery patients, 13% underwent gastric bypass, 19% gas-
tric banding, and 68% vertical-banded gastroplasty. Controls received conventional
obesity treatment.
MainOutcomeMeasures Annual hospital days (follow-up years 1 to 20; data cap-
ture 1987-2009; median follow-up 15 years) and nonprimary care outpatient visits
(years 2-20; data capture 2001-2009; median follow-up 9 years) were retrieved from
the National Patient Register, and drug costs from the Prescribed Drug Register (years
7-20; data capture 2005-2011; median follow-up 6 years). Registry linkage was com-
plete for more than 99% of patients (4044 of 4047). Mean differences were adjusted
for baseline age, sex, smoking, diabetes status, body mass index, inclusion period, and
(for the inpatient care analysis) hospital days the year before the index date.
Results In the 20 years following their bariatric procedure, surgery patients used a total
of 54mean cumulative hospital days comparedwith 40 used by those in the control group
(adjusted difference, 15; 95% CI, 2-27; P=.03). During the years 2 through 6, surgery
patients had an accumulated annual mean of 1.7 hospital days vs 1.2 days among con-
trol patients (adjusted difference, 0.5; 95% CI, 0.2 to 0.7; P .001). From year 7 to 20,
both groups had amean annual 1.8 hospital days (adjusted difference, 0.0; 95%CI, −0.3
to 0.3; P=.95). Surgery patients had a mean annual 1.3 nonprimary care outpatient vis-
its during the years 2 through 6 vs 1.1 among the controls (adjusted difference, 0.3; 95%
CI, 0.1 to 0.4; P=.003), but from year 7, the 2 groups did not differ (1.8 vs 1.9 mean
annual visits; adjusted difference, −0.2; 95%CI, −0.4 to 0.1; P=.12). From year 7 to 20,
the surgery group incurred a mean annual drug cost of US $930; the control patients,
$1123 (adjusted difference, −$228; 95% CI, −$335 to −$121; P .001).
Conclusions Compared with controls, surgically treated patients used more inpatient
and nonprimary outpatient care during the first 6-year period after undergoing bariatric
surgery but not thereafter. Drug costs from years 7 through 20 were lower for surgery
patients than for control patients.
Trial Registration clinicaltrials.gov Identifier: NCT01479452
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has had a high degree of follow-up.
Consequently, this study can analyze
health care use patterns among
patients after undergoing surgery.
The aim of this current study was to
assess over 20 years the amount of
health care obese patients have used
after undergoing bariatric surgery
compared with those who were con-
ventionally treated. Hospital days,
nonprimary care outpatient visits,
and drug costs were investigated
using nationwide registries.
METHODS
The prospective, nonrandomized,
controlled Swedish Obese Subjects
intervention study recruited patients
from September 1, 1987, to January
31, 2001.7,8 After recruitment cam-
paigns in the mass media and at 480
primary health care centers, an eligi-
bility examination was completed by
6905 individuals, 5335 of whom were
eligible and were offered surgery. The
2010 who elected surgical treatment
constituted the surgery group. From
individuals not electing surgery, a
contemporaneously matched control
group of 2037 individuals was created
using 18 matching variables8: sex, age,
weight, height, waist-hip circumfer-
ences, systolic blood pressure, serum
cholesterol and triglyceride levels,
smoking status, diabetes, menopausal
status, 4 psychosocial variables with
documented associations with the risk
of death, and 2 personality traits
related to treatment preferences.
Although a surgery patient and his/
her conventionally treated control
started the study in the same calendar
period, matching was not performed
at an individual level. Instead the
matching algorithm selected controls
so that the current mean values of the
matching variables in the control
group became as similar as possible to
the current mean values in the sur-
gery group according to the method
of sequential treatment assignment.13
Seven regional ethical review boards
approved the study protocol. In-
formed consent was obtained from all
patients.
Inclusion and Exclusion Criteria
Studygroupshad identical inclusion and
exclusion criteria. The inclusion crite-
ria were age 37 to 60 years and BMI of
34 or more in men and 38 or more in
women. These BMI cut points corre-
sponded to an approximate doubling of
themortality rate inboth sexes.14 The ex-
clusion criteria were earlier surgery for
gastric or duodenal ulcer, earlier bariat-
ric surgery, gastric ulcer during the past
6 months, ongoing malignancy, active
malignancyduring thepast 5years,myo-
cardial infarction during the past 6
months, bulimic eating pattern, drug or
alcohol abuse, psychiatric or coopera-
tive problems contraindicating bariat-
ric surgery, or other contraindicating
conditions (such as chronic glucocorti-
coidoranti-inflammatory treatment).Pa-
tients with hypertension, diabetes, or
lipid disturbances were allowed to par-
ticipate, as were patients who had had a
myocardial infarction or a stroke more
than 6 months before inclusion.
Examinations
The index date was the day of sur-
gery for patients in the surgery group
and for their matched controls. Base-
line examinations in both groups
took place approximately 4 weeks
before the index date. At baseline
and follow-up visits (0.5, 1, 2, 3, 4,
6, 8, 10, 15, and 20 years after the
index date), measurements of weight,
height, waist circumference, blood
pressure, and biochemical variables
(not all visits) were obtained.8 Blood
samples were obtained after a 10 to 12
hour overnight fast and analyzed
at the Central Laboratory of Sahl-
grenska University Hospital (accred-
ited according to European Norm
45001).
Interventions
The choice of surgery type was made
by the operating surgeon, and 265
participants (13%) underwent gastric
bypass; 376 (19%), gastric banding;
and 1369 (68%), vertical-banded gas-
troplasty.15 Eighty-nine percent of
the patients underwent open surgery.
Control patients received the cus-
tomary nonsurgical obesity treatment
at their registration center. No
attempt was made to standardize
their treatment, which ranged from
sophisticated lifestyle intervention
and behavior modification to no
treatment.
Outcomes
The primary outcome of the Swedish
Obese Subjects study (total mortal-
ity) was published in 2007.9 The
main outcome in our current analysis
was health care use, measured by
hospital days, nonprimary care out-
patient physician visits, and drug
costs. Outcome data were retrieved
from nationwide registries managed
by the Swedish National Board of
Health and Welfare. Inpatient and
nonprimary care outpatient visit data
were retrieved from the National
Patient Register, and drug dispensa-
tion data from the Prescribed Drug
Register. The data were linked to the
study database via the unique per-
sonal identification number assigned
to each Swedish resident.
Reporting to the National Patient
Register is mandatory for all public
hospitals in Sweden. The inpatient
registry component commenced in
1964 and attained national coverage
in 1987 (the start-year of this study).
The nonprimary outpatient care com-
ponent commenced on a national
level in 2001.
The Prescribed Drug Register con-
tains all dispensed prescription drugs
from pharmacies in Sweden since July
2005. Because patients were recruited
into the Swedish Obese Subjects study
between 1987 and 2001, we did not
have drug dispensation data for the
early follow-up years and show avail-
able data from year 7 after the index
date.
Follow-up
Patients were followed up from the in-
dex date or date of first data capture in
the respective outcome registries
(nonprimary outpatient care and drug
costs), until 20 years after the index
date, death, emigration or date of last
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data capture from the registries, which-
ever came first. End of data capture
from the National Patient Register was
December 31, 2009, and from the Pre-
scribed Drug Register was May 31,
2011. Because recruitment into the
study occurred between1987 and2001,
while registry data were only available
on nonprimary care outpatient visits for
2001-2009 and drug costs for 2005-
2011, patients contributed outcome
data and person-time in different fol-
low-up years, depending on year of
study entry.
During follow-up, 2 surgery group
patients requested to be deleted from
the research database, and a third later
obtained an unlisted personal identifi-
cation number making linkage from
that time point impossible. Follow-up
regarding inpatient and nonprimary
care outpatient visits and prescription
drug dispensations was hence com-
plete for 99.9% (4044 of 4047).
Statistical Analysis
Analyses were performed by inten-
tion to treat, including all patients
according to their initial treatment
group allocation. Mean values and
standard deviations or 95% confi-
dence intervals were used to describe
the baseline characteristics and
changes over time in the study
groups. Statistical analyses were per-
formed using SAS version 9.2 (SAS
Institute Inc). Reported P values are
2-sided, and P values .05 were con-
sidered statistically significant.
Primary Analysis
Mean annual hospital days (follow-up
years −4 to 20, data capture 1983-
2009), nonprimary care outpatient vis-
its (2 to 20 years, 2001-2009), and drug
costs (7 to 20 years, 2005-2011) were
calculated for up to 20 years after the
index date (1987-2001). All outcomes
were skewed, with a longer right tail.
Although use of mean values as mea-
sure of central tendency for skeweddata
are generally not considered appropri-
ate, the arithmetic mean has been de-
scribed as the most informative mea-
sure for cost and health care resource
use data.16,17 Statistical testing was per-
formed on untransformed values with
parametric methods and was checked
using nonparametric bootstrap-
ping.16,17 The percentage with inpa-
tient or nonprimary care outpatient vis-
its per year andmedian drug costs were
also calculated.
Mean differences were estimated
using linear regression, adjusting for
baseline age, sex, BMI, diabetes sta-
tus, smoking (current smoker yes/
no), inclusion period (before or after
1995), and (for inpatient care analy-
sis) hospital days the year before the
index date. These adjustments were
also used in logistic regressions esti-
mating odds ratios for having an
inpatient or nonprimary care outpa-
tient visit.
Mean annual differenceswere also es-
timated for the following periods: in-
dex year (hospital days), years 2
through 6 (hospital days, nonprimary
care outpatient visits), and years 7
through 20 (all 3 outcomes). These es-
timates were adjusted for the same co-
variates as mentioned above and
weighted by the number of person-
years under observation. The period cut
pointsweremade post hoc based on ob-
servation of the data, previous publi-
cations,13,14 and the availability of data
for the cost of drugs.
Cause of Nonprimary Care
Outpatient Visits
Based on main diagnosis classified ac-
cording to the International Classifica-
tion of Diseases (ICD), the nonprimary
care outpatient visits were also ana-
lyzed for visits with diabetes (ICD-10
codes, E10-E14; ICD-9 code, 250), car-
diovascular disease (ICD-10, chapter I;
ICD-9 codes, 390-459), or tumors as
the main diagnosis (ICD-10 codes,
C00-D48; ICD-9 codes, 140-239). This
was not done for hospital days because
inpatient care admissionsweremore rare
than nonprimary care outpatient visits.
Drug Costs
Drug costs were inflation adjusted
to 2011 Swedish crowns using the
Swedish drug price index,18,19 and
converted to US dollars (exchange
rate, 7:1). Based on the Anatomical
Therapeutic Chemical (ATC) drug
classification system, the drug cost
was calculated by drugs for diabetes
(ATC code, A10), gastrointestinal dis-
orders (ATC codes, A02-A07), anemia
and vitamin deficiency (ATC codes,
A11 and B03), cardiovascular disease
(ATC codes, C01-C10), psychiatric dis-
orders (ATC codes, N05-N06), and an-
tiasthmatics (ATC code, R03; eTable 1
available at http://www.jama.com).
RESULTS
At baseline, patients in the surgery
group were on average 6.3 kg heavier,
1.3 years younger, more frequently
smokers; more often had diabetes; and
less likely to have a university degree
than the control group (TABLE 1). The
relative weight changes for those in the
surgery group was a loss of 17% at 10
years, 16% at 15 years, and 18% at 20
years vs a gain of 1% at 10 years, a loss
of 1% at 15 years, and a loss of 1% at
20 years among those in the control
group.
Inpatient Care
Hospitalization Frequency. Approxi-
mately 20% to 25% of surgically
treated patients were hospitalized
annually during follow-up (exclud-
ing the index surgery in year 1). In
the 20 years after bariatric surgery,
patients used a mean cumulative of
54 hospital days vs 40 days by the
control group (adjusted difference,
15; 95%CI, 2-27; P=.03; eTable 2). Be-
tween years 1 and 6, a higher percent-
age of surgery patients than controls
were admitted annually to inpatient care
(FIGURE 1). In the surgery group, the
proportion of hospitalized patients de-
creased and stabilized from years 6 to
16 before increasing again, while it in-
creased in controls from 13% to 24%
between years 1 and 20.
Hospital Days by Year. During the
4 years before the index date, therewere
no or negligible between-group differ-
ences in mean annual hospital days
(FIGURE 2). During year 1 (including
the index surgery admission), themean
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accumulated hospital days was 9.4 for
surgery patients and 0.9 for controls
(adjusted difference, 8.4; 95% CI, 7.8-
9.1; P .001). Thereafter the differ-
ence decreased, but remained the sec-
ond (adjusted difference, 1.0; 95% CI,
0.6-1.4; P .001), third (adjusted dif-
ference, 0.4; 95% CI, 0.1-0.7; P=.02),
and fourth year after surgery (ad-
justed difference, 0.5; 95% CI, 0.1-
0.9; P=.02). No differences were ob-
served thereafter. Within the surgery
group, no differences between surgery
types or between open vs laparoscopic
procedure were observed beyond year
1 (eFigure 1).
Hospital Days by Period. Between
years 2 and 6, surgery patients
incurred 1.7 mean annual hospital
days vs 1.2 among controls, respec-
tively (adjusted difference, 0.5; 95%
CI, 0.2-0.7; P .001; TABLE 2).
Between years 7 and 20, no differ-
ence was observed.
Nonprimary Outpatient Care
Visit Frequency. The percentage of
patients with 1 or more annual
nonprimary care outpatient visits
was higher than for inpatient care,
but otherwise followed a similar pat-
tern with greater use in surgery
patients than in controls for about 5
years (Figure 1). In both groups, the
percentage of patients with annual
visits generally increased over time.
Number of Visits by Year. Similar
to the finding for hospital days, the
annual mean for nonprimary care
outpatient visits was higher in sur-
gery patients than in controls during
years 2 to 4, with no differences
thereafter (FIGURE 3). For visits with
diabetes, cardiovascular disease, or
tumors as main diagnosis (conditions
for which we have previously dem-
onstrated beneficial effects of sur-
gery8,10-12), the annual mean was
lower in surgery patients than in
controls between years 6 and 15 (eFig-
ure 2).
Number of Visits by Period. From
years 2 to 6, patients who underwent
surgery incurred amean annual nonpri-
mary care outpatient visits of 1.3 vs 1.1
among control patients (adjusted dif-
ference, 0.3; 95% CI, 0.1-0.4; P=.003;
Table 2). From years 7 to 20, no differ-
ence was observed.
Drug Costs
Overall Drug Costs. Nearly all pa-
tients had 1 or more drugs dispensed
annually during the follow-up years for
which we had registry data (years,
7-20). Overall drug costs were lower in
surgery patients than in controls for 8
of the 14 years investigated, and point
estimates were consistently lower
(FIGURE 4). Averaging over the 7- to 20-
year period, surgery patients incurred
an annual mean cost of US $930 and
controls, US $1123 (adjusted differ-
ence −$228, 95% CI −$335 to −$121;
P .001; Table 2).
Drug Cost Distribution. Consis-
tently lower costs were observed in
surgery patients than in control pa-
tients for antidiabetic and anti–
cardiovascular disease agents (except
for year 8 due to an outlier with pul-
monary hypertension who was taking
bosentan;FIGURE 5). Asthmadrug costs
were lower in surgery patients than con-
trols from year 7 to year 11, whereas
drug costs associated with anemia and
vitamin deficiencies were higher from
year 7 to year 10. Few differences were
seen for gastrointestinal and psychiat-
ric drug costs, although the point esti-
mates were generally greater for the
surgery group.
Adverse Events
Within 90 days from study start, 5 of
2010 patients (0.2%) in the surgery
group and 2 of 2037 patients (0.1%)
in the control group had died. As
reported elsewhere, out of 1164 sur-
gically treated patients, 151 (13%)
experienced 193 postoperative com-
plications.10
COMMENT
Although the study patients mostly
received vertical-banded gastroplas-
ties, an operation that is no longer
commonly performed, they achieved a
high degree of weight loss that was
sustained for many years. They had a
20-kg greater weight loss than non-
surgery controls. Despite the weight
loss, surgically treated patients used
more health care resources both on an
inpatient and outpatient basis in the
first 6-year period after surgery.
Beyond that, use between groups was
Table 1. Patient Characteristics at Baseline
Surgery
(n = 2010)
Controls
(n = 2037) P Value
Women, No. (%) 1420 (71) 1447 (71) .79
Age, mean (SD), y 47 (6) 49 (6) .001
Height, mean (SD), cm 169 (9) 169 (9) .64
Women 165 (6) 165 (6) .59
Men 179 (7) 180 (7) .34
Weight, mean (SD), kg 121 (17) 115 (17) .001
Women 116 (14) 111 (15) .001
Men 133 (17) 125 (17) .001
Body mass index, mean (SD)a 42.4 (4.5) 40.1 (4.7) .001
Women 42.8 (4.3) 40.7 (4.6) .001
Men 41.3 (4.8) 38.6 (4.7) .001
Waist circumference, mean (SD), cm 126 (11) 120 (11) .001
Women 124 (10) 119 (11) .001
Men 131 (11) 124 (11) .001
University education, No. (%) 257 (13) 431 (21) .001
Smoking, No. (%) 518 (26) 422 (21) .001
Diabetes, No. (%)b 345 (17) 262 (13) .001
aCalculated as weight in kilograms divided by height in meters squared.
bBased on blood glucose, use of antidiabetic medication, or both.
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the same. Drug costs were lower in
surgery patients than in the controls
between years 7 to 20. These differ-
ences were attributable to lower costs
for treating diabetes and cardiovascu-
lar disease.
A recent meta-analysis of the asso-
ciation between bariatric surgery,
weight loss, operativemortality, and co-
morbidities highlighted the paucity of
long-term outcomes for bariatric sur-
gery.6 Another review of bariatric sur-
gery by the National Institute of Clini-
cal Excellence (NICE) in the United
Kingdom, concluded that long-term
studies were needed to provide data on
“resource use across the entire patient
pathway to develop robust costings” for
economic evaluations.20 Consequently,
we used the Swedish Obese Subjects
study to determine health care use fol-
lowing bariatric surgery because it is the
only multicenter, prospective, long-
term study of bariatric surgerywith very
good matching between groups.
Our results were similar to an ob-
servational study fromCalifornia show-
ing increased hospitalizations of bar-
iatric surgery patients for up to 5 years
after surgery.21 A Canadian study re-
ported health care cost savings over 5
years vs age- and sex-matched obese
controls.22 Controls in that study were
identified via ICD-9 codes for morbid
obesity in a health insurance claims da-
tabase. Thismight bias the cohort in fa-
vor of patients with a greater disease
burden. This appears to be true since
their control group had a worse prog-
nosis than ours9 and a worse progno-
sis than that observed in another con-
trolled cohort study.23
We previously reported that the sur-
gery group hadmore hospital days than
did controls over 6 years based on 481
surgery patients and 481 controls.24 The
current study adds the information that
nonprimary care outpatient visits were
higher during this period. We now re-
port beyond 6 years that inpatient and
outpatient resource use is the same be-
tween groups. We had also reported
self-reported medication use patterns
for a sample (n=510, surgery; n=455,
controls) of the Swedish study popu-
lation for the first 6 years.25 The cur-
rent study of the entire cohort using
pharmacy dispensing data confirms
some of the 6-year results and extends
the observations to 20 years. At years
7 through 20, there were lower overall
drug costs for surgery patients than for
controls. These differences were attrib-
utable to savings for medications that
treat diabetes and cardiovascular dis-
ease. In contrast, our previous studywas
using self-reported data for the first 6
years, no savings were identified be-
cause savings onmedication for diabe-
tes and cardiovascular disease were off-
set by increased use of gastrointestinal
medications and vitamins.25 In the cur-
rent study using pharmacy rather than
self-reported data, we found signifi-
cantly less medication use by bariatric
surgery patients for the 7- through 20-
year period. At the same time, it appears
Figure 1. Adjusted Odds Ratio for Percentage of Any Annual Inpatient or Nonprimary
Outpatient Care Visits
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Figure 2. Mean Annual Hospital Days From 4 Years Before to 20 Years After the Index Date
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Table 2. Annual Hospital Days, Nonprimary Care Outpatient Visits, and Drug Costs by Follow-up Period in Relation to the Index Date
Outcome, Data Capture
No. of
Patients
Median
Years of
Follow-up (IQR)
Weighted
Median per
Year (IQR)
Weighted
Mean per
Year (95% CI)
Adjusted
Mean Difference
(95% CI)a
P
Value
Hospital days, 1987-2009
Year 1 (index year)
Surgery 2008 1.0 (1.0 to 1.0) 7 (5 to 9) 9.4 (8.8 to 9.9)
8.4 (7.8 to 9.1) .001
Controls 2037 1.0 (1.0 to 1.0) 0 (0 to 0) 0.9 (0.6 to 1.1)
2-6 y
Surgery 1997 5.0 (5.0 to 5.0) 0.6 (0 to 1.6) 1.7 (1.5 to 1.9)
0.5 (0.2 to 0.7) .001
Controls 2027 5.0 (5.0 to 5.0) 0 (0 to 1) 1.2 (1.0 to 1.3)
7-20 y
Surgery 1958 9.1 (6.7 to 11.4) 0.6 (0 to 1.6) 1.8 (1.6 to 2.0)
0.0 (−0.3 to 0.3) .95
Controls 1985 8.8 (5.7 to 11.3) 0.4 (0 to 1.6) 1.8 (1.6 to 1.9)
Nonprimary care outpatient visits,
2001-2009
2-6 y
Surgery 887 3.1 (1.9 to 4.7) 0.8 (0 to 1.8) 1.3 (1.2 to 1.5)
0.3 (0.1 to 0.4) .003
Controls 964 3.3 (2.3 to 4.3) 0.5 (0 to 1.4) 1.1 (1.0 to 1.2)
7-20 y
Surgery 1936 8.6 (6.5 to 9.0) 1.2 (0.6 to 2.3) 1.8 (1.6 to 2.0)
−0.2 (−0.4 to 0.1) .12
Controls 1962 8.2 (5.7 to 9.0) 1.1 (0.4 to 2.4) 1.9 (1.8 to 2.1)
Drug cost, US $, 2005-2011
7-20 y
Surgery 1889 5.9 (5.2 to 5.9) 529 (177 to 1171) 930 (860 to 1001)
−228 (−335 to −121) .001
Controls 1893 5.9 (5.2 to 5.9) 626 (225 to 1435) 1123 (1040 to 1206)
Abbreviation: IQR, interquartile range.
aAdjusted for age, sex, baseline body mass index, baseline diabetes, smoking status, inclusion period (before 1995 or 1995 and beyond), and (for the hospitalization analysis)
annual hospital days the year prior to the index date. The analysis was weighted by person-years under observation in the respective time periods.
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to reflect the pattern for health care use,
whichwas elevated in the surgery group
during the 6-year period after the in-
dex date (when there was no differ-
ence in drug costs25), and then showed
no differences from year 7 to 20 (when
drug cost savings were observed in our
current analysis).
After the index year of the proce-
dure, the difference in annual hospital
days decreased between surgery and
control patients until year 5 when
there were no more differences, a
finding that persisted for the remain-
der of the study. Increased hospital
use resulted from complications, ane-
mia, revisional surgery, gallstones,
and need for plastic surgery in surgery
patients as opposed to controls.25
These conditions probably also
resulted in the corresponding increase
in nonprimary outpatient care use
during the same period.
Bariatric surgery reduced cardio-
vascular events,11 cancer,10 and dia-
betes.8,12 Translating these benefits
into reduced health care resource use
may not be evident for many years
because these diseases take many
years before they become problem-
atic. In the Swedish Obese Subjects
study, improved outcomes for these
compl icat ions of obes i ty were
observed during 10 to 15 years of
follow-up. Given that, there should
have been a detectable benefit in
resource use during those periods.
However, we did not observe that for
overall health care resource use. The
10-year cumulative incidence of can-
cer was 5.5% and 6.0% for cardiovas-
cular disease events.10,11 The 20% to
30% benefit in these diseases attrib-
utable to bariatric surgery coupled
with the low incidence might explain
why we did not observe an overall
benefit to bariatric surgery in terms
of health care resource use during
this period.10,11
The difference in drug costs was
driven by costs for medications for
diabetes and cardiovascular disease,
reflecting the effects of bariatric sur-
gery on diabetes remission,8 diabetes
Figure 3. Mean Annual Nonprimary Outpatient Care Visits From Year 2 to 20
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Adjusted for baseline age, sex, smoking, diabetes status, body mass index, and inclusion period (before 1995 or 1995 and beyond). Error bars indicate 95%CIs. Registry
data are from 2001-2009.
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prevention,12 and cardiovascular dis-
ease events.11
Our findings indicate that bariatric
surgery is associated with increased
health care use in the first 6 years after
surgery.24,25 Thereafter, inpatient and
nonprimary outpatient care use were
similar between treatment groups. The
surgery group experienced a savings in
drug cost between years 7 to 20. Based
on our findings, bariatric surgery ap-
pears to result in greater health ben-
efits9-12 than conventional obesity treat-
ment, but at a higher cost over the time
of the study. However, a formal cost-
effectiveness analysis is needed to
quantify the cost-per-unit health ef-
fect that is associated with bariatric
surgery.
To date, the Swedish Obese Sub-
jects study is the largest and longest
prospective, controlled study of
bariatric surgery. Although mortality
was the primary outcome,9 health
care use data were also collected
prospectively. Inpatient data were
sourced from the National Patient
Register and available for patients
after (and before) the index date
until death or emigration. Registry-
based nonprimary outpatient care
and drug dispensing data were avail-
able from 2001 and 2005, respec-
tively. Using registry linkage over-
comes limitations associated with
questionnaire-based data collection
such as nonresponse and recall
bias. Also, because there is universal
health care access in Sweden, utiliza-
tion is not distorted by insurance sta-
tus, and likely a reasonable reflection
of overall morbidity.
Our study was limited because the
ethical review boards did not permit
randomization. Therefore selection
bias and residual confounding
beyond that eliminated by matching
and adjustments may exist. Analysis
of hospital use before the surgery
index date suggested that the groups
were similar. Preindex date registry
data on the other outcomes are
unavailable. Although imbalances
existed at baseline, we compensated
for them by multivariable adjust-
ment. Another limitation is that there
is no natural time point in which to
determine that bariatric surgery is
more costly and then more beneficial
or no different from conventional
treatment. We chose to segregate our
analysis before and after 7 years
based on the availability of data and
previous publications rather than on
there being some change that should
occur at that time.
The patient cohort reported herein
underwent surgery between 1987
and 2001. Since then, surgical proce-
dures changed with greater use of
laparoscopic techniques and Roux-
en-Y gastric bypass procedures. Nev-
ertheless, our cohort had dramatic
and sustained weight loss despite the
application of now outdated proce-
dures. Patients experienced low post-
operative mortality (90-day mortal-
ity, 0.25% in surgery patients vs
0.10% in controls,9 compared with a
30-day mortality of 0.33%21 and
1.9%26 in 2 US studies). Although
the procedures differ from contem-
porary operations, it is likely that
the results from our study are typical
of those that might be expected
from other procedures that result in
similar weight loss outcomes with
similar perioperative adverse event
profiles.
Figure 4. Mean and Median Annual Prescription Drug Costs From Year 7 to 20 (Registry
Data 2005-2011)
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Wewere limited in not having regis-
try data for primary care visits. Also, the
Prescribed Drug Registry contains all
prescriptiondrugs dispensed fromphar-
macies, but not in-hospital drug use.
Althoughwe had inpatient hospital-
ization information for nearly all pa-
tients for 10 or more years, we did not
have similar information for nonpri-
mary outpatient visits and dispensed
drugs because no registries for these ser-
vices existed when recruitment started
in 1987. Therefore, fewer patients were
available for nonprimary care outpa-
tient visits and drug costs in the first
few years after surgery.
CONCLUSIONS
Despite considerably greater and sus-
tained weight loss than convention-
ally treated controls, surgically
treated patients used more inpatient
and nonprimary outpatient care dur-
ing the 6-year period after the index
date but not thereafter. Cost savings
Figure 5. Mean Annual Prescription Drug Costs From Year 7 to 20 for Selected Drug Groups (Registry Data 2005-2011)
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aAdjusted for baseline age, sex, smoking, diabetes status, body mass index, and inclusion period (before 1995 and 1995 and beyond). Error bars indicate 95% CIs.
Sample sizes are the same as those in Figure 4.
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in the surgery group were seen for
medications that treat diabetes and
cardiovascular disease between year
7 and 20, resulting in lower overall
drug costs during that period.
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Abstract   
Context Bariatric surgery prevents and induces remission of type 2 diabetes. The effect of 
glucose status before bariatric surgery on long-term health care use is unknown.  
Objective To assess health care use over 15 years by obese patients treated conventionally 
or with bariatric surgery stratified by baseline glucose categories.   
Design, Setting, and Participants The Swedish Obese Subjects study is an ongoing, 
prospective, nonrandomized, controlled intervention study conducted in the Swedish health 
care system that included 2010 adults who underwent bariatric surgery and 2037 
contemporaneously matched controls recruited between 1987 and 2001. Inclusion criteria 
were age 37 to 60 years and body mass index (BMI) ш34 in men and D/ш38 in women.  
Interventions Bariatric surgery vs conventional obesity treatment. 
Main Outcome Measures Total hospital days (follow-up years 1-15; data capture 1987-2012; 
and non-primary  care outpatient visits (follow-up years 2-15; data capture 2001-2012) were 
retrieved from the Swedish National Patient Register. Prescription drug costs were retrieved 
from questionnaire data (follow-up years 1, 2, 3, 4, 6, 8, 10, 15, data capture 1987-2012) and 
from the Swedish Prescribed Drug Register (follow-up years 7-15; data capture 2005-2012). 
Register linkage was complete for >99% of patients (4040/4047). Mean differences were 
adjusted for baseline age, sex, smoking, BMI, inclusion period, and (for inpatient care) hospital 
days the year prior to the index date.  
Results During years 1-15, surgery patients with normal and impaired fasting glucose 
accumulated higher mean total hospital days relative to controls, whilst no between-group 
difference was observed in patients with type 2 diabetes. During years 2-15, there was no 
difference in mean total non-primary care outpatient visits between treatment groups. 
During years 1-15, total prescription drug costs did not differ between treatment groups in 
patients with normal glucose, whilst lower mean drug costs were observed in surgery patients 
with impaired fasting glucose and type 2 diabetes.  
Conclusions Relative to controls, surgery patients with normal glucose used more hospital 
days; surgery patients with impaired fasting glucose used more hospital days, but incurred 
lower drug costs; and surgery patients with type 2 diabetes incurred lower drug costs. 
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Abstract table: 
 Mean  Adjusted mean  
difference (95% CI) 
P 
value  Surgery Control 
Hospital days (years 1-15) Days 
Normo-glycemic 30.3 16.9 12.9 (9.9-15.9) <.001 
Impaired Fasting Glucose 32.5 21.8 12.5 (5.6-19.4) <.001 
Type 2 Diabetes 38.7 36.7 3.4 (-6.4; 13.3) .49 
Non-primary  care outpatient visits 
(years 2-15) 
Visits 
Normo-glycemic 21.6 21.2 -0.4 (-2.4, 1.7) .71 
Impaired Fasting Glucose 20.5 21.2 1.3 (-1.9, 4.5) .43  
Type 2 Diabetes 28.7 27.4 -0.9 (-8.8, 7.1) .83 
Drug costs, $US 2012 (years 1-15) $US 2012 
Normo-glycemic 10,264 10,635 -40 (-2190, 1310) .62 
Impaired Fasting Glucose 10,048 12,845 -2911 (-5605, -218) .034 
Type 2 Diabetes 14,245 19,488 -5597 (-8631, -
2563) 
<.001 
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Introduction 
The severely obese population (body mass index [BMI] ш35, calculated as weight in kilograms 
divided by height in meters squared) is growing faster than less severe obesity sub-classes1,2, 
with prevalence currently estimated at 15% in the United States3. The risk of type 2 diabetes 
in the severely obese population is 93-fold higher in women4, and 42-fold higher in men5, 
relative to the healthy weight population (BMI 18.5-24.9). Severely obese patients have 
difficulty sustaining weight loss through diet and exercise interventions6. In contrast, bariatric 
surgery facilitates sustained weight loss7, and for patient with type 2 diabetes, remission or 
improvements for the majority of patients8-10. The Swedish Obese Subjects study has 
previously demonstrated superior type 2 diabetes remission11 and prevention12 in patients 
receiving bariatric surgery (relative to conventional treatment) over 15 years.  
It is foreseeable that diabetes prevention and remission induced by bariatric surgery will 
prevent future diabetes-related health care use, and therefore offset, wholly or partially, the 
healthcare use associated with bariatric surgery. Therefore prioritizing patients with 
prediabetes or diabetes may lead to greater returns on investment from limited health care 
budgets.  
In the current study, we aimed to assess health care use over 15 years by obese patients 
treated conventionally or with bariatric surgery in sub-groups of patients with normal glucose, 
impaired fasting glucose and type 2 diabetes prior to surgery. Linkage with Swedish health 
care register data was undertaken and hospital days, non-primary care outpatient visits, and 
prescription drug costs were assessed.  
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Methods 
The SOS study has previously been described14. In brief, 2010 individuals chose to undergo 
surgery, and a contemporaneously matched obese control group of 2037 participants was 
created using 18 variables from a matching examination and a group matching procedure 
(eAppendix). The surgery and control groups had identical inclusion and exclusion criteria. 
The inclusion criteria were an age of 37 to 60 years and a body mass index (BMI) ŽĨш34 in 
men and ш38 in women before or at the time of the matching examination.  
The exclusion criteria (eAppendix) were established to exclude patients with unacceptable 
surgical risks. Baseline examinations were undertaken 4 weeks before the start of the 
intervention. Control patients received the customary nonsurgical obesity treatment at their 
registration center. Both study groups had identical follow-up with physical examinations and 
questionnaires at baseline and after 0.5, 1, 2, 3, 4, 6, 8, 10, and 15 years. Centralized 
biochemistry was performed at baseline and after 2, 10, and 15 years. All samples were taken 
after an overnight fast and analyzed at the Central Laboratory, Sahlgrenska University 
Hospital, Gothenburg, Sweden, accredited according to International Organization for 
Standardization/International Electrochemical Commission 15189:2007 standards. 
Health care use  
Health care use outcomes were retrieved from nationwide registries managed by the Swedish 
National Board of Health and Welfare (except drug data for follow-up years 1-6). The register 
data were linked to the study database via the unique personal identity number assigned to 
each Swedish resident.  
Data on inpatient and non-primary outpatient care were retrieved from the Swedish National 
Patient Register. Inpatient care has been recorded since 1964, and attained national coverage 
in 1987. The non-primary outpatient care component commenced at a national level in 2001. 
Drug use data for follow-up years 1-6 were sourced from questionnaires completed by study 
participants at baseline, years 1, 2, 3, 4 and 6 (data for years 8, 10, 15 were also used in the 
imputed data-set). Information on prescribed medications, including dosage and strength 
were collected, and unit costs were applied as detailed previously15. Drug costs for follow-up 
years 7-15 were sourced from the Swedish Prescribed Drug Register, which captures date, 
drug name, therapeutic categories, and cost of all dispensed prescription drugs from 
pharmacies in Sweden from July 2005. There was a strong correlation between self-reported 
drug costs and register based costs during the years when both data were available. Drug 
costs were inflation adjusted to 2012 Swedish Crowns using the Swedish drug price index16, 
and converted to US dollars (exchange rate, 7 Crowns:1USD).  
In Sweden, primary care is implemented at the local level and administrative data varies by 
region. Data for one region is presented (eAppendix). 
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Glucose categories 
Self-reported information about diabetes medication and diabetes duration and glucose 
concentrations measured during a baseline examination were assessed. From 1987 through 
2009, fasting glucose concentrations were measured in venous whole blood. After 2009, 
venous fasting plasma glucose was measured, and the concentrations were converted to 
those for blood glucose12. The study was initiated before repeated measurements were 
routinely used for the diagnosis of type 2 diabetes; therefore, single fasting glucose 
determinations were used. 
Three baseline glucose categories were defined and assigned to all patients. Type 2 diabetes 
was defined as fasting blood glucose of  ш110 mg/dL, corresponding to a fasting plasma 
glucose ш126 mg/dL17,18 or diabetes medication use (insulin, oral antidiabetic drugs, or both). 
Impaired fasting glucose was defined as a fasting blood glucose between 90 and 110 mg/dL, 
or a fasting plasma glucose level between 100 and 126 mg/dL19,20. Remaining patients were 
designated as normo-glycemic. 
Follow-up 
During follow-up, 2 normo-glycemic surgery patients requested to be deleted from the 
research database, and a third obtained an unlisted personal identification number making 
linkage thereafter impossible. Four patients with type 1 diabetes were also excluded from 
analysis. Register linkage was hence complete for 99.8% of participants (4040/4047). 
The index date was the day of surgery for patients in the surgery group and their matched 
controls. Follow-up year 1 was the first 365 days after the index date. Patients were followed 
from the index date or date of first data capture in the respective health care registries, until 
15 years after the index date, death, emigration or date of last data capture from the 
registries, whichever came first. End of data capture from both Registers was 31 December, 
2012. Recruitment into the study occurred between 1987 and 2001, therefore patients 
contributed health care data in different follow-up years. Register data relating to non-
primary outpatient care was limited in 2001 (the final year of study recruitment), therefore 
results are presented for follow-up years 2-15 only. Data for follow-up years 1-15 are 
presented for inpatient care and prescription drugs. 
Statistical Analysis 
Analyses were performed by intention to treat. Mean annual hospital days, non-primary  care 
outpatient visits and drug costs were calculated for up to 15 years after the index date (1987-
2001) for each treatment-glucose group based on observed data. Mean annual differences 
between treatment groups were estimated for each follow-up year, using linear regression 
and 95% confidence intervals based on untransformed values, adjusting for age, sex, hospital 
days in the year prior to the index date (for hospital days), smoking and inclusion period 
(recruitment фͬш 1995). Mean differences were also estimated for each health care outcome 
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for the “total” follow-up period available. First, multiple imputation was utilized to handle 
missing data (eAppendix). Next, the same linear regression method used on observed data 
was repeated. Sensitivity analyses are described in the eAppendix. 
Statistical analyses were performed using SAS version 9.3 (SAS Institute Inc) and Stata version 
11. Reported P values are 2-sided, and P values <.05 were considered statistically significant.  
Results 
Patient characteristics  
At baseline, patients in the surgery group were on average 6.3 kg heavier, 1.3 years younger, 
more frequently smokers, and less likely to have a university degree than the control group 
(Table 1). Similar trends were observed across all glucose categories. The relative weight 
change in the surgery group was a loss of 16%, 18% and 18% in the normo-glycemic, glucose-
impaired and diabetes group respectively at 15 years. Equivalent figures in the control group 
were 0%, 0% and 0%. 
Inpatient care  
During years 1-15, in normo-glycemic patients, mean imputed total hospital days were 30.3 
in the surgery group and 16.9 in the control group (adjusted difference, 12.9; 95%CI, 9.9-15.9; 
P<.001) and comparable figures in glucose-impaired patients were 32.5 and 21.8 (adjusted 
difference, 12.5; 95%CI, 5.6-19.4; P<.001). In patients with diabetes, no difference between 
the surgery and control group was observed (38.7 vs 36.7; adjusted difference, 3.4; 95%CI, -
6.4 to 13.3; P=.49, Table 2, Figure 1).  
Non-primary outpatient care 
During years 2-15, there was no difference between treatment groups in imputed non-
primary outpatient care use for any glucose category (Table 2, Figure 2).  
Drug costs  
During years 1-15, mean imputed total drug costs did not differ between the surgery and 
control group in normo-glycemic patients ($10,264 vs $10,635, adjusted difference -$40; 
95%CI, -$2190 to $1310; P=.62). In contrast, mean imputed total drug costs were lower for 
the surgery group in glucose-impaired patients ($10,048 vs $12,845, adjusted difference -
$2911; 95%CI, -$5605 to -$218; P=.034), and in patients with diabetes ($14,245 vs $19,488, 
adjusted difference -$5597; 95%CI, -$8631 to -$2563, P<.001, Table 2, Figure 3). These cost 
savings were driven by diabetes drugs (Figure 4, eAppendix). Time trends are reported in the 
eAppendix. 
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Discussion 
Overall results 
Recent bariatric surgery reviews have highlighted “examining long term healthcare and cost 
data”, and “which patient level factors predict success” as priorities for future research21-23. 
Our current study fills these evidence gaps by analysing total inpatient care, non-primary 
outpatient care and prescription drug costs for obese patients treated conventionally or with 
bariatric surgery over up to 15 years according to their glucose profile before surgery. We 
observed that normo-glycemic and glucose-impaired patients accumulated more hospital 
days relative to controls, whilst no between-group difference was observed in patients with 
diabetes. There was no difference in mean total non-primary care outpatient visits between 
treatment groups. Finally, prescription drug costs did not differ between treatment groups in 
normo-glycemic patients, whilst lower mean drug costs were observed in surgery patients 
with impaired glucose and type 2 diabetes.  
Implications 
The use of bariatric surgery globally is largely governed by a US National Institutes of Health 
consensus statement defining ĞůŝŐŝďůĞƉĂƚŝĞŶƚƐĂƐƚŚŽƐĞǁŝƚŚĂD/шϰϬŽƌD/шϯϱĐŽŵďŝŶĞĚ
with a serious obesity-related morbidity24. Our previously reported clinical endpoints 
including remission11 and prevention of type 2 diabetes12 and the prevention of 
cardiovascular events25 favour patients with impaired glucose or diabetes. Consequently, we 
have recommended that a measure of glucose impairment (rather than BMI), be used to 
prioritize obese patients who can achieve the greatest health benefits from surgery. Other 
groups have called for similar revisions26-28, which are partially reflected in the recently 
revised National Institute for Health and Care Excellence (United Kingdom) obesity 
guidelines29. In the current study, we report for the first time, that long-term economic 
outcomes also favour the glucose-impaired and diabetes sub-groups (relative to the normo-
glycemic group), adding further evidence to support the prioritization of these sub-groups to 
receive bariatric surgery. 
Previously published modelled studies report that bariatric surgery is a cost-effective 
intervention for treating severe obesity in the currently eligible population30. Based on our 
previous clinical14 12, and current health care use outcomes reported herein favoring the 
glucose-impaired and diabetes groups, it is likely that economic evaluations published  for the 
“total” eligible population underestimate the economic benefits of bariatric surgery for 
glucose-impaired and diabetes sub-groups and overestimate the benefits for normo-glycemic 
patients. A formal cost-effectiveness analysis of bariatric surgery relative to conventional 
therapy for obese patients stratified by glucose sub-groups is needed.  
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Inpatient care 
We observed greater use of inpatient care in the surgery patients in the normo-glycemic and 
glucose-impaired groups, whilst no between-group difference in patients with diabetes was 
detected. Increased hospital use in the surgery group was primarily due to the index bariatric 
surgery, and to a lesser extent, revisional bariatric surgery, plastic surgery, gallstones and 
anemia as reported previously13. Since patients in our study received bariatric surgery 
between 1987 and 2001, surgical procedures have changed. The rate of laparoscopic surgery 
in our study was 11%; this compares to 97% in 2012 in Sweden31. The mean length of stay 
after the index bariatric surgery in our study was 7.1 days, longer than the 1.9 days in Sweden 
in 201231. Also many SOS surgery patients receiving gastric banding and vertical-banded 
gastroplasty were later converted to gastric bypass. Therefore results may be more favorable 
to the surgery group in contemporary settings (eAppendix). Regardless, no difference 
between treatment groups was observed for the diabetes group, suggesting that any 
admissions related to bariatric surgery were offset by the prevention of diabetes-related 
hospitalization.  
Outpatient care 
We did not observe a difference in the use of non-primary outpatient care between treatment 
groups for any glucose group. However, we did not have national registry data for primary 
care, which plays a significant role in the management of type 2 diabetes. Analysis of data for 
one local region suggests that the use of primary care did not differ between treatment 
groups for the normo-glycemic patients, but was higher in control patients for the glucose-
impaired and diabetes groups in several follow-up years. Therefore, exclusion of primary care 
data is likely to under-estimate healthcare differences between treatment groups for the 
glucose-impaired and diabetes sub-groups. 
Drug costs 
Mean drug cost savings of approximately $2900 and $5600 were accrued in surgery patients 
with impaired glucose and diabetes, respectively, over 15 years, whilst no between-group 
difference was observed in the normo-glycemic patients. Cost savings were driven by 
differences in diabetes drug costs. For glucose-impaired patients, the cost of diabetes drugs 
was $0-$39 during years 1-15 for surgery patients, similar to the $0-$16 range observed in 
normo-glycemic surgery patients. This is consistent with our observed diabetes prevention 
results; progression to diabetes was prevented in most glucose-impaired surgery patients 
(87% prevention over up to 15 years)12.  
Strengths and limitations 
To date, the Swedish Obese Subjects study is the largest and longest prospective, controlled 
study of bariatric surgery. Both the surgical and control group were recruited 
contemporaneously, carefully matched and followed for up to 27 years to date (15 years 
reported herein). To our knowledge, this is the first prospectively controlled study to assess 
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long-term health care use in bariatric surgery patients according to their glucose status prior 
to intervention.  
However, our study was limited because the ethical review boards did not permit 
randomization. We aimed to reduce any residual confounding by multivariable adjustments. 
Our analysis adopted intention to treat methods. However, approximately one in ten control 
patients subsequently received bariatric surgery during the first 15 years of follow-up which 
will have increased hospital days due to index bariatric surgery (and any revisional surgery 
required) and decreased healthcare use due to diabetes for this sub-group. 
The analysis of health care register data maintained by the Swedish government enabled a 
very high degree of follow-up. This is notable because a recent review reported that very few 
bariatric surgery studies report long-term results with sufficient patient follow-up to minimize 
biased results32. Register linkage also overcame limitations associated with questionnaire-
based data collection such as nonresponse and recall bias. Universal health care access in 
Sweden ensured that use was not distorted by insurance status, and therefore health care is 
likely a reasonable reflection of overall morbidity.  
The health care use data were also subject to limitations. Whilst we had register-based 
hospitalization information for all but 3 patients for greater than 10 years, we did not have 
similar information for non-primary outpatient visits and dispensed drugs because no 
nationwide registries for these services existed when recruitment started in 1987. Therefore, 
fewer patients were available for these register outcomes during the earlier follow-up years 
(and no data was available for follow-up year one for non-primary outpatient care). We 
utilised multiple imputation to handle missing data. For drugs costs, we also supplemented 
register data with self-reported data collected by our study. Furthermore, the most recently 
recruited patients did not accumulate a full 15 years, which may have led to underestimation 
of the total number of inpatient care days and non-primary care visits. However, comparisons 
should not be affected.  
Conclusion 
This study presents for the first time, health care use over 15 years by obese patients treated 
conventionally or with bariatric surgery stratified by baseline glucose categories. Relative to 
controls, normo-glycemic surgery patients used more hospital days; glucose-impaired surgery 
patients used more hospital days, but incurred lower drug costs; and surgery patients with 
type 2 diabetes incurred lower drug costs. This study adds further evidence to support the 
prioritization of obese patients with pre-diabetes and diabetes to receive bariatric surgery.  
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Tables and Figures 
Table 1: Patient Characteristics at Baseline (mean (standard deviation)) 
  Normo-glycemic Impaired Fasting Glucose Diabetes 
  Surgery 
(n=1355) 
Controls 
(n=1481) 
P Surgery 
(n=301) 
Controls 
(n=290) 
P Surgery 
(n=343) 
Controls 
(n=260) 
P 
Women, n (%) 
998 
(74%) 
1083 (73%) .75 213 (71%) 
203 
(70%) 
.84 202 (59%) 156 (60%) .78 
Age, years 47 (6) 48 (6) <.001 48 (6) 50 (6) <.001 49 (6) 50 (6) .001 
          
Height, cm          
Women 165 (6) 165 (6) .85 164 (6) 165 (6) .75 164 (6) 166 (6) .10 
Men 179 (6) 180 (7) .01 179 (7) 179 (7) .66 180 (7) 178 (7) .03 
          
Weight, kg          
Women 116 (13) 110 (14) <.001 119 (15) 114 (16) .001 115 (14) 112 (14) .09 
Men 132 (16) 125 (16) <.001 132 (18) 126 (15) .03 135 (18) 123 (18) <.001 
           
Body Mass Index, 
kg/m
2
 
         
Women 42.7 (4.2) 40.5 (4.5) <.001 44.0 (4.5) 41.9 (4.8) <.001 42.4 (4.4) 40.9 (4.5) .002 
Men 41.2 (4.7) 38.4 (4.7) <.001 40.9 (4.8) 39.5 (4.9) .054 41.8 (5.0) 38.7 (4.6) <.001 
          
Waist Circumference, 
cm 
         
Women 123 (10) 118 (11) <.001 126 (10) 121 (11) <.001 126 (11) 122 (9) <.001 
Men 130 (10) 123 (11) <.001 130 (11) 126 (10) .04 133 (12) 125 (10) <.001 
  
         
Smoking, n (%) 
360 
(27%) 
301 (20%) <.001 70 (23%) 66 (23%) .90 85 (25%) 53 (20%) .24 
University Education, 
n (%) 
177 
(13%) 
330 (22%) <.001 40 (13%) 55 (19%) .06 39 (11%) 45 (17%) .04 
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Table 2: Total Hospital Days, Non-primary Care Outpatient Visits, and Drug Costs over 15 
years 
 
N 
(observed 
data) 
N missing  
15 years follow 
up* 
Mean  
(95% CI) 
Adjusted mean 
difference 
(95% CI) 
P 
value 
Hospital days (years 
1-15) 
  
Hospital days 
Normo-glycemic      
Surgery 1355 306 (23%) 30.3 (27.9-32.7) 
12.9 (9.9-15.9) <0.001 
Controls 1481 466 (31%) 16.9 (15.1-18.6) 
Impaired Fasting 
Glucose 
     
Surgery 301 78 (26%) 32.5 (27.4-37.5) 
12.5 (5.6-19.4) <0.001 
Controls 290 93 (32%) 21.8 (17.3-26.2) 
Diabetes      
Surgery 343 107 (31%) 38.7 (33.6-43.7) 
3.4 (-6.4; 13.3) 0.49 
Controls 260 110 (42%) 36.7 (28.0-45.4) 
Non-primary  
outpatient care visits 
(years 2-15) 
  Visits 
Normo-glycemic      
Surgery 1049 306 (23%) 21.6 (19.9, 23.2) -0.4 (-2.4, 1.7) 
  
0.71 
  Controls 1015 466 (31%) 21.2 (20.1, 22.3) 
Impaired Fasting 
Glucose 
  
        
Surgery 223 78 (26%) 20.5 (18.4, 22.6) 1.3 (-1.9, 4.5) 
  
0.43 
  Controls 197 93 (32%) 21.2 (19.1, 23.3) 
Diabetes           
Surgery 236 107 (31%) 28.7 (24.6, 32.8) -0.9 (-8.8, 7.1) 
  
0.83 
Controls 150 110 (42%) 27.4 (21.4, 33.3) 
Drug costs (USD)   $US 2012 
Normo-glycemic      
Surgery 1355 306 (23%) 10264 -40 (-2190, 
1310) 
0.62 
Controls 1481 466 (31%) 10635 
Impaired Fasting 
Glucose 
     
Surgery 301 78 (26%) 10048 -2911 (-5605, -
218) 
0.034 
Controls 290 93 (32%) 12845 
Diabetes      
Surgery 343 107 (32%) 14245 -5597 (-8631, -
2563) 
<0.001 
Controls 260 110 (42%) 19488 
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Notes: Results are based on imputed data. *Subjects missing 15 year follow up included those 
with no register data or who had not accumulated 15 years of follow-up due to date of 
recruitment into study, death or emigration 
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Figure 1: Mean Annual Hospital days from Years 1-15 (data capture 1987-2012)  
 
aAdjusted for baseline age, sex, smoking, body mass index and inclusion period (фͬш 1995) and hospital days in the year prior to the index date. Error bars indicate 95%CIs. 
Results are based on observed data. 
C Keating thesis page 136
Figure 2: Mean Annual Non-primary  Outpatient Care Visits From Years 2 to 15 (data capture 2001-2012) 
 
aAdjusted for baseline age, sex, smoking, body mass index and inclusion period (фͬш 1995). Error bars indicate 95%CIs. Results are based on observed data. 
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Figure 3: Mean Annual Prescription Drug Costs From Year 0 to 15 (Years 0-6: questionnaire data 1987-2012, years 7-15 Registry Data 2005-
2012) 
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aAdjusted for baseline age, sex, smoking, body mass index and inclusion period (фͬш 1995).  
* Self-reported drug data collected by Swedish Obese Subjects Study for follow-up years 0-6 (left) and Swedish Prescribed Drug Register data for follow-up years 7-15 (2005-
2012) (right). Data was not collected in year 5 and therefore no data are presented. Results are based on observed data. 
Error bars indicate 95%CIs. Values for high 95% CI errors bars which are excluded: adjusted difference in normo-glycemic group: year 11 (1620), year 12 (1339).   
Year 0 is the year prior to the index year.
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Figure 4: Mean Annual Prescription Diabetes Drug Costs From Year 0 to 15 (Years 0-6: questionnaire data 1987-2012, years 7-15 Registry Data 
2005-2012) 
aAdjusted for baseline age, sex, smoking, body mass index and inclusion period (</> 1995).  
* Self-reported drug data collected by Swedish Obese Subjects Study for follow-up years 0-6 (left) and Swedish Prescribed Drug Register data for follow-up years 7-15 (2005-
2012) (right). Data was not collected in year 5 and therefore no data is presented. Results are based on observed data. 
C Keating thesis page 140
Error bars indicated 95%CIs.  
Drugs presented are those included in category “A10 – Drugs used in Diabetes” from the Anatomical Therapeutic Chemical Classification System.  
Year 0 is the year prior to the index year.
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Supplementary Online Content 
Supplementary methods 
SOS study design and recruitment 
After recruitment campaigns in mass media and at primary health care centers, a matching 
examination was completed by 6905 patients. Among 5335 eligible individuals, 2010 choosing 
surgery formed the surgery group. A contemporaneously matched control group of 2037 
individuals was created using 18 matching variables. The matching variables were sex, age, 
weight, height, waist and hip circumferences, systolic blood pressure, serum cholesterol and 
triglyceride levels, smoking status, diabetes, menopausal status and four psychosocial 
variables with documented associations with the risk of death [social support, life events, 
health perception, psychosocial functioning], and two personality traits related to treatment 
preferences [monotony avoidance, psychastenia] (Karlsson J, Sjöström L & Sullivan M. J Clin 
Epidemiol, vol 48:817-823, 1995). According to the method of sequential treatment 
assignment, a matching algorithm selected controls so that the current mean values of the 
matching variables in the control group became as similar as possible to the current mean 
values in the surgery group (Pocock SJ, Simon R. Sequential treatment assignment with 
balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31:103-15.) 
The two study groups had identical inclusion and exclusion criteria, and all controls were 
eligible for surgery. The inclusion criteria were aged 37 to 60 years and BMI of 34 or more for 
men and 38 or more for women before or at the matching examination. The exclusion criteria 
were earlier surgery for gastric or duodenal ulcer, earlier bariatric surgery, gastric ulcer during 
the past 6 months, ongoing malignancy, active malignancy during the past 5 years, myocardial 
infarction during the past 6 months, bulimic eating pattern, drug or alcohol abuse, psychiatric 
or cooperative problems contraindicating bariatric surgery, other contraindicating conditions 
(such as chronic glucocorticoid or anti-inflammatory treatment).  
The choice of surgery type was made by the operating surgeon, and 265 participants (13%) 
underwent gastric bypass; 376 (19%) gastric banding; and 1369 (68%) vertical-banded 
gastroplasty. Eighty-nine percent of the patients underwent open surgery. Control patients 
received the customary nonsurgical obesity treatment at their registration center. No attempt 
was made to standardize their treatment, which ranged from sophisticated lifestyle 
intervention and behavior modification to no treatment. 
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Imputation methods 
Multiple imputation using chained equations was utilized to handle missing data in the using 
ice command in Stata version 11.Fifty imputed datasets were created using the following 
model: age, sex, allocation, diabetes status, interaction term allocation*diabetes status, BMI, 
smoking status, self-reported drug costs from all assessments, annual drug costs from the 
Prescribed Drug Register for each year. Imputations resulting in negative costs were set to 0. 
The imputed and observed results were similar. 
Supplementary results 
Hospital day time trends. Mean annual hospital days were higher in the surgery group during 
the index year (year 1) for all glucose groups. During years 2-15, in normo-glycemic patients, 
the surgery group accumulated more hospital days in four separate years, and the glucose-
impaired surgery patients accumulated more hospital days in three separate years. In 
contrast, in patients with diabetes, no between-group differences in hospital days were 
detected between years 2-15 (Figure 1). 
Drug cost time trends. In normo-glycemic patients, total annual drug costs did not differ 
between treatment groups in any of the years investigated, except year 1. One patient taking 
very expensive drugs (Trepostinil, Bosentan, Tadalafil) in years 10, 11 and 12 accounted for 
the higher point estimates in the surgery group. In glucose-impaired and diabetes patients, 
annual drug costs were lower in the surgery group in 7 and 8 (out of 14) separate years, 
respectively (Figure 3).  
Diabetes drug costs 
Diabetes drug costs are presented in Figure 4. For glucose-impaired patients, the cost of 
diabetes drugs was $0-39 during years 1-15 for surgery patients, similar to the $0-16 range 
observed in normo-glycemic surgery patients. This is consistent with our observed diabetes 
prevention clinical endpoints; progression to diabetes was prevented in most glucose-
impaired surgery patients (number needed to treat 1.3, 87% prevention over up to 15 
years)12. In contrast, the cost of drugs to treat diabetes in glucose-impaired patients in the 
control group increased over time. Within the diabetes sub-group, diabetes drug cost savings 
increased over time to a maximum of $640 in year 11 and then persisted until year 15, despite 
steady increases in costs in both treatment groups. This is consistent with our observed higher 
diabetes remission rates in surgery patients during the early years, followed by frequent 
relapse11 (Figure 4).  
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Hospital days sensitivity analysis 
A sensitivity analysis was undertaken for hospital days, where the observed length of stay 
associated to the index bariatric surgery (mean 7.1 days), was replaced with the length of stay 
observed in Sweden in 2012 (mean 1.9 days)31 to explore the impact of observed changes in 
lengths of stay. In the scenario analysis, the magnitude of differences decreased, but overall 
results did not change (eTable 1). However, the sensitivity analysis only adjusted the length 
of stay related to the index bariatric surgery and not any revisional surgeries). Therefore 
hospital days in the surgery groups in the sensitivity analysis are still likely to be higher than 
in contemporary settings. 
eTable 1: Total Hospital Days over 15 years – sensitivity analysis to reflect contemporary 
settings 
 N 
N missing  
15 years 
follow up 
Mean hospital 
days 
(95% CI) 
Adjusted mean 
difference 
(95% CI) 
P 
value 
Normo-glycemic      
Surgery 1355 306 (23%) 25.3 (23.0-27.7) 8.0 (5.0-11.0) <0.001 
Controls 1481 466 (31%) 16.9 (15.1-18.6) 
Impaired Fasting 
Glucose 
     
Surgery 301 78 (26%) 27.0 (22.1-31.9) 7.0 (0.2-13.9) 0.04 
Controls 290 93 (32%) 21.8 (17.3-26.2) 
Diabetes      
Surgery 343 107 (31%) 33.4 (28.4-38.4) -2.0 (-11.7; 7.8) 0.69 
Controls 260 110 (42%) 36.7 (28.0-45.4) 
 
Primary Care 
We ascertained primary care data for Västra Götaland (Gothenburg area, the second most 
populous local area, with a population of 1.63 million inhabitants, representing 17% of the 
Swedish population) and linked data with SOS participants who were living in Västra Götaland 
at the time of entry into the study (n=511 surgery, n=540 control, eTable 3). For normo-
glycemic patients, there was no difference in primary care between treatment groups during 
years 2-15, whilst surgery patients in the glucose-impaired and diabetes groups used less care 
in 6 and 4 separate follow-up years respectively (eFigure).  
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eTable 3: Samples sizes for primary care data, Västra Götaland, 2000-2102* 
 Surgery Control 
Year 
Normo-
glycemic 
Impaired 
glucose 
tolerance Diabetes 
Normo-
glycemic 
Impaired 
glucose 
tolerance Diabetes 
1 31 4 15 20 6 4 
2 52 4 19 45 10 7 
3 59 9 22 74 16 11 
4 72 15 29 90 19 16 
5 85 19 32 118 24 20 
6 112 22 41 175 29 26 
7 152 30 46 224 33 34 
8 198 38 57 272 38 43 
9 236 45 66 305 47 45 
10 271 49 71 319 48 49 
11 279 54 76 340 50 53 
12 287 58 78 361 61 56 
13 258 61 69 344 59 54 
14 244 60 64 317 55 45 
15 237 56 59 287 47 41 
*Data capture 1 January 2000 to 31 October 2012 
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eFigure: Mean Annual Primary Outpatient Care Visits From Years 1 to 15 (data capture 2000-2012*) 
 
Upper panels: mean visits, Lower panels: Adjusted differences (same variables as primary analysis). *Data capture 1 January 2000 to 31 October 
2012.
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Cost estimates  
We have reported healthcare use in metrics maintained by Swedish authorities. Using 
estimated standard costs per hospital day (SEK 16,027/$2289) and per non-primary  
outpatient care visit (SEK 2926/$418) in 2012, we estimated global healthcare costs 
(comprising inpatient care, non-primary outpatient care, prescription drugs). For the 
“contemporary” sensitivity analysis where the length of stay associated to bariatric surgery 
reflected practice in Sweden in 2012 (which is more relevant to decision making today), the 
estimated total healthcare cost (undiscounted) over 15 years is an excess of $18106 per 
normoglycemic patient, excess $13657 per glucose-impaired patient and a saving of $4955 
per patient with diabetes. Importantly, the sensitivity analysis only adjusted the length of stay 
related to the index bariatric surgery and not any revisional surgeries. Therefore hospital days 
in the surgery groups are likely to be higher than in contemporary settings. These costs results 
confirm that bariatric surgery is likely to be associated with health care cost saving in patients 
with type 2 diabetes.  
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Publication 10 (Letter) 
Keating C, Peeters A, Neovius M. Beyond BMI: the need for new guidelines 
governing the use of bariatric and metabolic surgery (correspondence). The 
Lancet Diabetes & Endocrinology. 2014;2(6):448-9. 
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Bariatric surgery
We read with great interest the 
fourth paper1 in the Series about 
bariatric surgery (February, 2014). In 
this valuable paper, David Cummings 
and Ricardo Cohen correctly 
underlined the limitations and the 
outdated nature of the 1991 National 
Institutes of Health Consensus 
Statement that still governs the 
use of bariatric surgery worldwide, 
limiting its use to very obese people 
(BMI >40 kg/m² or BMI 35–40 kg/m² 
with obesity-related comorbidities). 
We agree with the authors that there 
is now suﬃ  cient evidence to update 
this statement. Class 1 obesity 
(BMI 30–35 kg/m²) conveys an 
increased risk of comorbidities, 
impairs physical and mental-
health-related quality of life, and 
is associated with an increased 
psychosocial burden, particularly in 
women. The need for eﬀ ective and 
safe therapies for class 1 obesity is 
therefore great and has not yet been 
met by non-surgical approaches.
The International Federation for 
the Surgery of Obesity and Metabolic 
Disorders  (IFSO)  recognises its 
responsibility to develop evidence-
based position statements to guide 
its members, and health service 
providers generally, regarding new 
and emerging topics related to 
bariatric surgery. Extension of the 
indications for bariatric surgery 
beyond traditional boundaries 
defined by age, BMI, extent of 
comorbidities, and operative risk 
is such a topic. In the past year, a 
multidisciplinary IFSO expert working 
group led by IFSO president elect 
2013–14, Luigi Angrisani, developed a 
position statement entitled “Bariatric 
Surgery in Class I Obesity”.2 The 
scope of the group was to critically 
review the current knowledge about 
the epidemiology, health risks, and 
current therapies for class 1 obesity, 
review the evidence for bariatric 
surgery in people with class 1 
obesity, examine the broader issues 
involved in extension of bariatric 
surgery to people with class 1 obesity 
from the perspective of health-
care prioritisation and delivery, and 
develop practical recommendations 
for clinicians.
Obese patients with the same BMI 
can have very diﬀ erent levels of health, 
risk, and quality of life. Individual 
patients with class 1 obesity can have 
a comorbidity burden similar to, or 
even greater than, that of patients 
with more severe obesity. Therefore, 
the IFSO working group concluded 
that the denial of bariatric surgery 
to a patient with class 1 obesity 
suﬀ ering from a clinically signiﬁ cant 
obesity-related health burden and not 
achieving weight control with non-
surgical therapy, simply on the basis of 
BMI, does not seem clinically justiﬁ ed. 
A clinical decision should be based on 
a more comprehensive assessment 
of the patient’s current overall health 
and on a more reliable prediction of 
morbidity and mortality than that 
provided by BMI alone.
After a careful review of available 
data about safety and efficacy of 
bariatric surgery in patients with class 1 
obesity, the panel reached a consensus 
on ten clinical recommendations. The 
IFSO position statement has been 
discussed and approved by the IFSO 
Executive Board and published in 
Obesity Surgery, the oﬃ  cial journal of 
the federation, in April, 2014.2
We hope that this effort will 
fuel the ongoing discussion about 
the extension of bariatric surgery 
beyond current BMI cutoff points, 
and stimulate the adoption of more 
advanced and updated clinical 
recommendations.
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David Cummings and Ricardo Cohen1 
eloquently justify the need for 
revisions to eligibility guidelines for 
bariatric surgery. They describe that 
the 1991 National Institutes of Health 
consensus statement, which largely 
governs the use of bariatric surgery 
worldwide, is grossly outdated. The 
statement defines eligible patients 
as those with a BMI of 40 kg/m² 
or greater, or a BMI of 35 kg/m² or 
greater combined with a serious 
obesity-related morbidity. The authors 
advocate that clinical evidence 
strongly suggests that a measure of 
glucose impairment, rather than BMI, 
should be used to prioritise patients 
who can achieve the greatest health 
beneﬁ ts from treatment. 
We would like to highlight an 
additional reason to prioritise patients 
with impaired glucose (including 
diabetes), which is to increase the 
return on investment from limited 
health-care budgets. Currently 
available modelled analyses show 
that compared with conventional 
medical therapy, bariatric surgery 
for patients with recently diagnosed 
type 2 diabetes and a BMI of 
30–40 kg/m² at best leads to cost 
savings to the health-care system (a 
rare cost-effectiveness result),2 and 
at worst is highly cost eﬀ ective with a 
cost-eﬀ ectiveness ratio substantially 
more favorable than comparable 
ﬁ gures for the total population with 
a BMI of more than 40 kg/m² (the 
cost to gain 1 quality-adjusted life-
year was predicted to be three times 
lower for the diabetes group).3 This 
diﬀ erential cost-eﬀ ectiveness would 
likely be even greater if the obese 
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The Series on bariatric surgery 
(February, 2014) brings the current 
management of morbid obesity into 
sharp focus. Alfons Pomp1 elegantly 
highlights the dangers associated with 
obesity and attempts to deﬁ ne some 
of the challenges of its treatment. He 
stresses that bariatric surgery is safe 
and eﬀ ective in the management of 
obesity and its comorbid conditions. 
John Dixon and Jane Blazeby2 
eloquently explain the benefits for 
patient-perceived quality of life after 
surgery-induced weight loss. It has 
therefore been rightly questioned why 
bariatric surgery remains a last resort 
for the treatment of obesity.
We wish to highlight another issue 
that has gone largely unnoticed—
the huge gender disparity in the use 
of bariatric surgery. Despite similar 
rates of obesity in men and women 
at 24% and 26%, respectively, of 
8794 bariatric surgical procedures 
performed in England in 2011–12 
only 2081 (24%) were in men.3 This 
statistic is echoed globally. Although 
health-care use is universally higher 
by women than by men,4 little is 
known of the reasons underlying 
the gender inequality in the uptake 
of bariatric surgery. A perception of 
poorer outcomes of bariatric surgery 
in men among patients and the 
wider medical community might be 
one barrier to treatment. However, 
this view is clearly erroneous. Men 
generally present later in life, with 
more advanced obesity, and with 
more complex comorbidities,5 which 
might adversely aﬀ ect outcomes. In 
our experience, however, there were 
no significant differences in weight 
loss and metabolic outcomes between 
men and women matched for six key 
baseline characteristics including 
age, BMI, type of bariatric procedure, 
presence of type 2 diabetes, insulin 
treatment, and treatment with 
continuous positive airway press ure 
for obstructive sleep apnoea 
(unpublished data).
We call for further studies and urgent 
action to raise awareness and increase 
population with type 2 diabetes was 
compared with the obese population 
with normal glucose tolerance (rather 
than the total population); however, 
no such studies have been published 
up to now.
Observed long-term data for the 
eﬀ ects of bariatric surgery relative to 
conventional therapy on health-care 
use and costs are needed to conﬁ rm 
modelled results. So far, data from 
the Swedish Obese Subjects study 
show that in a 20-year period, health-
care use was similar or greater in the 
surgically treated group than in the 
conventionally treated group when 
all patients were analysed, including 
mostly patients without diabetes.4 
This comparison is likely to mask 
important diﬀ erences that may exist 
for patients with impaired glucose or 
diabetes,5 which is an area requiring 
additional research.
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acceptance of a potentially life-
changing intervention in this clinically 
disadvantaged group of patients.
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Subconjunctival 
bevacizumab for iris 
neovascularisation
Antivascular endothelial growth factor 
injections have been increasingly 
used in the treatment of rubeosis and 
neovascular glaucoma, and several 
studies have reported regression of iris 
neovascularisation with intravitreal 
and intracameral bevacizumab.1–2 
The subconjuntival approach is 
less commonly reported and has 
more often been associated with 
treating disorders such as corneal 
neovascularisation.3 
Rao and colleagues4 described the 
use of subconjunctival bevacizumab 
in a patient with ocular ischaemic 
syndrome and diabetic retinopathy. 
Bevacizumab is a 149 kDa full-length 
immunoglobulin G1 antibody, which 
is three times the molecular weight of 
ranibizumab (48 kDa). When injected 
subconjunctivally, bevacizumab  has a 
direct transcleral route intraocularly or 
via conjunctival and lymphatic ﬂ ow. 
Findings of animal studies have shown 
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Letters
RESEARCH LETTER
Differences in the Rates of Treatment
of SevereObesity Using Bariatric Surgery
Across Socioeconomic Groups
A socioeconomic gradient in obesity, with greater prevalence
observed inmoredisadvantagedgroups, has been reported in
most high-income countries.1 Severe obesity is a substantial
and growing problem, affecting 1 in 7 Americans,2 and is as-
sociatedwith far greater adverseconsequences relative tomild
obesity (with a body mass index [BMI] of 30.0-34.9 [calcu-
lated as weight in kilograms divided by height in meters
squared]). Lesser access to treatment for the severely obese in
socioeconomicallydisadvantagedpopulationswould risk fur-
ther widening inequalities. Bariatric surgery is currently the
only evidence-based option available that induces signifi-
cant andsustainedweight loss in severelyobesepatients.3 The
present study aims to quantify the rates of treatment of se-
vere obesity using bariatric surgery, according to the socio-
economic positions of severely obese Australian adults.
Methods |Customizeddata relating to all bariatric surgery epi-
sodes undertaken in Australian adults between July 2011 and
June 2012 (n = 14 056) were obtained from the National Hos-
pital Morbidity database and provided by the Australian In-
stituteofHealth andWelfare.4Bariatric surgery episodeswere
selected based on 3 Australian Refined Diagnosis Related
Groups codes (K04A-S, K04B-S, andK07Z-S). For privacy rea-
sons, de-identified, aggregate data were provided to the re-
search team by Medicare. This project was approved by the
DeakinUniversityHumanResearch and IntegrityBoard (proj-
ect 2010-116). Customized data relating to the annual esti-
matednumber of adultswith severe obesity inAustraliawere
provided by the Australian Bureau of Statistics based on re-
sults from the nationally representative 2011-2012 Australian
Health Survey.5 Weight status classifications were based on
measured height and weight. All data were stratified by In-
dexofRelativeSocio-economicDisadvantagequintiles,anarea-
levelmeasureof socioeconomicposition (a lowerquintile rep-
resents greater disadvantage).5
Bariatric surgery rateswere calculatedas theobservedan-
nual number of bariatric surgery episodes divided by the es-
timated annual number of adultswith severe obesity for each
socioeconomic stratum in Australia (2011-2012). Severe obe-
sity was defined as either class II (BMI = 35.0-39.9) or class III
obesity (BMI ≥ 40.0) and represented the population poten-
tially eligible to receive bariatric surgery. Equitable treatment
across socioeconomic stratawouldbe representedby roughly
equal treatment rates.
The statistical significance of these comparisons was as-
sessed using a z score and an associated P value. The z score
was calculated as the difference between the annual treat-
ment rate estimates divided by the standard error of this dif-
ference,with this standard error calculated as the square root
of the sum of the squares of the individual annual treatment
rate standard errors (Figure). Associated P values were de-
rivedusing the standardnormalprobabilitydistribution:quin-
tile5vsquintile4 (P = .25),quintile5vsquintile3 (P = .17),quin-
tile 5 vs quintile 2 (P < .001), and quintile 5 vs quintile 1
(P < .001).
Figure. Annual Bariatric Surgery Rate by Socioeconomic Position in Australian Adults, 2011-2012
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Socioeconomic Position, Index of Relative Socio-economic Disadvantage Quintiles
Observed No. of bariatric surgery 
episodes in Australia
Estimated No. of people with severe 
obesity (class II or class III obesity) 
in Australia
2712
343 000
2766 3267 2927 2361
340 000 288 000 215 000 187 000
Calculated as the observed number
of bariatric surgery episodes or the
number of Australian adults with
severe obesity. Severe obesity was
defined as either class II obesity (with
a bodymass index [BMI] of 35.0-39.9
[calculated as weight in kilograms
divided by height in meters squared])
or class III obesity (BMI = 40.0). The
95% CIs (error bars) reflect the
variability in the survey estimates of
population size. A lower
socioeconomic position quintile
reflects greater disadvantage. Data
on the observed number of bariatric
surgery episodes in Australia were
obtained from the National Hospital
Morbidity database,4 and data on the
estimated number of people with
severe obesity were obtained from
the Australian Bureau of Statistics
National Health Survey,5 2011-2012.
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Results | The lowest annual treatment rates were observed in
the most disadvantaged quintiles (quintiles 1/2: 7.9/8.1 epi-
sodes per 1000 severely obese adults), whereas the highest
treatment rateswereobserved in the leastdisadvantagedquin-
tiles (quintiles 4/5: 13.6/12.6 episodes per 1000 severely obese
adults) (Figure).During2011-2012, severelyobesepeople in the
2most disadvantaged quintileswere approximately 40% less
likely to receivebariatric surgery relative to counterparts in the
2 least disadvantaged quintiles.
Discussion | The present study found socioeconomic differ-
ences in the treatment of severe obesity using bariatric sur-
geryamongAustralianadults. These findingsare supportedby
apreviousstudyintheUnitedStates.6 It is likely that thesetreat-
ment inequalities will further increase the already large num-
ber of socioeconomic inequalities in the prevalence and con-
sequencesof severeobesity.A limitationof thepresentanalysis
is that theseverelyobesepopulationpotentiallyeligible for sur-
gery will include a small number of people with class II obe-
sity and no associatedmorbidity who are currently ineligible.
This analysis relates to Australia, where bariatric surgery
isprimarily available through theprivatehospital system(89%
of episodes in 2011-2012)4; eligible patientsmust have private
health insurance and pay an out-of-pocket fee. In the public
hospital setting (11% of 2011-2012 episodes), no fees are in-
curredbypatients; however, longwait times are common.Af-
fordability is likely to be a key contributor to the observed so-
cioeconomic inequalities. Other factors, such as geographical
access to services and health literacy, may also play a role.
Access tobariatric surgery fordisadvantagedgroupsshould
be improved so that all members in society can benefit from
this treatment. In Australia, this will most likely be achieved
by increasing the fundingallocated tobariatric surgery inpub-
lichospitals.Futureresearchshouldexaminethecostsandben-
efits of bariatric surgery according to socioeconomic strata.
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Population-Based Estimates of the Prevalence
of Uterine SarcomaAmong PatientsWith
Leiomyomata Undergoing Surgical Treatment
Uterine leiomyomata are one of the most common gyneco-
logicproblemsamongwomen in theUnitedStates,withanan-
nual diagnosis range from 2.0 to 12.8 per 1000 reproductive-
age women.1 Intervention is a standard management for
symptomatic patients, and various procedures include open
and laparoscopic hysterectomy, myolysis, uterine artery em-
bolization, and magnetic resonance–guided focused ultraso-
nographic surgery.
The practice of electricmorcellation has been used by gy-
necologic surgeons during laparoscopic and robotic-assisted
hysterectomies andmyomectomies as a less invasive alterna-
tive to open surgery.2 In April 2014, theUS Food andDrugAd-
ministration (FDA) stated that theydiscouraged theuseof this
technique over concern thatmorcellationmay spread unsus-
pected sarcoma tissue.3,4 Based on the literature, the FDA re-
ported that 1 in 352 women have unsuspected uterine sar-
coma while undergoing surgery for presumed benign
leiomyoma.5A recent study6usinganall-payerdatabase found
that 1 in 368 women who underwent morcellation had uter-
ine cancer. However, the estimates in this study6 were lim-
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 5 Discussion 
5.1 Introduction 
This chapter summarises the key results from this PhD, their implications for policy and practice and 
key strengths and weaknesses. It also briefly reviews significant publications since the literature 
review was undertaken and highlights priorities for future research. Each of these themes is detailed 
in the individual manuscripts (provided in Chapter 4), therefore the focus of this chapter is on 
conclusions that can be drawn from the collective results for each original research question / 
research stream.   
5.2 Significant publications since literature review 
The literature review for this thesis was undertaken early during the PhD (2012), to synthesise 
existing research and highlight gaps leading to the relevant PhD publications. Since this time there 
have been some notable publications relating to my theses topic which are summarised in Table 10. 
Table 10: Notable publications since PhD thesis literature review 
Theme area Comparison to my studies 
Healthcare utilization and costs after bariatric 
surgery for all eligible patients 
 
Several new studies compare costs before and after 
after bariatric surgery vs conventional therapy and 
report mixed results.  
Over six years, Weiner et al assessed the impact of 
bariatric surgery on health care costs of obese 
persons and matched controls based on claims data 
and found no evidence to support short-term cost-
savings in the surgery group(133). 
Maciejewski et al compared health expenditures 
among high-risk patients after gastric bypass and 
matched controls in a cohort of predominantly older 
men based on claims data and found that bariatric 
surgery does not appear to be associated with 
reduced health care expenditures 3 years after the 
procedure(131). 
In contrast, Finkelstein analysed claims data for a 
surgery group and matched control group and found 
healthcare cost savings were generated between 5-
10 years after surgery, depending on the bariatric 
surgery undertaken (132).  
My study on healthcare use in surgery relative to 
conventional therapy patients (without glucose 
stratification) over 20 years found that inpatient and 
nonprimary outpatient care were higher in the 
surgery, relative to the conventional therapy group in 
the short-term (years 1-6), but did not differ between 
treatment groups thereafter(147), whilst long-term 
savings in drug costs were observed in the surgery 
group (147). Therefore, my findings (short term 
higher costs in surgery group) are roughly consistent 
with the short-term (3-6 years) timeframes reported 
by Weiner et al and Maciejewski et al. Importantly, 
our study extend the evidence out to 20 years and 
demonstrates substantial differences in the year 7-20 
follow-up period. Our similar study, which provides 
similar result for groups with normal glucose, pre-
diabetes and diabetes at baseline also extends this 
evidence, by highlighting that results differ by glucose 
status, with patients with type 2 diabetes likely to 
achieve cost-savings. 
 
Healthcare utilisation and costs after bariatric 
surgery for patients with type 2 diabetes 
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 One study assessed health insurance claims for 
patients with diabetes before and after bariatric 
surgery. Relative to the year prior to surgery,  Bleich 
et al observed similar costs in the six years after 
surgery(134). 
Omission of a non-surgery comparison group means 
that differences relative to the alternative clinical 
pathway of conventional medical care, which is often 
associated with intensification of therapies over 
time(135), could not be quantified.  
My thesis study on ”Pre-Operative Glucose Status 
and Health Care Use During 15 Years Following 
Bariatric Surgery” differs from the most recent 
previous study in relation to comparison groups 
(normo-glycemic vs glucose-impaired vs diabetes), 
control group (prospectively recruited), and time 
horizon (up to 15 years) making direct comparisons 
difficult.  
Part 1. Burden of severe obesity. 
5.3 How has the prevalence of severe obesity changed in Australian adults over the past two 
decades and what are the characteristics of the current severely obese population?  
This research stream compared the prevalence of class-I, II and III obesity in Australian adults 
between 1995 and 2011-12(4). Nationally representative population samples were assessed and 
obesity classifications were based on measured height and weight. My research observed that over 
the past two decades, the prevalence of all obesity sub-classes has increased, with the greatest 
relative growth in the more severe obesity sub-classes (relative increases in class-I, II and III obesity 
were 1.3-, 1.7- and 2.2-fold respectively). 
In 2011-12, one in every four adults was obese and one in every ten adults was severely obese. 
Women were more likely to be severely obese, including twice as likely to be class-III obese. Severe 
obesity prevalence of up to 15.5% was observed in women aged 64-74 years and 10.1% in men aged 
55-64 years. I also found that class-I, II and III obesity prevalence increased with increasing levels of 
disadvantage based on both education and an area-level marker of socioeconomic position. The 
gradient was most pronounced in the more severely obese sub-classes, such that severe obesity 
affected 6 out of every 100 people in the least disadvantaged quintile of the population, and 13 out 
of every 100 people in the most disadvantaged quintile of the population. On a population-level, my 
research estimated that in 2011-12, 2.6 million Australian adults were class-I obese and 1.4 million 
adults were severely obese and potentially required treatment. 
To my knowledge, this is the first study to examine obesity trends by severity sub-class for a large 
nationally representative sample population in Australia. Historically, severe obesity affected a small 
proportion of the population in Australia (eg. 1-2% in 1980) and has received little attention. This 
PhD now demonstrates that severe obesity affects a substantial proportion of the adult population 
(10%). Similarly high prevalence (15%) has been reported for US adult populations in 2010(148). The 
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 current study on the prevalence of obesity, including severe obesity, can be combined with another 
study included in my PhD which quantifies the quality of life(6) and healthcare cost consequences(8) 
associated with severe obesity to estimate the economic consequences of severe obesity.  
The age distribution of severe obesity was found to be similar for males and females and generally 
the most substantial increases were observed in age groups 18-24 years and 35-44 years.  This 
suggests that targeting interventions in settings with young adults will be important for prevention. 
For women, there were two notable increases in the prevalence of severe obesity: between the age 
groups 25-34 and 35-44 years, as well as between age groups 45-54 and 55-64 years. These 
increases likely coincide with key life phases of child-bearing and the onset of menopause, 
highlighting these as key risk periods for weight gain in women, and hence ideal windows for 
targeted interventions. Importantly the data assessed was cross-sectional rather than cohort data, 
so conclusive statements cannot be made about critical periods of life. These results highlight the 
need to understand the drivers of the rapid increases in severe obesity better so that the key risk 
periods and sub-groups can be confirmed. 
Policy responses to the obesity epidemic will have a direct impact on socioeconomic disparities in 
obesity prevalence reported herein. A recent review reported that the effectiveness of obesity 
prevention programs  can differ by socioeconomic position, with some programs (those focussed on 
the delivery of education programs) realising benefits primarily for high socioeconomic position 
populations(149). It is foreseeable that if delivered in isolation, these types of interventions may 
exacerbate the already large socioeconomic differences in obesity. It is important that universal 
interventions continue to be implemented to reduce population-wide weight gain. However, the 
delivery of complementary interventions that are tailored for, and targeted towards high risk low 
socioeconomic position groups may also be needed to reduce socioeconomic inequalities in obesity 
and future inequalities in health.  
In the most recent decade, studies from the USA (2003-2012)(150) and the UK (1992-2010)(151) 
have reported a plateauing in the overall prevalence of obesity. However, it appears that the results 
for overall prevalence mask ongoing large increases at the extreme levels of obesity in both 
settings(148, 151). This result highlights that continued growth in the most severe end of the obesity 
spectrum in adults appears to be a consistent pattern across many countries, including Australia 
over the last decade, demonstrating the importance of stratifying by obesity severity sub-classes in 
epidemiological studies, as undertaken in my research.  Understanding the drivers for ongoing 
increases in severe obesity should be prioritized in future research to assist with the targeting of 
interventions to stem current trends. The key lessons from this research stream are summarised in a 
letter, in which I advocated the need to report obesity trends stratified by socioeconomic position 
and obesity severity category within future obesity surveillance studies(5). 
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 5.4 What is the utility-based quality of life associated with severe obesity? 
This research stream involved the analysis of utility-based (economic) quality of life (UQoL) for a 
large nationally representative adult population in Australia and a large adolescent population from 
an intervention trial. For the adult population, I analysed the Australian Diabetes, Obesity and 
Lifestyle (AusDiab) study sample and found that relative to healthy weight, reductions in UQoL, were 
1.2%, 2.0% and 6.9% for class-I, class-II and class-III obesity respectively (6). To my knowledge, this is 
the first study internationally to report UQoL according to each obesity severity class as defined by 
the World Health Organisation. For the adolescent population, I analysed data from the Obesity 
Prevention in Communities (OPIC) sample and found that relative to healthy weight, obesity was 
associated with a 5.9% reduction in utility and a 0.025 utility reduction with each BMI z-score 
standard deviation (7).  
As discussed in the literature review, one of the key strengths of UQoL measures is the ability to 
compare results across different disease areas. For the adult population, the UQoL differences for 
obesity sub-classes-I, II and III were similar in magnitude to those attributable to glaucoma (1.3%), 
asthma (2.1%) and depression (6.3%)(152). For adolescents, the magnitude of UQoL losses 
associated to overweight and obesity were similar to those reported for asthma (2.1%) and 
depression(152) (6.3%) respectively. Our adolescent study was not powered to examine UQoL losses 
by class of obesity. Another strength of UQoL measures is the ability to convert results to estimate 
subjects’ willingness to forgo life expectancy. For example, (assuming that the UQoL differences 
observed in the adult study were attributable to excess weight), the result indicates that class-III 
obese Australian adults are willing to forgo 6.9% of their remaining life to spend it in perfect health. 
This means that UQoL and survival can be combined to estimate quality-adjusted-life-years, the 
outcome measure recommended by many national regulatory authorities for adoption in CEA(49).  
Therefore, results presented in this PhD can be utilized to inform more sensitive cost-effectiveness 
analysis by incorporating UQoL data which are specific to the sub-classes of obesity. For example, at 
the time of my previous cost-effectiveness analysis of surgically induced weight loss for the 
management of type 2 diabetes (1), no UQoL data were published stratified by obesity severity sub-
classes. Therefore only the UQoL benefits associated to diabetes remission were captured, which 
meant that the reported quality-adjusted life years gained by the intervention group (for whom 
mean body mass index reduced from 36.9 to 29.5 during the two year trial) were likely to be 
significantly under-estimated.  
The adult and adolescent utility-based quality of life studies assessed were based on different source 
studies (The Australian Diabetes, Obesity and Lifestyle [AusDiab] study and Obesity Prevention in 
Communities [OPIC] Project respectively). The UQoL outcome measures were chosen prior to my 
involvement in these studies and therefore instrument selection was outside of my control. It is 
possible that the two instruments differ in relation to their sensitivity to detect health-related utility 
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 impacts of excess weight and therefore utility weight for adults and adolescents reported by my PhD 
thesis may not be directly comparable. 
5.5 What are the healthcare utilisation and cost burdens associated with severe obesity?  
In this stream, I expanded the burden of severe obesity research theme to focus on healthcare costs 
attributable to severe obesity. I analysed observed data sourced from Australia’s national health 
insurer (Medicare) for a nation-wide population of individuals prior to undergoing bariatric surgery, 
and compared healthcare use/costs to an age-sex matched general population sample. I found that 
annual mean healthcare costs incurred by the Australian government for people with severe obesity 
(prior to receiving bariatric surgery) are more than double the comparable costs for the general 
population (AUD $1735 vs $837)(8). The cost differences were largely driven by greater annual 
healthcare costs related to the treatment of diabetes, cardiovascular disease and depression in the 
severely obese subjects. Results from this study can be combined with prevalence data to estimate 
the economic burden of obesity.  
To my knowledge, the current study was the first internationally to quantify the cost of severe 
obesity based on observed data which stratifies results by therapeutic categories (previous studies 
reported global costs). The therapeutic categories with the greatest excess healthcare costs in the 
severely obese population observed by this study align with the diseases with the highest obesity-
related relative risks for morbidity(153). These included type 2 diabetes (diabetes drugs costs were 
8-fold higher), cardiovascular disease (lipid modifying drugs costs were 2.6-fold higher, agents acting 
on the renin-angiotensin drug costs were 2.8-fold higher), obstructive sleep apnoea (OSA) (OSA 
investigations costs were 11-fold higher) and depression (psychoanaleptic drugs costs were 2.2-fold 
higher). As these estimates were based on analysis of cross-sectional data, the relationship between 
severe obesity and excess healthcare costs cannot be confirmed as causal. However, a causal 
relationship between obesity and morbidity has been clearly demonstrated in the medical literature 
(153, 154). 
Previous studies report that costs in the severely obese are 65–113% higher relative to healthy-
weight samples(84-90). My PhD study analysed observed healthcare utilisation data and found costs 
were 107% higher (2.1-fold) in the severely obese relative to the general population.  Costs are 
unlikely to be directly comparable across studies due to different inclusion criteria (i.e. inclusion of 
one or more of pharmaceuticals, inpatient and outpatient costs), healthcare settings and analytical 
methods. Nevertheless, there is a consistent relationship reported across these studies for far 
greater healthcare costs in the severely obese relative to healthy weight or general population 
samples.  
A key limitation of this study was the analysis of severely obese patients prior to undertaking 
bariatric surgery, which may not be transferable to the general population of people with severe 
obesity. However, given no register exists for severe obesity and it is not sufficiently represented 
(underpowered) in national health surveys to undertake healthcare use research (in Australia), this 
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 was the best available population. The excess costs attributable to severe obesity would have been 
even higher if the comparator group had been a healthy weight sample. A priority for future 
research should be to analyse healthcare costs in the general (not treatment-seeking) severely 
obese population.  
Part 2. Efficiency and equity of treatment (bariatric surgery) 
Bariatric surgery is currently the only available intervention which induces large and sustained 
weight loss in severely obese patients(9) and therefore was adopted as the “treatment” modality in 
the following research streams.  
5.6 How does the healthcare utilisation and cost burden in the severely obese population change after 
treatment using bariatric surgery?  
In this research stream, I analysed healthcare utilisation after bariatric surgery in both a 
contemporary bariatric surgery population (short-term follow-up, but high transferability due to 
contemporary surgical procedures) and a historical cohort (long-term follow-up, but uncertain 
transferability due to partially outdated surgical procedures). Firstly, I analysed healthcare data for a 
nationwide Australian population of patients receiving bariatric surgery in both the two years after 
bariatric surgery (laparoscopic adjustable gastric banding, LAGB), and the year before surgery. An 
overall reduction in pharmaceutical use after surgery was observed(10), including an approximate 
halving in the use of drugs to treat type 2 diabetes. However, these savings were partially offset by 
greater utilisation of therapies related to post bariatric surgery management, such as 
anemia/vitamins and pain medications. With regards to medical services, I assessed revisional 
surgery rates in the same nation-wide population of LAGB patients and found that revisional surgery 
was required by one in five patients in the three years after surgery (11).  
Secondly, I collaborated with the Swedish Obese Subject Study (SOS Study) to examine the 
healthcare use in surgery relative to conventional therapy patients over 20 years. Hospital days, non-
primary care outpatient visits, and drug costs were investigated using nationwide Swedish registries. 
This study found that inpatient and non-primary outpatient care were higher in the surgical group, 
relative to the conventional therapy group in the short-term (years 1-6), but did not differ between 
treatment groups thereafter(147), whilst long-term savings in drug costs were observed in the 
surgery group14, 15.  
In the context of limited healthcare budgets, authorities around the world(49, 50, 52) consider both 
intervention effectiveness and “costs” when making healthcare priority-setting decisions. An 
important issue in undertaking cost-effectiveness analysis of new interventions is to ascertain the 
degree to which the costs of the intervention can be offset by reductions in the future use of 
healthcare resources. Previous CEAs consistently report that bariatric surgery is cost-effective 
relative to conventional therapy (diet and exercise with or without pharmacotherapy) for treating 
severe obesity(137, 138). However, reliance on patient-reported and/or modelled (rather than 
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 observed) healthcare costs introduces significant uncertainty. This research stream, reporting 
evidence on observed healthcare consumption after bariatric surgery, based on national registers 
from both Australia and Sweden, can be utilised to inform future cost-effectiveness analyses. 
A key strength of this stream was the retrieval and analysis of healthcare administrative data with its 
associated full participation rates and high reliability. To my knowledge, the short term Australian 
analyses are the first to report healthcare use after bariatric surgery for a nation-wide cohort, whilst 
the long-term analysis (SOS study) provides the longest follow-up to date on healthcare use trends 
after bariatric surgery. Since undertaking the literature review in this PhD, several notable studies 
have been published in this theme area. Over up to six years, similar to the SOS study results 
reported herein, two studies found no evidence to support short-term cost-savings in the surgery 
group (133) (131)(note the latter study assessed a predominantly older male population), whilst 
another reported cost savings in the surgery group(132). However, in the long term (years 7-20), my 
study did not observe any healthcare use difference in inpatient or non-primary outpatient care, and 
observed drug cost savings in the surgery group. This highlights the importance of capturing a longer 
term follow-up. 
Bariatric surgery is associated with dramatic weight loss and improvements in many clinical 
endpoints (155, 156). However, results from this stream also highlight some of the negative 
consequences, such as a short-term increase in selected pharmaceutical therapeutic categories, and 
most importantly, the need for reoperations. The benefits of surgery must be compared to the risk 
of adverse events, need for reoperations and associated costs for each patient.  
5.7 Could the technical efficiency8 of bariatric surgery be improved by prioritizing patients 
according to their glucose profile (normal, prediabetes, diabetes) at the time of surgery? 
In this stream, my research assessed health care use over 15 years by obese patients treated 
conventionally or with bariatric surgery in sub-groups of patients with normal glucose, impaired 
fasting glucose and type 2 diabetes prior to surgery. Participants of the SOS study were linked with 
Swedish health care register data, and hospital days, non-primary care outpatient visits, and 
prescription drug costs were assessed. Normo-glycemic and glucose-impaired patients accumulated 
more hospital days relative to controls, whilst no between-group difference was observed in 
patients with diabetes. There was no difference in mean total non-primary care outpatient visits 
between treatment groups. Finally, prescription drug costs did not differ between treatment groups 
in normo-glycemic patients, whilst lower mean drug costs were observed in surgery patients with 
impaired glucose and type 2 diabetes.  
The use of bariatric surgery globally is largely governed by a US National Institutes of Health 
ĐŽŶƐĞŶƐƵƐƐƚĂƚĞŵĞŶƚĚĞĨŝŶŝŶŐĞůŝŐŝďůĞƉĂƚŝĞŶƚƐĂƐƚŚŽƐĞǁŝƚŚĂD/шϰϬŽƌD/шϯϱĐŽŵďŝŶĞĚǁŝƚŚĂ
serious obesity-related morbidity (101). Previously reported clinical endpoints from the SOS study 
8 Maximising outputs (i.e. health benefits or cost savings) from a given input (allocation of surgical resources) 
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 including remission(106), prevention of type 2 diabetes(107) and the prevention of cardiovascular 
events(105) favour patients with impaired glucose or diabetes. Consequently, the SOS study 
investigators have recommended that a measure of glucose impairment (rather than BMI), be used 
to prioritize obese patients who can achieve the greatest health benefits from surgery. Other groups 
have called for similar revisions(13, 103, 104). My current PhD study reports for the first time, that 
long-term economic outcomes also favour the glucose-impaired and diabetes sub-groups (relative to 
the normo-glycemic group), adding further evidence to support the prioritization of these sub-
groups to receive bariatric surgery.  
This research responds to recent calls for additional research “examining long term healthcare and 
cost data”, and “which patient level factors predict success”(98, 157, 158).  The analysis of health 
care register data maintained by the Swedish government enabled a very high degree of follow-up. 
This is notable because a recent review reported that very few bariatric surgery studies report long-
term results with sufficient patient follow-up to minimize biased results(159). 
Previously published modelled studies report that bariatric surgery is a cost-effective intervention 
for treating severe obesity in the currently eligible population(160). Based on previous clinical 
studies (not part of my PhD)(114) (107), and the current health care use outcomes reported in my 
study favoring the glucose-impaired and diabetes groups, it is likely that economic evaluations 
published  for the “total” eligible population underestimate the economic benefits of bariatric 
surgery for glucose-impaired and diabetes sub-groups and overestimate the benefits for normo-
glycemic patients. A priority for future research is a formal cost-effectiveness analysis of bariatric 
surgery relative to conventional therapy for obese patients stratified by glucose sub-groups.  
This stream observed greater use of inpatient care in the surgery patients in the normo-glycemic and 
glucose-impaired groups, whilst no between-group difference in patients with diabetes was 
detected. Increased hospital use in the surgery group was primarily due to the index bariatric 
surgery, and to a lesser extent, revisional bariatric surgery, plastic surgery, gallstones and anemia as 
reported previously(147). Since patients in the study received bariatric surgery between 1987 and 
2001, surgical procedures have changed. The rate of laparoscopic surgery in the SOS study was 11%; 
this compares to 97% in 2012 in Sweden(161). The mean length of stay after the index bariatric 
surgery in our study was 7.1 days, longer than the 1.9 days in Sweden in 2012(161). Therefore 
results may be more favorable to the surgery group in contemporary settings. Regardless, no 
difference between treatment groups was observed for the diabetes group, suggesting that any 
admissions related to bariatric surgery were offset by the prevention of diabetes-related 
hospitalization.  
5.8 Is access to bariatric surgery equitable across different socioeconomic groups? 
In this stream, I examined bariatric surgery treatment rates for Australian adults according to 
socioeconomic position in 2011-12 for a nationwide population of Australians receiving bariatric 
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 surgery. I found that large socioeconomic inequalities in the use of bariatric surgery exist in 
Australia. Between 2011 and 2012, severely obese people in the two most disadvantaged quintiles 
were approximately 40% less likely to receive bariatric surgery relative to severely obese 
counterparts in the two least disadvantaged quintiles(15). These findings are supported by a 
previous study in the US setting(162).  
This analysis relates to the Australian setting, where bariatric surgery is primarily available through 
the private hospital system (89% of episodes in 2011-12)(146); eligible patients must hold private 
health insurance and pay an out-of-pocket fee. In the public hospital setting (11% of 2011-12 
episodes), no fees are incurred by patients, however long waiting times are common.  Affordability is 
likely to be a key contributor to the observed socioeconomic inequalities. Other factors, such as 
geographical access to services and health literacy may also play a role. Confirming the barriers to 
treatment for severe obesity in disadvantaged groups is an area requiring further research. 
My prevalence research (previously described within section 5.3) demonstrated the greatest relative 
socioeconomic inequalities in the more severely obese groups. Therefore, policy responses to 
reduce inequalities in severe obesity are particularly important. The current research stream 
quantified socioeconomic inequalities in access to bariatric surgery treatment in Australia(163). 
These inequalities in access to treatment risk further widening the inequalities in the prevalence of 
severe obesity. With increasing rates of severe obesity, proven treatments such as bariatric 
surgery(110), must be more accessible to Australians from all socioeconomic groups if we are to 
reduce the future associated morbidity burden. An increase in funding to treat severe obesity using 
bariatric surgery in public hospitals is one tangible step which could be taken to address 
socioeconomic inequalities in severe obesity. 
An important area for future research will be to assess whether any differences exist in bariatric 
surgery outcomes according to socioeconomic position, and if so, how these differences can be 
mitigated. It is foreseeable that outcomes could differ between SEP strata due to differences in 
health literacy and therefore compliance with recommendations for diet and exercise to optimise 
bariatric surgery outcomes and / or access (geographic and financial) to follow-up care. 
5.9 Conclusions 
In summary, my PhD research found that the prevalence of severe obesity has doubled in Australian 
adults over the last twenty years, and currently affects one in ten adults. My research also found 
that severe obesity is associated with a large burden at an individual level (quality of life), but also 
importantly at the societal level (government healthcare costs). After treatment for severe obesity 
using bariatric surgery, my research found that pharmaceutical utilisation was reduced in the ‘real 
world’ (rather than trial) setting, however savings were partially offset to due to an increase in the 
use of medical services, primarily for revisional bariatric surgery. 
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 Next, I examined the allocation of bariatric surgery to severely obese patients with regards to both 
technical efficiency (according to glucose profile at the time of surgery) and equity (across 
socioeconomic groups). Based on analysis of observed healthcare data for a bariatric surgery and 
conventional therapy group over up to 15 years, I found that bariatric surgery is associated with 
greater long-term health care use for patients with normal glucose at the time of surgery, trade-offs 
between increased hospital use and reduced drug use for patient with pre-diabetes and lower 
health care use for patients with type 2 diabetes, relative to conventional therapy counterparts. In 
relation to equity of access to bariatric surgery, I found large socioeconomic inequalities in access to 
surgery in Australia, with lower treatment rates observed in the most disadvantaged populations.   
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